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Bordetella pertussis, the etiological agent of whooping cough, colonizes the 
human respiratory tract very efficiently and triggers strong and protective local and 
systemic immune responses upon a single nasal administration, inducing immunity 
even at distant mucosal sites. With suitable attenuation, B. pertussis thus represents a 
promising vector for the nasal delivery of heterologous vaccine antigens.  
Recently, a highly attenuated B. pertussis strain named BPZE1 was engineered 
and found to induce markedly reduced lung inflammation in mice upon intranasal 
infection, while maintaining the ability to colonize and protect against pertussis 
infection. In addition to being an attractive live pertussis vaccine candidate, this novel 
strain is also promising as a vehicle to deliver heterologous vaccine candidates. 
However, the expression of foreign antigens in BPZE1 and the ability of the live 
recombinant bacteria to evoke antigen-specific immune responses upon nasal 
administration has yet to be investigated. In this study, we have evaluated the 
feasibility of using the attenuated BPZE1 strain as a vehicle for vaccine delivery of 
heterologous antigens. 
Filamentous hemagglutinin (FHA), the major B. pertussis adhesin, has so far 
been used as the antigen carrier in the development of live recombinant B. pertussis-
vectored vaccines. However, efficient secretion of FHA-chimeras across the outer 
membrane necessitates a totally unfolded conformation of the passenger antigen, 
thereby precluding the use of FHA to present foreign proteins containing disulphide 
bonds. To investigate other potential B. pertussis carriers, we have explored the 
possibility of using the B. pertussis autotransporter BrkA to expose heterologous 
vaccine candidates at the bacterial surface.   
 xii 
One or three copies of the neutralizing peptide SP70 from the VP1 capsid 
protein of Enterovirus 71 (EV71) was fused within the passenger domain of BrkA and 
expressed in BPZE1. A recombinant B. pertussis strain in which three copies of SP70 
were fused to FHA was also constructed. All three BrkA-(SP70)1, BrkA-(SP70)3 and 
FHA-(SP70)3 chimera were efficiently expressed, with successful surface-exposure 
for the former two and secretion for the latter. Furthermore, nasal administration of 
the BrkA-(SP70)3 recombinant strain triggered a strong anti-SP70 antibody response 
in mice, with titers and neutralizing activities significantly higher than those obtained 
in mice immunized with the FHA-(SP70)3 recombinant strain. These data clearly 
indicate that BrkA represents a promising carrier for the surface-exposure of 
heterologous antigens in attenuated B. pertussis. 
In addition, to further characterize the B. pertussis virulence mechanisms, a 
preliminary study on the B. pertussis polysaccharide capsule was conducted. The 
existence of a functional capsule in B. pertussis has been debated for decades. In an 
attempt to address this controversy, we constructed a capsule-knockout strain and 
found this mutant to be severly impaired in its colonization efficiency. This 
prelimnary study suggests that the B. pertussis polysaccharide capsule represents a 
novel virulence factor, and opens up avenues for future studies to unravel the 
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Chapter 1:   INTRODUCTION 
 
 Live recombinant bacteria adapted to the respiratory tract appear to be 
attractive and promising vehicles for the presentation of vaccine antigens to the 
respiratory mucosa, due to their ability to stimulate strong and long-lasting immunity 
of superior quality to that elicited by conventional vaccines (Stevenson and Roberts, 
2003). Bordetella pertussis, the etiological agent of whooping cough, colonizes the 
human respiratory tract very efficiently and induces strong and protective local and 
systemic immune responses upon a single nasal administration (Mielcarek et. al., 
1997; 2006; Renauld-Mongenie et. al., 1996a), with the induction of immunity even 
at distant mucosal sites, such as the urogenital tract (Mielcarek et. al., 2000). 
Consequently, B. pertussis has been successfully used as a live bacterial vector for the 
presentation of foreign antigens to the respiratory mucosa in mouse models (Locht, 
2000; Mielcarek et. al., 2001). However, suitable attenuation is mandatory in order to 
use B. pertussis as a live recombinant vector for vaccination. Recently, a highly 
attenuated B. pertussis strain named BPZE1 was constructed and found to induce a 
markedly reduced lung inflammation in mice upon intranasal infection, while 
maintaining the ability to colonize and induce protective immunity (Mielcarek et. al., 
2006). Furthermore, BPZE1 was found to induce protection in infant mice superior to 
that provided by current acellular pertussis vaccines. These features not only make the 
B. pertussis BPZE1 strain an attractive live pertussis vaccine candidate, but also a 
promising vehicle for vaccine delivery via the nasal route. The expression of 
heterologous antigens in BPZE1 and the ability to induce specific immune responses 
upon nasal administration of the live recombinant bacteria have not been reported yet.   
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Several heterologous antigens have been produced in recombinant B. pertussis 
(Alonso et. al., 2005; Coppens et. al., 2001; Mielcarek et. al., 1998; Reveneau et. al., 
2002) and they all have been fused to the filamentous haemagglutinin (FHA), a major 
adhesin of B. pertussis (Locht et. al., 1993). FHA is a 220 kDa monomeric protein 
that is both surface-exposed and secreted into the extracellular milieu (Coutte et. al., 
2003; Jacob-Dubuisson et. al., 2001). It is highly immunogenic (Alonso et. al., 2002; 
Shahih et. al., 1992) and displays adjuvant properties (Poulain-Godefroy et. al., 2003), 
prompting its use as a carrier to present heterologous antigens to the respiratory 
mucosa. However, efficient secretion of FHA-chimeras across the outer membrane 
necessitates a totally unfolded conformation of the passenger antigen (Guedin et. al., 
1998; Reveneau et. al., 2002), thereby limiting the use of FHA as a carrier. 
  Autotransporters have been successfully used in Salmonella and Escherichia 
coli to present heterologous antigens at the bacterial surface (Kramer et. al., 2003; 
Lattemann et. al., 2000), and they are able to translocate folded protein domains 
across the outer membrane (Veiga et. al., 2004). Autotransporters are large secreted, 
often virulence-associated proteins of Gram-negative bacteria (Henderson et. al., 
2004). They display a characteristic domain structure that includes: (a) a signal 
peptide at the N-terminus; (b) a passenger domain, which encodes the functional part 
of the protein, and (c) a C-terminal translocation unit, conserved within the 
autotransporter family. The latter domain is a beta barrel in the outer membrane, 
through which the passenger domain is translocated to the cell surface (Henderson et. 
al., 1998). Most autotransporters are proteolytically processed to release an a-domain 
which comprises most of the passenger domain.  
The B. pertussis BrkA autotransporter is believed to confer serum resistance 
by inhibiting the classical pathway of complement activation (Barnes and Weiss, 2001; 
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Fernandez and Weiss, 1994) and plays a role in B. pertussis adhesion to and invasion 
of host cells (Ewanowich et. al., 1989; Fernandez and Weiss, 1994). Recently, it was 
found that a truncated version of BrkA with a large deletion within its passenger 
domain could still be efficiently translocated and expressed at the bacterial surface 
(Oliver et. al., 2003b). This thus raises the possibility of using BrkA as a carrier by 
replacing part of its passenger domain with heterologous vaccine candidates.  
In this study, we have used BrkA and FHA as carrier proteins to deliver a 
vaccine antigen candidate, allowing comparison between the efficiency of BrkA and 
FHA as carriers. The chimeras were expressed in the attenuated BPZE1 strain, 
thereby addressing the potential of this strain as a live vehicle for vaccine delivery. 
We have selected the neutralizing SP70 peptide from Enterovirus 71 (EV71) as the 
heterologous antigen candidate, as EV71 shares two important similarities with B. 
pertussis, namely, both are mucosal pathogens and both mainly cause serious disease 
in young children. EV71 is a major etiological agent of Hand, Foot and Mouth 
Disease (HFMD) and has the propensity to cause severe neurological complications 
leading to significant morbidity and mortality in infants and children (McMinn, 2002; 
Palacios and Oberste, 2005). Since 1997, several outbreaks of EV71 infection have 
been reported in East and Southeast Asia, and its epidemic activity is on the rise in the 
Asia-Pacific region (Cardosa et. al., 2003; Chan et. al., 2003; Ho et. al., 1999). 
Several reports indicate that the viral VP1 capsid protein is protective in animal 
models (Chen et. al., 2006b; Chiu et. al., 2006; Sivasamugham et. al., 2006; Wu et. 
al., 2002) and highly immunogenic in humans (Tan and Cardosa, 2007). It has been 
recently shown that the SP70 peptide, spanning amino acids 208 to 222 of VP1, 
contains a neutralizing (Foo et. al., 2007a) and protective (Foo et. al., 2007b) B-cell 
epitope and is highly conserved amongst the EV71 subgenogroups. Thus, we have 
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investigated the anti-SP70 and anti-B. pertussis immune responses elicited by the 
different recombinant B. pertussis strains using the FHA or BrkA carrier system in 
mice models. 
To further develop safe and attenuated live bacterial vaccines acceptable for 
human use, it is necessary to achieve a better understanding of the bacterium, 
including its virulence factors. As a complement study to the development of live B. 
pertussis vaccines, some preliminary experiments were carried out to better 
characterize the role of the polysaccharide capsule in B. pertussis virulence.  
The capsule is an elaborate polysaccharide matrix that surrounds the entire 
microbial cell and has been shown to increase bacteria invasiveness through various 
mechanisms, some of which include resistance to antimicrobial peptides (Campos et. 
al., 2004), inhibition of neutrophil recruitment (Raffatellu et. al., 2006), and resistance 
to phagocytosis (Stokes et. al., 2004) and to complement killing (Jarva et. al., 2005). 
The capsule therefore represents an essential factor in the virulence of many 
pathogenic bacteria.  
Earlier literature has reported the existence of a capsule in B. pertussis, but it 
is not clear what structure is being referred to, and so far such a capsule has not been 
isolated and characterized (Lawson, 1940). The recent analysis of the B. pertussis 
genome has revealed the presence of a locus predicted to encode a type II 
polysaccharide capsule (Parkhill et. al., 2003). However, some of the genes of this 
locus have undergone inversion or Insertion Sequence Element (ISE)-mediated 
rearrangement, making the functionality and integrity of the B. pertussis capsule 
questionable.  
In an attempt to address this controversy, we have constructed a mutant 
deleted for the entire capsule operon and tested it in the mouse model of infection. 
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The data generated from this preliminary study will shed some light on the 
functionality of the B. pertussis capsule and open up avenues for future studies to 
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Chapter 2:   SURVEY OF LITERATURE 
 
(A)   MUCOSAL VACCINATION 
 
2.1   MUCOSAL IMMUNITY 
 
The mucosa is the boundary inside the body that primarily deals with its 
environment. It includes the conjunctival sac, the nasal mucosa, the buccal and 
gastrointestinal mucosa, the vaginal mucosa and the rectal mucosa. Many pathogens 
first encounter the body at these surfaces and thus, mucosal immunity can be said to 
constitute the body’s first line of defence (Service, 1994). The mucosa-associated 
lymphoid tissue (MALT) and its associated mucous membranes, the nasal-associated 
lymphoid tissue (NALT), the bronchial-associated lymphoid tissue (BALT) and the 
gastrointestinal-associated lymphoid tissue (GALT), all form part of this defence 
system. The NALT consists of the tonsils and adenoids (Zuercher et. al., 2002) while 
the BALT is made up of secondary lymphoid tissue of the respiratory epithelium 
(Sato, 2000) and the GALT includes the appendix and Peyer’s patches, which are 
specialized tissues in the gastrointestinal tract (Shields, 2000). The lining of all these 
mucosal tissues is composed of a single column of epithelial cells continually bathed 
in mucus containing glycoproteins, proteoglycans, enzymes, and specialized immune 
cells and immunoglobulin – principally secretory IgA (sIgA) (Parham, 2000).   
The mucosal immune system is anatomically and functionally divisible into 
inductive and effector sites (McGhee et. al., 1992; Staats et. al., 1994). Antigen is first 
encountered and initial responses are induced at the inductive sites while effector sites 
consist of the larger surface areas where IgA plasma cells are found and sIgA 
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production results in local protection. A major mucosal inductive site is the intestinal 
Peyer’s patches (Nagler-Anderson, 2001). The epithelium overlying the Peyer’s 
patches contains specialized cells called microfold (M) cells, which function to 
transport intact antigen from the apical membrane exposed to the lumen of the gut to 
the basolateral surface, where the antigen may then interact with lymphoreticular cells 
to evoke an immune response. M cells have been shown to be the portal of entry for 
various bacterial and viral pathogens, including reoviruses (Morin et. al., 1994) and S. 
typhimurium (Jang et. al., 2004). Just as the Peyer’s patches is the inductive site in the 
gastrointestinal tract, the NALT appears to be the inductive site of the upper 
respiratory tract (Bernstein et. al., 1994). Similar to the Peyer’s patches, the palatine 
tonsils of the NALT are also structurally organized lymphoid tissues containing B and 
T lymphocytes (Staats et. al., 1994).  
Following antigenic stimulation, the activated T and B cells leave the 
inductive sites via the efferent lymphatics and reach the systemic circulation through 
the thoracic duct, ultimately entering mucosal effector sites such as the lamina propria 
of the respiratory, gastrointestinal and reproductive tracts, as well as the glandular 
tissues (i.e., salivary and mammary glands) (McGhee et. al., 1992; Staats et. al., 1994). 
This circular pathway for dissemination of T and B cells to mucosal effector sites is 
termed the common mucosal immune system. This means that specific antigen 
reactivity can extend quickly over all mucosae including distal mucosal sites, thereby 
ensuring constant communication between all compartments of the mucosal immune 
system (Locht, 2000; Mestecky, 1987). Thus not surprisingly, it has been found that 
immunization at one mucosal site, such as intranasally, can induce immune responses 
at a distal mucosal site, such as the vagina (Staats et. al., 1996).  
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A hallmark of mucosal immunity is the synthesis of sIgA by mucosal plasma 
cells. sIgA is noted for its ability to prevent infection at the epithelial surface by 
inhibiting microbial attachment, entry and replication (Lamm, 1998). It also helps 
shuttle antigens out of the lamina propria into the lumen where IgA-bound antigens or 
microorganisms are excreted (Williams, 2003). While mucosal immunity typically 
involves sIgA production, antigens picked up by mucosal lymphoid tissues can also 
trigger serum IgG production (Service, 1994). V. cholera infection, for example, 
triggers both mucosal sIgA and serum IgG secretion (Butterton et. al., 1996). In 
addition, cell-mediated immunity also operates at the mucosal surface, involving the 
action of CD4+ T-helper cells, CD8+ cytotoxic T cells and natural killer (NK) cells, as 
well as the production of numerous cytokines including IFN-g, TNF-a, IL-6 and IL-8 
(van Ginkel et. al., 2000).  
 
2.2   VACCINATION VIA THE MUCOSAL ROUTE 
 
Due to the lack of understanding of its mechanisms, mucosal immunity was 
largely left out by vaccine researchers for decades. Now, this is no longer the case and 
interest in developing mucosal vaccines has risen sharply over the years. Since most 
pathogenic microorganisms are either restricted to the mucosal membranes or need to 
transit them during the early stages of infection (Levine et. al., 1983), the elicitation 
of immune responses at the mucosal level after immunization is highly desirable 
(Staats et. al., 1994). Parenterally administered vaccines, however, stimulate only 
systemic responses (Medina and Guzman, 2001) and have been found to be less 
effective in protecting against mucosal pathogens (Holmgren et. al., 1992). Mucosal 
vaccines, on the other hand, can stimulate both systemic and mucosal immunity 
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(Medina and Guzman, 2001). In addition, the use of the mucosal route is itself 
associated with a considerable number of additional advantages, such as ease of 
administration and low delivery-associated costs. A brief summary of the advantages 
of mucosal vaccination compared to parenteral vaccine administration is shown in 
Table 2.1.  
Different strategies can be used to deliver vaccine antigens by the mucosal 
route. Among them, the use of live attenuated bacterial vectors probably constitutes 
the most studied strategy (Medina and Guzman, 2001). Delivery of vaccine antigens 
by live bacterial vectors has resulted in the elicitation of humoral and cellular 
responses at both systemic and mucosal levels (Medina and Guzman, 2000). The live 
attenuated Sabin oral polio vaccine provides a successful precedent for the use of 
attenuated vectors in mucosal immunization (Martin and Minor, 2002). More 
examples of studies using live attenuated bacterial vectors will be discussed in Section 
2.9.1. Mucosal vaccine delivery has also been accomplished using attenuated 
recombinant viruses or viral particles, as demonstrated by the induction of anti-HIV-
antigen splenic responses following intranasal administration of recombinant 
attenuated modified vaccinia virus Ankara (MVA) (Ramirez et. al., 2003), and the use 
of human Papillomavirus Type 16 (HPV-16) virus-like particles to elicit vaginal 
cytotoxic T-cell responses via the nasal route (Dupuy et. al., 1999). In addition, the 
use of biodegradable microspheres for mucosal antigen delivery has also received 
considerable attention. For example, poly-DL-lactide-poly(ethylene glycol) (PELA) 
microspheres have been used as a delivery system for hepatitis B surface antigens via 
the oral route (Li et. al., 2002). The use of immune-stimulating complexes (ISCOMS) 
and liposomes are two other possible strategies for mucosal antigen delivery. 
ISCOMS are antigen delivery systems composed of the immunizing antigen, 
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cholesterol, phospholipids and glycosides present in the adjuvant Quil-A (Staats et. 
al., 1994). Intranasal immunization of diphtheria toxin in ISCOMS has been shown to 
stimulate significant local and systemic immune responses (Aguila et. al., 2006), 
while intranasal immunization of mice with liposomes containing recombinant 
meningococcal OpaB and OpaJ proteins was found to induce local and some serum 
antibody responses (de Jonge et. al., 2004). Recently, there has been considerable 
interest in the development of transgenic plants expressing heterologous antigens. An 
example is the production of transgenic tomatoes expressing the EV71 VP1 antigen, 
which upon oral ingestion, was found to stimulate anti-EV71 immune responses in 
mice (Chen et. al., 2006). Edible transgenic plants could thus also be a viable source 
of mucosal vaccine material in future. Finally, to overcome the problem of poor 
immunogenicity for some mucosal vaccines, in particular oral vaccines, the cholera 
toxin from V. cholerae and the heat labile enterotoxin from E. coli are commonly used 
as mucosal adjuvants (Isaka et. al., 2004; Ryan et. al., 1999).    
 


















Table 2.1   Advantages of vaccination via the mucosal route over the parenteral 
route. 








Mucosal Administration Parenteral Administration 
Low reactogenicity Generally higher reactogenicity than 
mucosal 
High acceptance / increased compliance Reduced acceptance / reduced compliance 
due to pain   
Inductive sites are targeted Inductive sites are not targeted 
Systemic and mucosal responses are 
stimulated 
Only systemic responses are stimulated 
Protection against disease and infection Mainly protection against disease 
No risk from contaminated needles  Potential risk from contaminated needles 
Easy administration / simple logistics Requirement of trained personnel 
Low delivery associated costs High delivery costs 
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2.3   INTRANASAL VACCINATION 
 
Mucosal vaccination can be carried out through various routes such as orally, 
nasally or through the rectal and vaginal routes. Of these, oral and intranasal 
vaccinations have been most extensively studied. Immune induction via the nasal 
route offers several advantages over the oral route. Intranasal vaccination generally 
elicits stronger immune responses than oral administration of the same vaccine 
(Locht, 2000). This may be related to the fact that intranasally delivered antigens 
avoid the proteolytic and acidic environment of the stomach encountered by oral 
vaccines. In addition to local immunity, systemic immune responses are also achieved 
more easily by intranasal delivery. With less commensal flora in the respiratory tract 
than in the gut, there is less competition for persistence of the vector and for vaccine 
antigen uptake.  
 The first documented evidence of intranasal vaccination inducing protective 
immunity came from Bull and McKee (1929), who showed that rabbits immunized 
intranasally with a suspension of killed pneumococci were protected against lethal 
challenge with the pathogen. Although generally more effective than oral vaccination, 
intranasal vaccination usually still requires repeated delivery of large amounts of 
antigen, or the addition of mucosal adjuvants (Wu and Russell, 1997). The use of live 
attenuated bacterial vectors thus presents a good solution to this problem as 
pathogenic bacteria are particularly well-adapted to interact with mucosal surfaces, 
since most of them use this interaction to initiate infection (Locht, 2000). As 
extensive bacterial colonization occurs at the mucosal surfaces, this allows for enough 
time to prime a vigorous immune response. 
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Importantly, mucosal lymphocytes can undergo extensive trafficking due to 
the common mucosal immune system (Mestecky, 1987). It has been found that 
intranasal immunization can induce immune responses at distal mucosal sites such as 
the vagina (Staats et. al., 1996). In fact, due to the high antigen-sampling capacity of 
the NALT, caused by the presence of M cells, alveolar macrophages and dendritic 
cells that can carry antigens to distant draining lymph nodes, good mucosal immune 
responses at distal sites are usually best achieved with intranasal administration 
(Locht, 2000). A study by Hopkins et. al. (1995) to compare four different mucosal 
routes of immunization- oral, nasal, rectal and vaginal, found that the nasal route of 
immunization generated the highest amounts of IgA antibodies in serum, saliva, 
genital and bronchial secretions. More recently, another group successfully induced 
protective IgA antibodies in the intestines after nasal immunization of mice with a 
rotavirus DNA vaccine (Garcia-Diaz et. al., 2004). Thus, intranasal vaccination is 
feasible even for non-respiratory enteric pathogens like EV71 and is definitely a 
promising vaccination route to explore in mucosal vaccine development. 
 
(B)   BORDETELLA PERTUSSIS: A PROMISING CANDIDATE FOR THE  
        DELIVERY OF HETEROLOGOUS VACCINE ANTIGENS 
        THOUGH THE NASAL ROUTE  
 
2.4   THE BORDETELLA GENUS 
 
The Bordetella genus consists of eight species to date, namely B. pertussis, B. 
parapertussis, B. bronchiseptica, B. avium, B. hinzii, B. holmesii, B. trematum and B. 
petrii (Sebaihia et. al., 2006). Recently, another new species, B. ansorpii, was 
discovered and classified under the Bordetella genus based on phenotypic and 
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genotypic characteristics (Ko et. al., 2005). Of these, the three classical species, B. 
pertussis, B. parapertussis and B. bronchiseptica have been most extensively studied. 
They are aerobic gram-negative coccobacilli of about 1 mm (Figure 2.1) that cause 
respiratory disease in humans and animals and have a very close phylogenetic 
relationship (van der Zee et. al., 1997). Generally, it is accepted that B. pertussis and 
B. parapertussis were differentiated from B. bronchiseptica through substantial loss 
of genetic material (Cummings et. al., 2004). B. bronchiseptica, the only motile 
member of the three, mainly colonizes the respiratory tract of animals including a 
wide variety of mammals and birds (Cummings et. al., 2004). On the other hand, B. 
pertussis is a strict human pathogen and is the etiological agent of whooping cough 
(Hoppe, 1999). B. parapertussis consists of two phylogenetically distinct subspecies 
isolated from humans (B. parapertussishu) and sheep (B. parapertussisov) (van der Zee 
et. al., 1997). In humans, it causes a milder form of whooping cough than B. pertussis 
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Figure 2.1   Gram stain of B. pertussis. 
Adapted from http://medic.med.uth.tmc.edu/path/00001492.htm
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2.5   WHOOPING COUGH 
 
2.5.1   Pathogenesis and Clinical Features 
 
 Whooping cough is a non-invasive infection of the respiratory mucosa by B. 
pertussis. Bacterial pathogenesis occurs in two stages. In the initial colonization stage, 
the ciliated epithelium of the bronchi and trachea is colonized by vast numbers of 
bacteria, whose adhesins such as filamentous haemagglutinin (FHA) and pertactin 
play a vital role in attachment. During this stage, large amounts of B. pertussis can be 
recovered from the nasopharyngeal cultures of patients and treatment with antibiotics 
is usually effective. This is followed by the toxemic stage, during which a variety of 
soluble toxins are produced by the bacteria, such as the pertussis toxin (PT) and 
dermonecrotic toxin (DNT). Antimicrobial agents have little or no effect on 
progression of the disease at this stage and the bacteria can rarely be recovered from 
patient samples (Preston and Matthews, 2002). 
 The clinical presentation of a typical pertussis case involves an incubation 
period of 7-10 days, followed by three phases: catarrhal, paroxysmal and convalescent 
(Table 2.2). The catarrhal phase, which is non-apparent in neonates, consists of 
nonspecific cold-like symptoms, which makes diagnosis difficult at this time. Within 
about a week, the paroxysmal phase follows, with increasing cough severity that 
produces the high-pitched “whoop” characteristic of whooping cough when the 
patient inhales. In the convalescent phase, paroxysmal coughs diminish in severity 
and frequency but patients often continue to cough intermittently for weeks to months 
(CDC, 2000; Mattoo and Cherry, 2005).  
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This classical description of pertussis is based on nonimmunized young 
children (Sabella, 2005). Many factors can change the usual course of the disease, 
leading to an atypical presentation. For example, completely vaccinated children have 
shorter courses of illness than incompletely or non-vaccinated children (Tozzi et. al., 
2003) and previously vaccinated adolescents and adults may have less severe 
paroxysmal symptoms (Yaari, et. al., 1999). Generally, the younger the child, the 
more severe paroxysms tend to be (Tozzi et. al., 2003) and the more dangerous the 
infection. Atypical presentations of the disease can lead to misdiagnoses, especially 
during the early stages of pertussis, which are most contagious (Deeks, et. al., 1999). 
In addition, asymptomatic infections in adults and adolescents often go undiagnosed 






























Table 2.2   Stages of pertussis infection. 
Adapted and modified from Gregory, 2006. 











Incubation 1-2 Asymptomatic 
 
- 
Catarrhal 1-2 Lacrimation, low-grade fever, malaise, 
mild conjunctival inflammation, 







Paroxysmal 1-6 Paroxysms (bursts of coughing during a 
single exhalation) followed by an 
inspiratory “whooping” sound, post-
tussive cyanosis, and emesis. 
 
In infants younger than six months 
(especially those younger than four 
weeks): apnea, bradycardia, prolonged 
cough, poor feeding, no paroxysms. 
 







Convalescent 2-12 Paroxysms gradually improve but recur 
with respiratory infections. 
White blood cell 
count normalizes. 
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2.5.2  Vaccination 
 
 Antimicrobials such as erythromycin and azithromycin can be used to treat 
pertussis (Tiwari et. al., 2005) but have little influence on disease prognosis unless 
started early in the catarrhal phase (Bergquist et. al., 1987). Unfortunately, diagnosis 
of pertussis is difficult. Culture of patient nasopharyngeal samples and direct 
fluorescent antibody testing are insensitive while pertussis-specific antibody detection, 
though sensitive, is impractical due to lack of commercially available kits and 
standardized ELISA protocols. Even more importantly, vaccinated individuals already 
have anti-pertussis antibodies regardless of whether they are infected or not, making 
serologic testing inaccurate and irrelevant. Bacterial detection by polymerase chain 
reaction (PCR) assay is becoming accepted but may give false-positives (Hallander, 
1999; Sabella, 2005; Heininger et. al., 2006). In view of the difficulty in diagnosing 
pertussis and more importantly, diagnosing it early enough for effective antibiotic 
treatment, vaccination is the best weapon against the disease. 
Danish physician Thorvald Madsen was the first to describe the use of a heat-
killed whole-cell pertussis vaccine on a large scale (Madsen, 1925; 1933). 
Subsequently, American scientists Kendrick and Elderling improved on the whole-
cell vaccine and combined it with diphtheria and tetanus toxoids to generate the first 
DTP combination vaccine, which became widely used in the late 1940s (Kendrick and 
Elderling, 1939; Sabella, 2005). Although the inactivated whole-cell vaccine was 
effective, it was associated with side effects like fever and inflammation at the 
injection site (Long et. al., 1990) and occasionally, neurological problems such as 
seizures and encephalopathies (Gale et. al., 1994). These observations prompted the 
development of acellular vaccines, which include only purified B. pertussis 
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components that would evoke a protective immune response while producing minimal 
adverse reactions. In 1981, Japan licensed the use of an acellular DTaP vaccine 
consisting of the B. pertussis FHA and PT antigens instead of the inactivated whole-
cell bacteria (Sato, 1984). PT subsequently became the cornerstone of second-
generation pertussis vaccine development, whereby an inactivated form of the toxin 
was included in most of future acellular pertussis vaccines.  
From the mid-1980s onwards, various acellular pertussis vaccines consisting 
of different quantity, combinations and formulations of B. pertussis antigens were 
developed and large-scale efficacy and safety studies were conducted in various 
countries including Sweden (Gustafsson et. al., 1996), Germany (Heininger et. al., 
1998) and the United States (Bisgard et. al., 2006). Generally, it was found that 
acellular vaccines led to fewer adverse reactions than whole-cell vaccines, and 
depending on the manufacturer and formulation of the acellular vaccines, some were 
found to be less efficient while others were found to have comparable efficacy to that 
of the whole-cell vaccines. Thus, most rich, industrialized countries such as the 
United States (CDC website, 2007) and Canada (Halperin and DeSerres, 2006) 
eventually switched to the acellular vaccines.  
Despite having lower reactogenicity, acellular vaccines are much more 
expensive (Tormans et. al., 1998). Thus, whole-cell vaccines remain widely used 
today in the poorer developing countries. Furthermore, acellular vaccines mainly 
stimulate the humoral immune response but it is becoming increasingly clear that T-
cell-mediated immunity is also an important arm in the defence against B. pertussis 
(Leef et. al., 2000). Thus, current research is targeted at modifying acellular vaccines 
to further improve their efficiency. For example, it has been shown that 
supplementation with lipopolysaccharide (LPS) analogs can improve the efficiency of 
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acellular pertussis vaccines while inducing considerably less reactogenicity than 
whole-cell vaccines (Geurtsen et. al., 2007). In addition, it has been shown that IFN-g 
production, which is indicative of a T-helper-1 (Th1) response essential to the 
development of protective immunity against pertussis (Mills, 2001), is significantly 
reduced in human newborns compared to older children (Lewis et. al., 1986). As such, 
significant amounts of antigen-specific IFN-g are only produced after several months 
in children vaccinated with pertussis vaccines, in particular, acellular vaccines 
(Ausiello et. al., 1997). On the other hand, infection with B. pertussis induces 
measurable antigen-specific Th1-type immune responses even in very young children 
(Mascart et. al., 2003). These observations have thus prompted researchers to 
investigate the development of live vaccines using highly attenuated B. pertussis 
strains (Mielcarek et. al., 2006).  
In Singapore, DTP is routinely used in the national vaccination of newborns 
except under special circumstances such as if the child has convulsion or brain 
problems, whereby DTaP is then recommended instead (Medical Hub Singapore 
website, 2007). The current vaccination schedule in Singapore is as follows: 1 dose of 
DTP each at 3, 4 and 5 months, followed by a DTP booster shot at 18 months 
(Medical Hub Singapore website, 2007).   
 
2.5.3   Pertussis Epidemiology: A Problem of Re-emergence 
 
 In the pre-vaccine years, pertussis was a leading cause of illness and death. In 
the United States, it accounted for up to 270,000 cases and 10,000 deaths each year 
(Cherry et. al., 1988). Following the implementation of large-scale vaccination 
programs, pertussis cases declined dramatically and by the early 1970s, the incidence 
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had declined by 99% compared to the pre-vaccine years in the United States (Davis et. 
al., 1992). Worldwide, however, pertussis remains one of the ten most common 
causes of death from infectious disease, accounting for 294,000 estimated deaths in 
2002 (WHO website, 2007).  
In recent years, there has been a resurgence of pertussis cases, even in 
countries with high vaccination coverage. Reports of increasing pertussis incidence 
among highly vaccinated populations in Australia (Andrews et. al., 1997), Canada 
(DeSerres et. al., 1995), Saudi Arabia (Al-Tawfiq and Abukhamsin, 2007) and Europe 
(de Melker et. al., 1997) have been accumulating for the past twenty years and in the 
United States, more cases (11,647) were reported in 2003 than in nearly four decades 
(CDC, 2005). There has also been a change in pertussis epidemiology, whereby 
reported cases in older age groups have increased (CDC, 2002; Lin et. al., 2007). This 
is believed to be due to the waning effects and sub-optimal efficacy of pertussis 
vaccines in adolescents and adults (Leung et. al., 2007). Currently, the precise time 
frame for protective immunity remains unresolved (Forsyth et. al., 2004). Although 
the effects of pertussis is usually much less severe in adolescents and adults, they can 
act as reservoirs of the disease, passing it on to vulnerable infants, thereby 
contributing to pertussis re-emergence (Bisgard et. al., 2004). A recent study has 
provided solid evidence that among pertussis-infected infants, household members 
were responsible for 76%-83% of pertussis transmission to this vulnerable group 
(Wendelboe et. al., 2007). As such, recent interest has focused on 
vaccinating/boosting older age groups. Several studies have shown that the acellular 
vaccines are safe and immunogenic in adolescents and adults (Ward et. al., 2005; 
Pichichero et. al., 2005) and they are already used in countries like France (Bonmarin 
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et. al., 2004) and Australia (Forsyth et. al., 2005) for adolescent and adult 
immunization.  
In addition, antigenic shift and adaptation of B. pertussis to current acellular 
vaccines may have allowed B. pertussis infection to remain endemic despite high 
vaccination coverage, contributing to the re-emergence of whooping cough (Mooi et. 
al., 2001). An extensive study has traced the problem of a dramatic surge in pertussis 
cases in The Netherlands in 1996 (de Melker et. al., 1997) to antigenic shifts in the B. 
pertussis population (Mooi et. al., 1998). This has thus led to recent attempts to 
produce a new generation of vaccines, such as intranasal (Shahih et. al., 1995) and 
DNA pertussis vaccines (Kamachi and Arakawa, 2007).  
 
2.6   GENETIC CONTROL OF VIRULENCE BY B. PERTUSSIS 
 
2.6.1   Antigenic Modulation 
 
Depending on environmental conditions, B. pertussis undergoes a reversible 
physiological adaptation known as antigenic modulation. The bacteria switches 
principally between two states, originally termed X and C modes by Lacey (Lacey, 
1960). The X mode corresponds to the virulent phase of the bacteria while the C mode 
corresponds to the avirulent phase. A third state known as the I mode was also 
recognized in the same study, whereby the growth characteristics of the bacteria was 
intermediate between the X and C modes. Most of the studies have focused on the 
virulent X mode and little is known about the avirulent and intermediate C and I 
modes. In 1997, an intermediate-phase B. bronchiseptica mutant expressing 
phenotypes characteristic of both the virulent and avirulent phase was isolated (Cotter 
Chapter 2: Survey of Literature 
24 
and Miller, 1997). This has prompted renewed interests in studying the B. pertussis I 
mode (intermediate phase), by using the B. bronchiseptica mutant as a model.  
The relevant in vivo signals involved in B. pertussis antigenic modulation are 
still unknown, but in vitro, low temperature (25oC) and the presence of magnesium 
sulphate or nicotinic acid has been used to switch the bacteria from the virulent to the 
avirulent phase (Melton and Weiss, 1993).  
 
2.6.2   The Bvg+ Phase and vags 
 
All the known B. pertussis virulence factors so far, with the exception of tracheal 
cytotoxin, are coordinately regulated by the Bordetella virulence gene (bvg) locus 
(originally termed the vir locus) (Weiss and Falkow, 1984), which encodes for a 
sensor protein BvgS, that ‘senses’ the environmental conditions, and a transcriptional 
activator protein BvgA, which controls expression of the virulence genes (Parkinson 
and Kofoid, 1992).  
The genes encoding BvgS and BvgA are contained in an operon (Arico et. al., 
1989) and transcription of this operon is controlled by three self-regulated promoters 
(P1, P3 and P4) and a constitutive promoter (P2) (Roy et. al., 1990). BvgS consists of 
an N-terminal periplasmic and transmembrane sensor domain, a linker region, a 
transmitter domain, a receiver domain and a C-terminal output domain (Uhl and 
Miller, 1996), while BvgA is a cytoplasmic protein consisting of an N-terminal 
receiver domain and a C-terminal output domain containing a helix-turn helix (HTH) 
motif characteristic of response regulators (Stibitz and Yang, 1991) (Figure 2.2). 
Upon reception of the external stimulus, BvgS autophosphorylates its transmitter 
domain, which leads to phosphorylation of the receiver domain followed by the 
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output domain. The output domain then donates the phosphoryl group to the receiver 
domain of BvgA (Uhl and Miller, 1994) (Figure 2.2). The increased affinity of 
phosphorylated BvgA (BvgA-P) for its target promoter sequences results in the 
activation of transcriptional activity for the virulence genes (Steffen et. al., 1996). The 
genes activated in the Bvg+ phase are collectively termed vags (virulence activated 
genes). Since the bvgAS operon is also a vag (Roy and Falkow, 1991), the signal is 
amplified in a positive feedback loop, thereby keeping the bacteria in the Bvg+ phase.  
The expression of vags has been shown to proceed via different kinetics for 
different genes, depending on the affinity of BvgA-P for the target promoter 
sequences (Scarlato et. al., 1991). The concentration of BvgA-P necessary to activate 
transcription of the PT gene was found to be ten times higher than the concentration 
necessary to activate fhaB transcription (Zu et. al., 1996). Correspondingly, a shift in 
temperature from 25oC to 37oC was shown to result in the production of FHA before 
PT, which was produced only several hours later. This temporal difference in 
activation of the vags allows the bacteria to produce appropriate virulence factors at 





































Figure 2.2   Model of the BvgS-BvgA phosphorylation cascade. 
The BvgS sensor domain receives an environmental signal that causes 
autophosphorylation of the H729 residue of the transmitter domain (open box), 
which transfers the phosphoryl group to the D1023 residue of the receiver domain 
(orange lightly shaded box), which in turn transfers the phosphoryl group to the 
H1172 residue of the output domain (orange heavily shaded box). The transfer 
from the receiver to the output domain can be reversed and the receiver domain 
can also totally dephosphorylate by reacting with water. From the output 
domain, the phosphoryl group is donated to the D54 residue of the BvgA receiver 
domain (green lightly shaded box), leading to transcription of the vags. BvgA 
binding of the vag promoter sequences is facilitated by the HTH motif (grey 
box) at the C-terminal of the BvgA output domain (green heavily shaded box). 
The transmembrane regions of the BvgS sensor domain (black boxes) and the 
BvgS linker region are also depicted.  
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2.6.3   The Bvg- Phase and vrgs 
 
Among the vags, the transcriptional repressor BvgR was shown to bind at the cis-
repressive sites of a set of genes named vrgs (for virulence repressed genes), and to 
repress their transcription (Beattie et. al., 1993; Merkel et. al., 2003). The bvgR gene 
lies adjacent to the bvgAS operon (Merkel and Stibitz, 1995). However, while bvgA 
and bvgS are transcriptionally-linked, bvgR is transcribed separately in the opposite 
orientation (Merkel et. al., 1998a). When the bacteria switches to the avirulent mode, 
BvgA is mainly unphosphorylated, resulting in non-activation of the vag genes, 
including bvgR, and the vrg genes are thus de-repressed. 
The products encoded by B. pertussis vrgs are collectively termed Vras (virulence-
repressed antigens) (Antoine et. al., 2000; Hot et. al., 2003; Stenson and Peppler, 
1995). While the vag-encoded products include most of the known pertussis virulence 
factors, little is known about the function(s) of the Vras. It has been shown that B. 
pertussis mutants lacking bvgR colonize less efficiently than wild-type strains in a 
mouse aerosol challenge model (Merkel et. al., 1998b) and ectopic expression of the 
vrgs also leads to a loss of bacterial virulence (Akerley et. al., 1995). At present, there 
is still no evidence showing any vrg-encoded products playing a direct role in B. 
pertussis virulence. In 1992, a group found that a B. pertussis mutant (SK6) 
harbouring a TnphoA insertion mutation in a vrg  (vrg6) was defective in tracheal and 
lung colonization in a mouse model of respiratory infection (Beattie et. al., 1992). 
However, this was inconsistent with the observation that a Bvg+ phase-locked 
B. bronchiseptica mutant was indistinguishable from the wild type in its ability to 
establish a persistent respiratory infection in rabbits and rats (Cotter and Miller, 1994; 
Akerley et. al.,1995). Subsequently, it was found that the vrg6 locus was indeed not 
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required for B. pertussis virulence and the attenuated phenotype observed for the SK6 
mutant was probably due to a secondary mutation in the genome (de Tejada et. al., 
1998).  
Recently, it has been found that expression of the vrgs is maximal late in the 
bacterial growth phase of B. bronchiseptica (Schneider et. al., 2002) and that 
individual B. pertussis vrgs are differentially modulated by different in vitro 
modulators (Hot et. al., 2003). In addition, a second two-component regulatory 
system independent from BvgAS and important in bacterial pathogenesis, named 
RisAS, was described in B. bronchiseptica; Zimna et. al., 2001). In B. pertussis, it 
was found that risA but not risS was required for maximal expression of the vrgs 
(Stenson et. al., 2005), including vraa, vrab (Stenson and Peppler, 1995), vrg6 and 
vrg18 (Croinin et. al., 2005). This suggests that there may be some level of cross-talk 
between the BvgAS and RisAS regulatory systems. Together, these studies help shed 
some light on the lesser-known vrgs and the Bvg- phase, contributing to the eventual 
elucidation of a physiological role for B. pertussis antigenic modulation.   
 
2.6.4   The Bvgi Phase 
 
In addition to the virulent Bvg+ and avirulent Bvg- phase, Bordetella bacteria 
undergoes an intermediate phase known as the Bvgi phase (Lacey’s I mode). Even less 
is known about this phase. In 1997, an intermediate-phase B. bronchiseptica mutant 
was identified whereby it expressed phenotypes characteristic of both the Bvg+ and 
Bvg- phase, such as increased resistance to nutrient limitation and a decreased 
colonizing ability (Cotter and Miller, 1997). Most importantly, it was found that under 
semi-modulating growth conditions, the mutant expressed elevated levels of a novel 
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class of gene products, termed Bvgi-phase-specific polypeptides (Bips). The first and 
most studied Bvgi-phase-specific gene, bipA, was identified in B. bronchiseptica 
(Stockbauer et. al., 2001). Its protein, which is exposed on the cell surface, shares 
sequence similarity with intimin of enteropathogenic and enterohemorrhagic 
Escherichia coli and invasin of Yersinia spp. (Stockbauer et. al., 2001). B. pertussis 
has also been found to harbour the bipA gene although the B. pertussis bipA differs 
from the B. bronchiseptica RB50 strain bipA in the number of 90-amino acid repeats 
and the C-terminal domain sequences (Fuchslocher et. al., 2003).  
The role of the Bvgi phase in B. bronchiseptica life cycle and the potential 
contribution of BipA to its pathogenicity are still unclear. Comparison between a 
bipA-deleted B. bronchiseptica mutant and the wild-type strain did not reveal a 
requirement for BipA in colonization of the respiratory tract (Stockbauer et. al., 2001). 
At present, it is hypothesized that the Bvgi phase is important in B. bronchiseptica 
transmission between hosts (Cotter and Jones, 2003), based on preliminary data 
showing the lack of transmission by Bvg+-phase-locked strains (Stockbauer et. al., 
2001). Studies on B. pertussis bipA have revealed that its transcription is both 
activated and repressed directly by BvgA-P, making it the first gene shown to be 
repressed directly by BvgA in B. pertussis (Williams et. al., 2005). In a murine 
respiratory infection model, it was found that a B. pertussis Bvgi-phase-locked mutant 
persisted at wild-type levels only in the upper respiratory tract and although it could 
establish an initial colonization in the nose and trachea as efficiently as the wild-type 
strain, it was out-competed by the wild-type at a later time point (Vergara-Irigaray et. 
al., 2005). In addition, it was found that anti-BipA antibodies were undetectable in a 
large collection of pertussis patient sera. All these suggest that the Bvgi phase 
probably does not play a significant role in B. pertussis colonization and as in the case 
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for B. bronchiseptica, may be more involved in facilitating bacterial transmission 
between hosts. The discovery of more Bvgi-phase-expressed proteins will no doubt 
help in elucidating the role of this phase in bacterial survival and pathogenesis. 
 
2.7   PERTUSSIS VIRULENCE FACTORS 
 
B. pertussis expresses a variety of virulence factors which classically, have 
been divided into two main groups: adhesins and toxins (Locht, 1999). Some of the 
better-studied adhesins include FHA, pertactin, fimbriae and the serum-resistance 
protein BrkA, while the toxins include exotoxins like PT, DNT, the adenylate cyclase 
toxin (ACT), the tracheal cytotoxin, and the heat stable endotoxin LPS (Figure 2.3). 
Here, only FHA and BrkA will be developed, while detailed discussions of the other 
virulence factors is beyond the scope of this thesis. In addition, a third section will be 
devoted to the polysaccharide capsule, which represents a potential virulence factor in 






































Figure 2.3   B. pertussis virulence factors and some of their functions. 
Dermonecrotic toxin: 
Exact function unknown; 
Can cause necrotic skin 
lesions in mice 
Fimbriae:  
Host cell adhesion 
ACT: 
Adenylate cyclase & 
haemolysin 
Pertactin:  






ribosyltransferase FHA:  
Host cell adhesion  
Tracheal cytotoxin:  
May be by-product of 
peptidoglycan synthesis; 
Damages respiratory epithelial 
cells 
Tracheal colonization factor:  
Exact function unknown 
LPS:  
Exact function unknown; 
Potent endotoxin activity 
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2.7.1   Filamentous Haemagglutinin (FHA) 
 
 FHA is considered the major adhesin of B. pertussis. It is a vag-encoded 
monomeric protein that is both secreted and cell-surface exposed (Locht et. al., 1993; 
Coutte et. al., 2003). The fhaB gene encodes a 367-kDa precursor protein named 
FhaB, which undergoes a series of modifications before the mature 220-kDa FHA is 
secreted into the extracellular milieu (Figure 2.4). Towards the N-terminus of FhaB is 
an atypical signal peptide (SP), which is cleaved from the molecule prior to export 
(Jacob-Dubuisson et. al., 1996). In addition, the C-terminal third of the precursor is 
also removed (Renauld-Mongenie et. al., 1996b). Although the C-terminal is not part 
of the mature protein, it is important in the secretion of full-length FHA (but not 
truncated analogs), probably as an intramolecular chaperone to stabilize the protein 
and prevent incorrect folding (Renauld-Mongenie et. al., 1996b). 
FHA secretion occurs in two steps. In the first step, FhaB is targeted to and 
traverses the inner membrane to the periplasmic space using the B. pertussis leader 
peptidase (Lep) and Sec machinery in a general SP-dependent pathway (Chevalier et. 
al., 2004). Although the FHA SP is unusually large (71 amino acid residues), it has 
been shown to undergo proteolysis at a Lep consensus cleavage site, suggesting that 
FhaB crosses the inner membrane via the Sec-dependent pathway (Lambert-Buisine et. 
al., 1998). In the second step, FHA secretion is mediated by an accessory protein 
located in the outer membrane, named FhaC (Jacob-Dubuisson et. al., 2001). FhaC is 
a pore-forming protein that interacts with the haemolysin-homologous secretion 
domain of FhaB (Hodak et. al., 2006; Meli et. al., 2006; Clantin et. al., 2007). It is 
believed that FhaB passes through the FhaC-derived b-barrel outer membrane pore in 
an extended conformation (Guedin et. al., 1998), with its folding into a b-helix at the 
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cell surface providing the energy for translocation (Kajava et. al., 2001). The 147-kDa 
C-terminal domain is then cleaved to liberate mature FHA into the extracellular 
milieu. A putative serine protease SphB1, has been reported to be responsible for this 
cleavage (Coutte et. al., 2001).  This FhaB/FhaC secretion belongs to the Two-Partner 
Secretion (TPS) pathway, commonly used in gram-negative bacteria for the secretion 
of large virulence proteins (Barenkamp and St Geme, 1994; Jacob-Dubuisson et. al., 
2004). Recently, Mazar and Cotter (2006) proposed a new model for this TPS 
pathway, whereby the N-terminus of FhaB binds to the N-terminal domain of FhaC 
and remains associated with it while the rest of FHA is transported through the 
channel (Figure 2.5). This model provides an explanation for their observation that, as 
opposed to what was previously proposed, it is the C-terminus and not the N-terminus 
of FHA that is exposed on the cell surface.  
In addition to the SP and secretion domain, FHA possesses several other 
domains and binding sites (Figure 2.4). The main target binding site for B. pertussis is 
the ciliated epithelium of the respiratory tract (Tuomanen and Weiss, 1985) and 
attachment to cells in this region is mediated by the carbohydrate recognition domain 
(CRD) (Relman et. al., 1989). This domain, which lies between amino acid (aa) 1141-
1279, has a unique affinity for glycolipids and ciliated cells (Prasad et. al., 1993). 
FHA also possesses a glycosaminoglycan binding site (aa 442-863), which allows it 
to bind to heparin and dextran sulphate (Hannah et. al., 1994; Menozzi et. al., 1994). 
This binding activity most likely allows the bacteria to bind non-ciliated cells as 
demonstrated using WiDr, HeLa and Vero cells (Sato et. al., 1981; Urisu et. al., 1986). 
The ability to bind heparin has also been exploited in the one-step purification of FHA 
using heparin sepharose (Menozzi et. al., 1991). In addition, FHA contains an 
arginine-glycine-aspartate (RGD) tripeptide that facilitates binding to complement 
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receptor type 3 (CR3) integrins present on the surface of macrophages. B. pertussis 
docks with integrin CR3, which may initiate entry into phagocytes without an 
oxidative burst (Relman et. al., 1990). 
FHA is known to be highly immunogenic, inducing high levels of mucosal 
and systemic antibodies upon B. pertussis infection in mice (Cahill et. al., 1995) and 
humans (Isacson et. al., 1995). This has led to the inclusion of FHA in most acellular 
pertussis vaccines, whereby it was shown that FHA inclusion in the vaccines indeed 
decreased rate of B. pertussis infection in humans (Storsaeter et. al., 1990). At present, 
the importance of individual FHA domains in inducing protective immunity is largely 
unknown. It has been demonstrated that the protein has two main immunodominant 
regions, with the C-terminal type I domain more immunodominant than the N-
terminal type II domain (Piatti, 1999). Recently, several studies have been conducted 
to identify immunogenic regions and epitopes in FHA capable of inducing protective 
immunity in mice (Alonso et. al., 2002; Knight et. al., 2006). In addition, FHA is also 
known to have adjuvant properties for co-delivered antigens (Poulain-Godefroy et. al., 
1998; 2003). This makes it an attractive candidate as a carrier in the development of 

























Figure 2.4   Schematic drawing of mature FHA and its precursor FhaB. 
The N-terminal signal peptide (SP) and C-terminal one-third of the precursor is 
cleaved in the maturation and translocation process of FHA to release the 220-
kDa mature protein into the extracellular milieu. The various domains and 
binding sites of mature FHA are labeled. RGD, Arginine-Glycine-Aspartate 
tripeptide motif; CRD, carbohydrate recognition domain. 
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Figure 2.5   New proposed model for FHA secretion. 
After crossing the cytoplasmic membrane using the SP-dependent Sec 
secretion system, the N-terminus of FhaB binds to the N-terminal domain of 
FhaC and remains associated with it while the rest of the protein translocates 
through the outer membrane. As the protein passes through the pore, it folds 
into a b-helix. Cleavage by SphB1 generates the C-terminus of mature FHA 
(CFHA), which then assumes the final conformation with the C-terminus 
oriented away from the cell-surface. The C-terminus of FhaB remains in the 
periplasm and is degraded by the proteases there. The various molecules and 
structures are labelled. om, outer membrane; cm, cytoplasmic membrane; S, 
SphB1; orange wedged circles, periplasmic proteases. The FhaB SP is green, 
the N-terminal 80% of FHA is purple, the C-terminal domain of mature FHA 
is pink, and the C terminal domain of precursor FhaB is blue. 
Adapted from Mazar and Cotter, 2006. 
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2.7.2   The Bordetella Resistance to Serum Killing Protein (BrkA) 
  
BrkA belongs to a family of proteins known as autotransporters. 
Autotransporters are an extensive group of large, secreted virulence-associated 
proteins of gram-negative bacteria. They perform various functions such as adhesion 
(Rose et. al., 2003), proteolysis (Klemm et. al., 2004), serum resistance (Fernandez 
and Weiss, 1994) and biofilm formation (Roux et. al., 2005). Autotransporters have a 
modular organization, typically comprising of (a) an N-terminal SP; (b) an internal 
passenger domain harbouring the functions of the protein; and (c) a C-terminal 
translocation unit conserved across autotransporters, which encodes a b-barrel that 
inserts into the outer membrane (Girard and Mourez, 2006) (Figure 2.6). Biogenesis 
of autotransporters occurs through multiple steps (Desvaux et. al., 2004). In the first 
step, the protein is targeted to and crosses the inner membrane via the Sec apparatus 
(Sijbrandi et. al., 2003). In the second step, the translocation unit forms a b-barrel, 
which inserts into the outer membrane and finally, in the third step, the passenger 
domain translocates through the b-barrel across the outer membrane (Shannon and 
Fernandez, 1999) (Figure 2.7). Once on the bacterial surface, most autotransporters 
are proteolytically processed, releasing an a-domain which comprises most of the 
passenger domain. This cleavage is often autoproteolytic and the a-domain either 
remains non-covalently associated with the cell surface (Suhr et. al., 1996), or it can 
be released into the extracellular milieu (Fink et. al., 2001). In some cases, secondary 
proteins in the outer membrane may also participate in the proteolytic processing of 
autotransporter passenger domains (van Ulsen et. al., 2003). 
The B. pertussis BrkA is encoded by the brkA gene, which together with 
another gene brkB, constitutes the serum resistance brk locus (Fernandez and Weiss, 
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1994). brkA and brkB are transcribed in opposite directions, producing the 103-kDa 
BrkA and 32-kDa BrkB respectively, both of which are believed to be involved in 
serum resistance. Consistent with the model of autotransporter secretion, BrkA is 
expressed as a 103-kDa precursor, which is processed during secretion to yield a 73-
kDa passenger domain and a 30-kDa translocation unit (Shannon and Fernandez, 
1999) (Figure 2.6). Following translocation, the cleaved passenger domain remains 
tightly associated with the bacterial surface (Oliver and Fernandez, 2001). Additional 
characterization of the protein has demonstrated that it also has a 42-aa signal peptide, 
a 31 to 39-aa linker region that is part of the translocation unit (Oliver et. al., 2003a), 
and a conserved “autochaperone” domain at the C-terminus of the passenger domain 
necessary for efficient translocation and/or folding of the passenger domain (Oliver et. 
al., 2003b) (Figure 2.6). Recently, it has been found that the 73-kDa passenger 
domain of BrkA has adjuvant and immunogenic activities when purified and injected 
subcutaneously into mice (Cainelli Gebara et. al., 2006). 
Like FHA, BrkA is a virulent factor of B. pertussis under positive BvgA/S 
regulation (Hot et. al., 2003). BrkA is important in bacterial pathogenesis, as mutants 
in BrkA have been shown to be ten-fold less virulent in a mouse model (Weiss and 
Goodwin, 1989). While BrkA has been implicated in adherence to and invasion of 
host cells in vitro (Ewanowich et. al., 1989), its best studied function is that of in vitro 
resistance to human immune serum killing (Fernandez and Weiss, 1994). It has been 
found that BrkA inhibits the classical pathway of complement activation and prevents 
the accumulation of deposited complement protein C4 (Barnes and Weiss, 2001). In 
addition, a real-time reverse transcriptase PCR assay (RT-PCR) on fifty Bordetella 
isolates showed that brkA expression is strain-dependent, which may help in 
explaining the different serum resistance or susceptibility phenotype exhibited by 
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different Bordetella strains (Stefanelli et. al., 2006). However, although BrkA has 
been shown to play a role in complement-resistance in vitro, the actual in vivo role of 
BrkA during infection remains largely unexplored. A 2004 study by Elder and Harvill 
demonstrated a strain-dependent role for BrkA during B. pertussis infection of mice. 
They found that while the protein seems to have a redundant or non-critical function 
in some recent clinical isolates, the in vivo function of BrkA in several strains of 
bacteria derived from Tohama I is critical, but is independent of its role in 
complement resistance. In addition, a recent study found that B. pertussis may have 
another mechanism to evade complement killing in addition to, but independent of, 
BrkA expression (Marr et al., 2007). Thus, the in vivo role of BrkA in B. pertussis 





































Figure 2.6   Primary structure of an autotransporter/BrkA.  
The aa residue numbers are specific for B. pertussis BrkA.   
Adapted from Oliver et. al., 2003. 
 












Figure 2.7   The autotransporter secretion pathway.  
Step I: insertion of the β-domain (orange) into the outer membrane (OM) and 
formation of the transmembrane β-barrel pore. Step II: the linker region (blue) 
is first secreted through the pore. Step III: the autochaperone domain (green) 
triggers the folding of the passenger domain (red and green). Step IV: the 
folded passenger domain is exposed on the cell surface and is released into the 
extracellular milieu (EM) after proteolytic cleavage. For BrkA, the passenger 
domain remains non-covalently associated with the membrane surface. 
Adapted from Desvaux et. al., 2004. 
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2.7.3   The Bordetella Capsule  
 
 In addition to adhesins and toxins, some bacteria also exert their virulence 
through the production of a capsule. Several ways in which the capsule has been 
shown to increase bacterial virulence include resistance to antimicrobial peptides 
(Campos et. al., 2004), inhibition of neutrophil recruitment (Raffatellu et. al., 2006), 
escape from phagocytosis (Stokes et. al., 2004) and resistance to complement killing 
(Jarva et. al., 2005). The capsule is an elaborate polysaccharide matrix composed of 
repeating single monosaccharide units joined by glycosidic linkages (Taylor and 
Roberts, 2005). It is found on the outermost surface of the bacteria, linked to the cell 
surface via covalent attachments to either phospholipid or lipid-A molecules 
(Whitfield and Valvano, 1993). Capsule polysaccharides are a diverse range of 
molecules that can differ both in their constituent monosaccharides and the manner in 
which they are joined (Roberts, 1996). In E. coli species alone, there are over 80 
distinct capsular serotypes (Whitfield and Roberts, 1999) while in Streptococcus 
pneumoniae, over 90 capsular serotypes have been described (Garcia et. al., 2000). 
Capsule gene clusters have been cloned from several gram-negative bacteria, 
including E. coli (Kim et. al., 2003), Salmonella typhi (Raffatellu et. al., 2005) and 
Klebsiella pneumoniae (Campos et. al., 2004). In all these cases the capsule genes are 
clustered at a single chromosomal locus, which allows the coordinate regulation of a 
large number of genes that may be involved in the biosynthesis and export of the 
capsular polysaccharides (Roberts, 1996).  
It has been reported in early literature that B. pertussis is capsulated (Lawson, 
1940) but it is not clear what structure is being referred to, and so far such a capsule 
has not been isolated and characterized. More recent analysis of the B. pertussis 
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genome has revealed the presence of a locus predicted to encode a type II 
polysaccharide capsule (Frosch et. al., 1991), including genes for transport (ATP-
binding cassette transporter), capsule polysaccharide synthesis and lipid modification 
(Antoine et. al., 2000) (Figure 2.8). The predicted products encoded by the 
biosynthesis genes are homologous to the S. typhi Vi capsular antigen biosynthesis 
enzymes (Parkhill et. al., 2003). In addition, the B. pertussis capsule operon has been 
shown to belong to the family of vrgs under negative BvgA/S regulation (Antoine et. 
al., 2000; Hot et. al., 2003). However, some of the genes at both ends of this locus 
have undergone inversion or ISE-mediated rearrangement (Parkhill et. al., 2003) 
(Figure 2.8), although it remains possible that the altered subset of genes can still have 
a biological function in B. pertussis. Thus, the functionality and integrity of the B. 
































kpsM kpsT kpsE wbpT vipC wza wbpO wbpP wcbA wcbO wcbQ wcbP 
Figure 2.8   The B. pertussis capsule operon.  
The capsule operon comprises capsule synthesis genes (hashed arrows), genes 
directing polysaccharide translocation from cytoplasm to periplasm (open arrows) 
and genes involved in capsule transport from periplasm to cell surface (black 
arrows). Gene disruption by IS insertion is indicated by a black cross. 
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2.8   B. PERTUSSIS-RELATED IMMUNE RESPONSES 
 
2.8.1   Immunity to B. pertussis Infection 
 
 Although B. pertussis has many well-studied virulence factors, the actual 
interplay between B. pertussis pathogenesis and host immunity remains largely 
unknown. It has been demonstrated that B. pertussis natural infection induces Th1 
cells and predominantly IgG2a antibodies (Mills et. al., 1998). In 2000, a study using 
DNA microarray revealed that upon B. pertussis infection, the transcriptional profile 
of a human bronchial epithelial cell line (BEAS-2B) was dominated by a 
proinflammatory response (Belcher et. al., 2000). Various studies have also provided 
indications for the role of other host genes in the course of B. pertussis infection, 
including the interferon gamma (IFN-g) receptor (Mahon et. al., 1997) and toll-like 
receptor 4 (TLR-4) (Mann et. al., 2005). IFN-g is believed to play a major role in 
protection against intracerebral challenge with B. pertussis (Barnard et. al., 1996). 
TLR-4, whose ligands include bacterial components like LPS, is essential for efficient 
IL-1b, tumour necrosis factor-alpha (TNF-a) and IFN-g response, as well as efficient 
bacterial clearance from the lungs through the recruitment and priming of 
polymorphonuclear leukocytes (PMNs) like neutrophils (Banus et. al., 2006). More 
recently, Banus et. al. (2007) investigated mRNA expression in the lungs of mice 
after B. pertussis infection. They identified upregulated genes as those involved in 
acute-phase response, antigen presentation, cytokine production, inflammation and 
apoptosis and subsequent pathway analysis determined the most significant pathways 
as those for regulation of PMN function, TLR signaling, extracellular matrix 
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remodeling and apoptosis. The authors concluded that B. pertussis infection induces a 
wide and complex response that is partly specific for B. pertussis and partly 
nonspecific.  
 
2.8.2   Pertussis Vaccines-induced Immunity  
 
Despite the successful development of pertussis vaccines, the mechanism of 
vaccine-induced protection against B. pertussis is still poorly understood. It has been 
shown that whole-cell pertussis vaccines are associated with a predominant IgG2a 
response (Mills et. al., 1998) and generally induce antigen-specific Th1 cells with 
high IFN-g and IL-12 production similar to natural infection (Mascart et. al., 2003). 
On the other hand, acellular vaccines induce mainly IgG1 antibodies (Mills et. al., 
1998) and a mixed Th1/Th2 response (also called Th0) with high IFN-g and IL-5 
(Ryan et. al., 1998), but no IL-12 production (Mahon et. al., 1996). A similar profile 
is seen in humans and mice models. Using different knockout mice, Mills et. al. (1998) 
showed that both humoral and cell-mediated responses are required in vaccine-elicited 
protective immunity. Anti-pertussis IgG antibodies play a key role in preventing 
bacterial adherence and initially, an antibody-mediated response may be important in 
restricting the extent of infection and minimizing damage to epithelial and immune 
cells. To achieve complete bacterial clearance, however, the induction of Th1 cells is 
important as they function in limiting the course of infection through enhanced 
bacterial uptake and killing by phagocytic cells (Mills et. al., 1999; Smith, et. al., 
2001). Indeed, it has been found that the Th0 response elicited after acellular 
immunization results in delayed bacterial clearance in a murine respiratory challenge 
model, while natural infection or immunization with killed whole cells was associated 
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with rapid clearance (Barnard et. al., 1996). Furthermore, strategies that can shift the 
acellular immune response to Th1, such as the inclusion of IL-12 in the vaccine 
formulation, have been found to enhance the rate of bacterial clearance (Mahon et. al., 
1996).  
Recently, it was found that TLR-4 mediates vaccine-induced protective 
cellular immunity to B. pertussis and that immunization with whole-cell vaccines but 
not acellular vaccines, induced IL-17 production by a novel subset of T lymphocytes 
termed Th17 cells (Higgins et. al., 2006). IL-17 has been shown to act as an important 
effector T cell cytokine in inflammatory responses (McKenzie et. al., 2005) and Th17 
cells have been shown to play a pathogenic role in autoimmunity (Langrish et. al., 
2005). In this study, the authors found a new effector function for IL-17 – activation 
of macrophage killing of B. pertussis. Presently, there is some limited evidence 
indicating a role for IL-17 in protection against infection by bacteria including 
Klebsiella pneumoniae (Ye et. al., 2001) and Mycobacterium tuberculosis (Khader et. 
al., 2005). Thus, it appears that the Th17 response may also play a significant role in 
protective immunity elicited by whole-cell pertussis vaccines. 
 
 2.8.3   Immunomodulation  
 
 To successfully infect and survive in its host, a pathogen must be able to 
counteract the host immune system. It appears that much of the activity of B. pertussis 
virulence factors is dedicated to immunomodulation of the host defense system so as 
to suppress, evade and subvert host immune responses (Carbonetti, 2007). In addition 
to its role in adherence, B. pertussis FHA has been shown to have immunosuppressive 
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and immunomodulatory activities whereby it stimulates IL-10 and inhibits TLR-
induced IL-12 production by macrophages and dendritic cells (DCs), resulting in the 
development of IL-10-secreting type 1 T-regulatory (Tr1) cells (McGuirk et. al., 
2002). Interestingly, the systemic administration of FHA was found to reduce 
intestinal inflammation in a T-cell-mediated model of colitis (Braat et. al., 2007). This 
was most likely achieved through the anti-inflammatory Tr1 responses induced by 
FHA. In addition, anti-FHA antibodies in convalescent human serum were found to 
reduce neutrophil phagocytosis of the bacteria (Mobberley-Schuman et. al., 2003).  
PT inhibits neutrophil recruitment to delay antibody-mediated bacterial 
clearance (Kirimanjeswara et. al., 2005) and targets airway macrophages to promote 
B. pertussis infection of the respiratory tract (Carbonetti et. al., 2007). PT has also 
been found to exert multiple suppressive effects on the immune system beyond those 
observed on innate immune cells, such as the suppression of serum antibody 
responses to B. pertussis antigens after infection (Carbonetti et. al., 2004), the 
reduction of major histocompatibility complex (MHC) class II molecules on the 
surface of human monocytes (Shumilla et. al., 2004) and the modulation of surface 
markers on DCs (Martino et. al., 2006). Recently, it was found that PT uses proximal 
components of the T-cell receptor complex to initiate signal transduction events in T 
cells (Schneider et. al., 2007).  
It has been shown that ACT can upregulate MHC II and costimulatory 
molecules on DCs, inducing a semi-mature state that decreases proinflammatory 
cytokine production (Skinner et. al., 2004). Recently, it was demonstrated that B. 
pertussis stimulated Th17-inducing IL-23 expression in human DCs instead of the 
expected Th1-inducing IL-12 (Fedele et. al., 2005). This immunomodulation towards 
a Th17 response was attributed to B. pertussis ACT (Spensieri et. al., 2006) and is 
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believed to cause a chronic autoimmune reaction in the airways (Carbonetti. 2007). It 
has been speculated that this Th17-skewed response is associated with the major 
pathology of B. pertussis infection – the persistent cough.  
 
2.8.4   Evasion of Complement-mediated Killing 
 
It has been shown, at least in vitro, that BrkA and BrkB are responsible for B. 
pertussis resistance to the classical complement pathway (Fernandez and Weiss, 1994; 
Barnes and Weiss, 2001). In terms of innate immunity, however, B. pertussis lacks an 
O antigen, unlike B. bronchiseptica and B. parapertussis, and is sensitive to rapid 
killing by naïve serum in vitro (Burns et. al., 2003). Yet in the normal course of 
infection, the bacteria manages to survive and multiply in the presence of an active 
innate immune response, showing that there must be a mechanism by which the 
organism evades alternative complement killing by the host innate immune system 
(Harvill et. al., 1999). Indeed it was observed by Pishko et. al.(2003) that the bacteria 
acquires resistance to complement-mediated killing in vivo, which seems to be 
specific against the alternative complement killing pathway and is both BvgAS and 
BrkA-independent. Their data also suggested that B. pertussis may rapidly recruit 
some as yet unidentified host factor that is present in blood, but in limited quantities 
in the lungs, to protect itself from alternative complement killing. Earlier, it had been 
shown by Berggard et. al. (1997) that B. pertussis can sequester the human 
complement regulator C4BP via binding to FHA, thereby downregulating 
complement activity. However, C4BP is primarily a regulator of the classical 
complement pathway (Berggard et. al., 1997) so it is not likely to be the factor 
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observed in Pishko’s study. In addition, it was recently demonstrated that B. pertussis 
binds human C1 esterase inhibitor during the Bvg+ phase to evade complement killing 
in a BrkA-independent process (Marr et. al., 2007). Thus, B. pertussis employs 
multiple mechanisms to evade the various complement killing pathways of the host 
innate and adaptive immune systems. 
 
2.9   B. PERTUSSIS FOR HETEROLOGOUS ANTIGEN DELIVERY 
 
2.9.1   Live Bacterial Vaccines 
 
Natural infection usually elicits humoral and cell-mediated immune responses 
effectively, resulting in strong and long-lasting immunity of superior quality to that 
elicited by conventional acellular and killed whole-cell vaccines. Live attenuated 
vaccines that can cause self-limiting, clinically inapparent infections come closest to 
achieving the level of immunity resulting from natural infection. They thus present an 
interesting alternative to the existing kinds of acellular and killed whole-cell vaccines 
available. In addition, they can also act as vectors for the delivery of heterologous 
antigens, thereby providing protection against more than one disease simultaneously 
(Stevenson and Roberts, 2003).     
The two main considerations when choosing live vaccine and vector 
candidates are that firstly, they must be safe for human use such that they do not cause 
any disease, and secondly, they should still be immunogenic enough to stimulate 
protective immunity (Medina and Guzman, 2001). Thus, there is a need to achieve a 
balance of attenuating pathogenic strains enough to render them harmless, but not to 
the extent of compromising their immunogenicity. Live recombinant vaccines can be 
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broadly classified into two categories, with 1) “generally recognized as safe” (GRAS) 
bacteria as vectors, or 2) attenuated pathogenic bacteria as vectors (Locht, 2000). 
GRAS bacteria are mainly human commensals or those commonly used in the food 
industry, such as Lactococcus lactis, Lactobacillus and Streptococcus gordonni. A 
major disadvantage of these food-grade bacteria is their limited capacity to persist in 
the human host, hence a lower ability to elicit protective immunity against their 
passenger antigens (Mielcarek et. al., 2001). In contrast, attenuated pathogenic 
bacteria usually colonize the human host efficiently and are able to elicit strong 
immune responses (Mielcarek et. al., 2001).  
Few promising live vaccine candidates have survived the licensing process 
and become registered for official human use (Dietrich et. al., 2003), mainly due to 
lack of success in clinical trials and concerns over their safety (Detmer and Glenting, 
2006). Mycobacterium bovis Bacillus Calmette-Guerin (BCG) was the first and 
continues to be the most widely used live bacterial vaccine in the world (Curtiss III, 
2002). As a vector, BCG is promising only if the foreign antigen is secreted or 
expressed on the cell surface since phagocytic cells do not readily lyse mycobacterial 
cells (Curtis III, 2002). Protective immunity against Borrelia burgdorferi was 
successfully induced in mice immunized with recombinant BCG producing OspA 
antigen. However, this recombinant vaccine candidate failed to induce antibody 
responses specific to OspA in human volunteers (Edelman et. al., 1999). S. typhi Ty21 
is a widely used licensed live vaccine that is exceedingly safe but it requires three to 
four immunizations for long-term protection up to seven years (Levine et. al., 1999). 
Newer, more immunogenic live S. typhi vaccines are currently under clinical 
evaluation with Ty800, a very promising typhoid vaccine candidate inducing high-
level immune responses with just a single dose in human trials (Roberts et. al., 2000). 
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As a vector, attenuated S. typhi Ty2 has been used to express various antigens like 
Hepatitis B antigens and Helicobacter pylori urease, but when evaluated in human 
volunteers, the recombinants strains induced diminished immune responses to 
Salmonella and insignificant or nonexistent immune responses to the heterologous 
antigens (Tacket et. al., 1997; Di Petrillo et. al., 1999). So far, tetanus toxin fragment 
C (TTFC) of Clostridium tetani is the only antigen delivered by attenuated S. typhi 
Ty2 to have induced a modest immune response in human volunteers (Tacket et. al., 
2000). In addition, two live attenuated Vibrio cholera vaccine candidates have entered 
human clinical trials, and one, CVD 103-HgR, is now commercially available (Ryan 
and Calderwood, 2000). Attenuated V. cholera has also been used as a vector for 
delivery of heterologous antigens like TTFC and B. pertussis tracheal colonization 
factor (Chen et. al., 1998) but these recombinant vaccine candidates have only been 
tested in animal models and have yet to enter human trials. Finally, live attenuated B. 
pertussis strains have also been engineered and will be developed in greater detail in 
the next section.  
 
2.9.2   Attenuated B. pertussis as a Live Recombinant Vector 
 
Several characteristics make B. pertussis an attractive candidate as a live 
attenuated vaccine or recombinant vector. Its infection is specific to the lungs and it 
generally does not cause systemic infections (Stevenson and Roberts, 2003). It 
colonizes the respiratory tract efficiently, which means that low infectious doses are 
required. Genetic manipulation of this organism is well-established and easy to 
perform. Finally, it possesses various bacterial protein secretion systems, which 
makes it possible to secrete foreign antigens if necessary (Stevenson and Roberts, 
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2003). Thus, the bacteria can be used in the development of live vaccines or as a live 
vector in the development of recombinant multivalent vaccines that can protect 
against several diseases in addition to whooping cough. 
As B. pertussis is a pathogenic bacterium, its attenuation is mandatory before 
it can be considered for use as a live vaccine in humans. Initial attempts to genetically 
attenuate B. pertussis were based on inactivation of genes involved in amino acid 
biosynthesis (Roberts et. al., 1990). Such mutations affecting the aromatic pathway 
gave rise to highly attenuated strains (aro mutants) (Hernanz et. al., 1998; Simmons et. 
al., 1997) that still express all the virulence determinants, which are often critical in 
stimulating protective immune responses. However, B. pertussis aroA mutants were 
greatly impaired in their colonization efficiency and thus turned out to be poor 
immunogens, requiring at least three doses for protection (Roberts et. al., 1990). 
Subsequently, a pt-deleted strain (BPRA) was developed (Mielcarek et. al., 1998). 
BPRA was found to be strongly attenuated, as evidenced by the absence of systemic 
effects associated with whooping cough such as lymphocytosis, and in much reduced 
inflammation of the airways. Nevertheless, this strain was still able to colonize the 
mouse respiratory tract almost as efficiently as the wild-type strain and a single 
intranasal administration provided protection against subsequent challenge with the 
wild-type strain. BPRA was also successfully used as a vector for several 
heterologous antigens fused to FHA or its truncated derivative (Coppens et. al., 2001; 
Mielcarek et. al., 1998; Reveneau et. al., 2002). Interestingly, it was found that serum 
antibody response against FHA and its heterologous antigen Sm28GST (Schistosoma 
mansoni glutathione S-transferase) was stronger in mice infected with the pt-deleted 
strain than the wild-type (Mielcarek et. al., 1998). Although BPRA displayed an 
attenuated phenotype, the deletion of PT alone was felt to be not safe enough for 
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human use. Furthermore, PT is known to be highly antigenic whereby its inactivated 
form is a major protective antigen found in all acellular pertussis vaccines to date. 
Hence a third generation of attenuated B. pertussis was recently developed (Mielcarek 
et. al., 2006). In this strain, PT has been inactivated, the DNT-encoding gene has been 
deleted, and the production of tracheal cytotoxin has been reduced. Mice infected with 
this BPZE1 strain showed greatly reduced lung inflammation compared to those 
infected with the wild-type strain and despite being highly attenuated, BPZE1 was 
still able to colonize the respiratory tract and induce strong protective immunity after 
a single nasal administration. In addition, protection against B. pertussis by BPZE1 
immunization was significantly better than that induced by two injections of acellular 
vaccine in infant mice. BPZE1 thus represents a promising live pertussis vaccine 
candidate. Moreover, it also appears to be an attractive candidate as a live 
recombinant vector for heterologous antigen delivery, which has yet to be explored.  
 
2.9.3   FHA as an Antigen Carrier 
 
FHA is both secreted and surface-exposed by B. pertussis. It induces strong 
mucosal and systemic antibody responses in humans (Isacson et. al., 1995) and mice 
(Cahill et. al., 1995) upon infection by the bacteria, and vaccination with purified 
FHA confers immune protection in mice (Sato et. al., 1984). Together with its 
adjuvant properties (Poulain-Godefroy et. al., 1998; 2003), FHA is thus highly 
suitable for use as a carrier to secrete foreign antigens into the extracellular milieu or 
to present foreign antigens at the bacterial surface of B. pertussis-based live 
recombinant vaccines. Sm28GST from S. mansoni has been fused to FHA in a BPRA 
background, and homologous and heterologous protection was achieved in mice after 
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a single intranasal administration of the live recombinant bacteria (Mielcarek et. al., 
1998).  
Owing to its large size (220 kDa), FHA is difficult to purify in large quantities 
and precipitates easily, leading to storage problems. A truncated form of FHA 
corresponding to the first 80-kDa N-terminal half of the mature protein (Fha44), has 
been described and was found to be produced in higher amounts and secreted more 
efficiently by B. pertussis than full-length FHA (Renauld-Mongenie et. al., 1996b). 
Although Fha44 was more efficiently expressed, it was found to be much less 
immunogenic than FHA, stimulating anti-FHA IgG production only in the presence of 
an adjuvant (Alonso et. al., 2005). Subsequently, Fha44 was used as a carrier for 
several antigens, including the Neisseria meningitidis transferring-binding protein B 
(TbpB) (Coppens et. al., 2001), TTFC from V. cholera (Reveneau et. al., 2002) and 
HtrA from nontypeable Haemophilus influenzae (Alonso et. al., 2005). In this last 
study by Alonso et. al., the FHA-HtrA chimera was found to elicit higher anti-HtrA 
serum antibody levels than the Fha44-HtrA chimera, suggesting that the C-terminal 
moiety in mature FHA contains immunodominant/adjuvant activity.  
The efficient secretion of FHA across the outer membrane necessitates a 
totally unfolded conformation of the protein. The folding of a passenger protein into a 
globular conformation prior to FhaC-mediated export was found to be incompatible 
with secretion (Guedin et. al., 1998). When secretion is hampered, both the FHA 
moiety and the passenger protein are readily degraded in B. pertussis (Reveneau et. al., 
2002). Not surprsingly, cysteine-containing passenger proteins like the cholera toxin 
B subunit (Guedin et. al., 1998) or TTFC of V. cholera (Reveneau et. al., 2002) were 
poorly secreted when fused to FHA and Fha44. Such limitations therefore make FHA 
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unsuitable for presenting many heterologous passengers, calling for the development 
of alternative antigen display systems.  
 
2.9.4   Other Potential Antigen Carriers 
 
 So far, only FHA has been explored as a carrier for presentation of 
heterologous antigens by live recombinant B. pertussis. Other B. pertussis virulence 
factors, however, also provide potential means of foreign antigen presentation. An 
example is ACT, which can penetrate a variety of eukaryotic cells (Basler et. al., 
2006). This property has been effectively harnessed and purified AC toxoids with 
disrupted catalytic activity but intact penetrating capability are becoming potent new 
tools for delivering vaccinal CD8+ T-cell epitopes into the cytosol of major 
histocompatibility complex (MHC) class I antigen-presenting cells (Osicka et. al., 
2000). Purified recombinant AC toxoids have also been successfully used for antigen 
delivery and induction of protective anti-viral responses (Fayolle et. al., 2001). 
Despite the fact that both ACT and its toxoids have been shown to have good 
antigenicity and adjuvanticity (MacDonald-fyall, et. al., 2004), ACT has not been 
evaluated as a carrier to present heterologous vaccine candidates in live B. pertussis 
bacteria.  
Autotransporters have been successfully used in E. coli and Salmonella 
species to present heterologous antigens at the bacterial surface (Kjærgaard et. al., 
2002; Kramer et. al., 2003; Lattemann et. al., 2000; Zhu et. al., 2006). Moreover, the 
efficient translocation of folded protein domains containing Cys residues across the 
bacterial outer membrane by autotransporters has been demonstrated (Veiga et. al., 
2004), thereby overcoming a limitation of the FHA display system. One of the 
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limitations encountered when using autotransporters as display systems is the size of 
the heterologous antigen fused to the passenger domain. B. pertussis encodes for 
several autotransporters among which BrkA has been most studied and characterized. 
Recently, it was found by Oliver et. al. (2003b) that a truncated form of BrkA, with a 
substantial deletion in the passenger domain from amino acid residues A52 to P600, 
could still be efficiently translocated and exposed at the cell surface. This finding thus 
raises the possibility of using the B. pertussis BrkA protein as a carrier by replacing 
part of its passenger domain with heterologous vaccine candidates. In addition, the 
passenger domain of BrkA has been shown to be immunogenic and possesses 
adjuvant properties (Cainelli Gebara et. al., 2006). All these suggest that BrkA is a 
promising carrier for heterologous vaccine candidates in live B. pertussis bacteria, 
awaiting further investigation. 
 
(C)   HAND, FOOT AND MOUTH DISEASE: A THREATENING  
        CHILDHOOD DISEASE 
 
2.10   ENTEROVIRUS 71 (EV71) 
 
2.10.1   Phylogeny and Classification 
 
Enteroviruses belong to the Picornaviridae family, which is subdivided into 
nine genera (Palmenberg and Sgro, 2002). This family includes several important 
pathogens of humans and domestic animals (Hughes, 2004), such as enteroviruses, 
rhinoviruses and hepatoviruses. A rooted phylogenetic tree based on the primary 
sequence of selected picornavirus polyproteins is shown in Figure 2.9.  
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Enteroviruses, as their name suggests, infect mainly through the gut, and 
members of this genera include the echoviruses, polioviruses, coxsackie A and B 
viruses and other enteroviruses types 68 to 71 (EV68-EV71) (Sawyer, 2001). Eighty-
nine enterovirus serotypes have been identified so far and 64 are known to infect 
humans (Pallansch and Roos, 2001). In 2000, the human enteroviruses were 
reclassified into five species and they now consist of human enteroviruses A to D 
(HEVA-HEVD) and polioviruses (King et. al., 2000). EV71 is an emerging agent of 
infectious diseases belonging to the HEVA species (Palacios and Oberste, 2005).  
 
2.10.2   Structure, Properties and Genome 
 
Enteroviruses are small, non-enveloped viruses with a protein capsid shell 
arranged in icosahedral symmetry around the genome, which consists of a single-
stranded positive-sense RNA (Chambon et. al., 2004) (Figure 2.10). Known to be one 
of the most stable viruses, enteroviruses can survive for several weeks at room 
temperature, for months at 4oC and for years at –20oC. They are also relatively stable 
at acidic pH. However, they can be readily killed by moist heat at 50-55oC but this is 
less effective in the presence of organic material (Burns, 2002). Some features 
common to all enteroviruses include the ability to attach to and replicate in intestinal 
cells, the propensity to cause asymptomatic infections that can protect against future 
infections with the same virus, and the capacity to occasionally cause infection of the 
central nervous system (CNS). Generally, children are more susceptible to enterovirus 
infection than adults (Burns, 2002; Hyypia et. al., 1997).  
The EV71 RNA genome consists of a single open reading frame that encodes 
a polyprotein of 2194 aa (Singh et. al., 2002). The polyprotein can be divided into 
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three regions: P1, P2 and P3 (Palacios and Oberste, 2005). P1 encodes the four 
structural capsid proteins VP1 to VP4, while P2 and P3 encode seven non-structural 
proteins (McMinn, 2002) (Figure 2.11). The structural capsid proteins of EV71 play a 
significant role in its pathogenicity (Yeo and Chow, 2007). While VP4 is tucked 
within the RNA genome away from the virion surface, VP1, VP2 and VP3 are 
surface-exposed. The localization and folding arrangements of VP1 to VP3 are 
integral in the formation of a canyon structure, which forms the receptor-binding site 
for the virus to infect susceptible host cells (Rossmann et. al., 2002). Of the four 
capsid proteins, VP1 has been most extensively studied due to its good 
























Figure 2.9   Phylogenetic tree of polyprotein sequences of selected picornaviruses, 
rooted with those of Caliciviridae.  
Adapted from Hughes, 2004.   












Figure 2.10   Transmission electron microscopy image of enterovirus 
particles at 350,000x magnification. 
Adapted from 
http://www.tulane.edu/~dmsander/Big_Virology/BVRNApicorna.html 






































5’ UTR 3’ UTR 
P1 P2 P3 
Figure 2.11   Organization of the EV71 RNA genome. 
The single open reading frame is flanked by untranslated regions (UTRs) at the 5’ and 3’ 
ends, with a variable-length poly-A tail at the 3’ UTR. P1 region encodes four structural 
proteins while P2 and P3 regions encode seven non-structural proteins. 
Adapted from McMinn, 2002. 
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2.11   EV71 INFECTION AND HAND, FOOT AND MOUTH DISEASE (HFMD) 
 
2.11.1   Pathogenesis and Clinical Features 
 
EV71 is mainly transmitted via the oral-faecal route but transmission in the 
form of respiratory droplets is also possible (Lin et. al., 2002a). Upon entry into the 
host, EV71 mainly infects and replicates in gastrointestinal cells. Occasionally, 
however, secondary infections of other tissues and organs such as the CNS and 
muscle can occur (Palacios and Oberste, 2005). EV71 infection is linked to several 
diseases, most notable of which is hand, foot and mouth disease (HFMD).  
HFMD usually manifests as a mild childhood disease characterized by fever 
and vesicular eruptions on the hands, feet and mouth (Figure 2.12). HFMD can also 
be caused by coxsackievirus A type 4, 5, 9, 10 and coxsackievirus B type 2 and 5, but 
the most common etiological agents of the disease are coxsackievirus A type 16 
(CA16) and EV71 (Chan and AbuBaker, 2004). However, unlike CA16 and the other 
causative agents, EV71 has the propensity to cause severe neurological complications 
like encephalitis, meningitis and poliomyelitis-like paralysis, leading to significant 
morbidity and mortality (Ho et. al., 1999). In particular, children below five years of 
age have been found to be more susceptible to EV71-infection-related neurological 
complications due to low herd immunity (Shah et. al., 2003). 
EV71 infection involves diverse clinical manifestations and the pathogenesis 
of EV71-related fatalities remains unclear. A proposed pathogenesis profile is shown 
in Table 2.3, whereby disease progression is divided into four stages (Lin et. al., 
2002a). After an incubation period of 3-5 days following viral infection (Queensland 
Health, Communicable Diseases Branch, 2003), patients present with stage 1, 
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characterized by typical HFMD symptoms like fever, rashes and ulcers.  Most of them 
recover without sequelae within a week, with only a few progressing to the next stage. 
In stage 2, most patients present with subtle neurologic symptoms such as drowsiness, 
limb weakness, ataxia and myoclonic jerks, recovering with minimal sequelae within 
days to weeks. Some patients, however, go on to develop further complications. In the 
third stage, patients generally experience pulmonary edema, hypertension, cold sweat, 
hyperglycemia and myoclonic jerks. Pulmonary edema may eventually improve but 
neurologic and cardiovascular condition usually deteriorates and patients may 
subsequently develop hypotension instead. A 2002 study by Lin et. al. (Lin et. al., 
2002b) demonstrated that patients with EV71-related encephalitis and pulmonary 
edema had significantly elevated levels of serum proinflammatory cytokines, 
including IL-6, IL-1b and TNF-a. This cytokine storm has thus been postulated to be 
responsible, or at least in part, for the pathogenesis of EV71 infection involving 
pulmonary edema and cardiopulmonary failure. Finally, stage 4 is characterized by an 
almost-complete recovery of cardiac output function. Most survivors of severe EV71 
infection who experienced cardiopulmonary failure develop moderate to severe 
neurologic sequelae (Lin et. al., 2002a). Recently, it was found that EV71 triggers 
neuronal apoptosis by activating Abl-Cdk5 signaling (Chen et. al., 2007). In contrast, 
CA16 can only weakly stimulate Abl and not Cdk5. Cdk5 is a critical signaling 
effector of various neurotoxic insults in the brain. This study thus sheds some light on 



















Figure 2.12   Typical symptoms of HFMD.  

























Table 2.3   Proposed pathogenesis of severe EV71 infections. 








Stage Syndrome Underlying cause 
Incubation period: 3-5 days 
1 HFMD/herpangina - 
2 Encephalomyelitis Direct invasion or viremia 




4 Convalescence - 
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2.11.2   Epidemiology – The EV71 Threat 
 
EV71 was first isolated in California in 1969 (Schmidt et. al., 1974) and its 
association with HFMD was made in 1973 during the small epidemics in Sweden 
(Blomberg et. al., 1974) and Japan (Hagiwara et. al., 1978). It was in the last ten years, 
however, that there was a sudden surge in the scale of epidemics and 
neuropathogenicity of EV71-associated HFMD, particularly in the Asia-Pacific region. 
A summary of the main outbreaks from 1997 to present is presented in Table 2.4. In 
general, although both CA16 and EV71 were identified as the causative agents in the 
outbreaks, EV71 was mainly responsible for the severe and fatal cases, characterized 
by hepangina with neurological complications, and the appearance of neurogenic 
pulmonary edema associated with severe brainstem encephalitis.     
In 2006, Singapore saw over 3,000 cases of HFMD reported to the Ministry of 
Health (Singapore Ministry of Health Press Release, 2006). More significantly, an 
increase in the circulation of EV71 was observed, with EV71 found in about three-
quarters of patients, in contrast to 2004 when CA16 was the predominant strain. The 
number of HFMD cases in Singapore for 2006 and 2007 up to July is shown in Figure 
2.13. Generally, it is believed that EV71 activity is on the rise in the Asia-Pacific 
region and there is much concern in particular over EV71-associated HFMD due to its 
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2, 628 EV71 and 
CA16 
At least 29 Chan et. al., 
2000 
 
1998 Taiwan 130,000 EV71 (2/3 
of cases) 
and CA16 
78 Ho et. al., 1999; 





6,000 EV71 and 
CA16 
29 Cardosa et. al., 
2003; McMinn 
et. al., 2001 
 
2000 Singapore 4,000 EV71 (73% 
of cases) 
and CA16 
4 Ahmad, 2000; 





14, 505 Mainly 
EV71 




























Figure 2.13   Weekly incidence of HFMD in Singapore, 2006-2007. 
Adapted from Singapore Ministry of Health Weekly Infectious Disease 
Bulletin, 2007. 
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2.11.3   Disease Diagnosis, Treatment and Prevention 
 
Several methods have been developed for the detection of EV71 infection and 
they mainly involve isolation of the virus, serodiagnosis or detection of viral nucleic 
acids. The different methods and their advantages and disadvantages are listed in 
Table 2.5. Currently, a reliable method for early diagnosis of EV71 infection is still 
lacking. Conventional immunological methods like immunofluorescent assay 
(Manzara et. al., 2002) and neutralization testing (Melnick et. al., 1973) are very 
useful in diagnosis of biopsy specimens from patients who have been infected for a 
while, but are not very sensitive in detecting the virus in specimens with low viral 
titers, thereby limiting their ability to diagnose the infection early (Chen et. al., 
2006a). Detection of viral RNA with RT-PCR is sensitive at detecting low-copy viral 
nucleic acid and has been used to diagnose EV71 infection early (Pozo et. al., 1998). 
However, genomic information for many enterovirus serotypes is limited and there is 
a high genetic heterogeneity among different strains, so misdiagnosis may be frequent 
(Perera et. al., 2004). Recently, Chen et. al. (2006a) combined multiplex RT-PCR and 
microarray analysis to develop a high-throughput assay for sensitive and accurate 
detection of EV71. The method uses serotype-specific probes to detect multiple viral 
targets, enabling detection of EV71 within 6 h with a diagnostic accuracy of 92%. 
This method also allows differentiation between EV71 and CA16, with a diagnostic 
accuracy of 95.8% for CA16.       
There is as yet no specific antiviral drug against EV71 and treatment remains 
symptomatic to provide relief from fever and pain. ‘WIN’ compounds, which are 
prototype drugs for curing colds, are most often used in anti-EV71 therapy but are 
rather ineffective in disease regression (Barnard 2006). A limited number of antiviral 
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agents are now being developed, including synthetic compounds like pyridazinyl 
oxime ethers, which targets the viral capsid proteins (Barnard et. al., 2004), and the 
use of RNA interference (RNAi) technology to treat EV71 infection (Lu et. al., 2004). 
Natural products like allophycocyanin (Shih et. al., 2004a) and lactoferrin (Lin et. al., 
2002c) have also been found to exhibit some anti-EV71 properties, mainly by their 
ability to bind to the viral capsid proteins, in particular VP1. A major disadvantage of 
antiviral drugs, however, is that treatment may be too late, given that the virus may 
have already caused substantial damage to the patient’s brain upon infection. Thus, 
preventing infection in the first place would be a more pro-active and ideal strategy.  
In the absence of readily available vaccines, the current strategy of preventing 
EV71 infection has to rely on public health surveillance and good hygiene practices. 
EV71 is excreted in large numbers from the gut, causing infection upon accidental 
ingestion (Burns 2002). This may occur by direct transfer from fingers or eating 
utensils, as well as through contaminated food and water. As the virus may survive on 
surfaces for up to several weeks, contact with soiled objects may also lead to infection 
(Burns 2002). Transmission of EV71 infections is increased by poor hygiene and 
overcrowded living conditions (Singapore Ministry of Health website, 2007). Thus, 
good hygiene practices like frequent handwashing, wiping and sanitizing of tables and 
covering the mouth and nose with tissue when coughing or sneezing can substantially 
lower the risk of infection and spread. In times of outbreaks, proper quarantine 



















Advantages Disadvantages References 
Tissue culture and 
neutralization assay  
Gold standard. Requires virus culture, 
which is time-
comsuming and 









detection of virus. 
Requires virus culture, 
which is time-
consuming and 
tedious. Dependent on 






Sensitive and rapid 
(within a day). 
Requires specific and 




Real-time RT-PCR Very sensitive, 
specific and rapid 
(within an hour). 
Direct use of clinical 
samples. 
Requires specific and 
expensive reagents and 
equipment. Need for 
skilled personnel. 
Tan et. al., 
2006. 
ELISA Low cost. Easy to 
perform so reduced 
need for experienced 
personnel. Relatively 




Antigen used needs to 
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2.12   DEVELOPMENT OF EV71 VACCINES 
 
2.12.1   Inactivated Virus Vaccines   
 
Previous work by Yu et. al. (2000) confirmed the protective role of antibodies 
in EV71 infection. They showed that passive transfer of serum from adult mice 
infected with live EV71 conferred protection against the virus in neonatal mice. In 
addition, they found that maternal immunization with a formalin-inactivated whole-
virus vaccine prolonged pup survival after EV71 challenge. Taking into consideration 
both their results and the nature of EV71 infection, they thus concluded that 
vaccination was the best strategy against EV71 infection.  
 Subsequently, Wu et. al. (2002) demonstrated that mice receiving inactivated 
whole virus vaccine developed protective immunity against EV71 while Lin et. al. 
(2002d) reported the characterization of a vero cell-adapted virulent strain of EV71 
suitable for use as an inactivated virus vaccine. More recently, a microcarrier cell 
culture process aimed at large-scale production of inactivated EV71 vaccines was 
developed and optimized (Wu et. al., 2004; Liu et. al., 2007).  
 
2.12.2   Subunit Vaccines 
 
In addition to an inactivated virus vaccine, Wu et. al.(2002) developed two 
subunit vaccines. Upon comparison of the three, they found that the inactivated virus 
elicited the greatest immune response. This is not surprising as inactivated whole 
virus vaccines with highly organized, complex structures have been shown to activate 
B cells more efficiently (Bachmann et al., 1996; Fehr et al., 1998) and were cross-
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presented more efficiently than soluble antigens on MHC I complexes, thereby 
inducing stronger cytotoxic T-cell responses (Shen et al., 1997). However, the high 
reactogenicity associated with cellular vaccines remains a major public concern, 
thereby prompting the development of safer subunit vaccines. In addition, virus 
production and purification on a large scale has yet to be optimized and remains 
problematic. Subunit vaccines thus allow this step to be by-passed. 
There have been numerous reports demonstrating the VP1 capsid protein to be 
the most immunogenic protein of enteroviruses  (Emini et al., 1982; Henke et al., 
2001; Ranganathan et. al., 2002). The predicted size of VP1 protein is about 32 kDa 
(Lal et. al., 2006). Previous computational analysis has predicted the multimeric self-
association of VP1 proteins (Raganathan et. al., 2002) and recently, Lal et. al. (2006) 
demonstrated this VP1 self-interaction and identified the region spanning amino acids 
66-297 as the dimerization domain. VP1 has also been shown to interact with several 
human proteins expressed in the brain and bone marrow, namely ornithine 
decarboxylase (ODC1), KIAA0697 and gene trap ankyrin repeat (GTAR) (Yeo and 
Chow, 2007). Such interactions have provided insight into the role of VP1 in the 
pathogenesis of HFMD, particularly in the neurological complications involved. In 
addition, RNA interference inhibiting expression of VP1 and other viral proteins has 
been shown to specifically attenuate EV71 replication (Lu et. al., 2004; Sim et. al., 
2005). Even single site-directed mutagenesis of the VP1 sequence has been found to 
confer virus resistance to imidazolidinones (Shih et. al., 2004b). In view of its 
significance, it is thus not surprising that VP1 is the prime target antigen in most 
EV71 subunit vaccine studies. 
The intraperitoneal (i.p.) injection of VP1 recombinant protein and 
intramuscular (i.m.) administration of VP1 DNA vaccine into maternal mice was 
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found to confer protection against lethal EV71 challenge in newborn mice (Wu et al., 
2002). Subsequently, it was found that recombinant Newcastle Disease Virus capsids 
displaying EV71 VP1 fragments could raise anti-EV71 antibodies but the antibodies 
failed to neutralize the virus (Sivasamugham et. al., 2006). In the same year, 
transgenic tomatoes expressing VP1 were engineered (Chen et. al., 2006b). It was 
found that these transgenic fruits could elicit humoral and cellular immunity against 
EV71 upon feeding to mice. In addition, Wong et. al. (2007) developed anti-EV71 
DNA vaccine constructs by inserting the vp1 gene from two EV71 isolates into a 
eukaryotic expression vector, pVAXI. Mice immunized (i.m.) with the DNA vaccines 
successfully developed neutralizing anti-VP1 IgG antibodies but the IgG levels 
declined after the second boost. Recently, Tan and Cardosa (2007) showed by indirect 
ELISA that high-titred human neutralizing antibodies to EV71 were significantly 
more reactive with the N-terminal half of VP1 than weak or negative sera. They thus 
concluded that the N-terminal half of VP1 is likely to have important immunogenic 
determinants in humans. Interestingly, two neutralizing epitopes in the C-terminal half 
of VP1 named SP55 and SP70 were also identified (Foo et. al., 2007a). Particularly, it 
was found that SP70 could elicit a neutralizing antibody titer comparable to that 
obtained using the whole virus, making it an attractive antigen candidate in the 
development of subunit vaccines against EV71. These two aforementioned studies are 
not in fact contradictory, as the former does not exclude the possibility of other 
neutralizing epitopes in the C-terminal region of VP1 and since the latter was 
conducted in mice, it remains to be seen if these two epitopes are also capable of 
eliciting neutralizing antibodies in humans. 
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2.12.3   Live Recombinant Vaccines 
 
 In recent years, there have been a few studies on the development of 
recombinant EV71 vaccines using live vectors. These studies mainly looked at the 
oral route of immunization. The successful display of VP1 epitopes on the surface of 
Lactococcus lactis was shown by Raha et. al. (2005). This provides the possibility of 
developing a recombinant L. lactis-based oral EV71 vaccine. In the following year, 2 
attenuated Salmonella strains were used as vectors to express VP1 (Chiu et. al., 2006). 
It was found that maternal immunization with these Salmonella-based EV71 vaccines 
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Chapter 3:   MATERIALS AND METHODS 
 
(A)   ESCHERICHIA COLI WORK 
 
3.1   BACTERIAL STRAINS, PLASMIDS AND GROWTH CONDITIONS 
 
3.1.1   E. coli Strains and Plasmids 
 
















Ampr, Kanr; high copy number TA cloning vector; LacZa 
gene for blue/white screening 
Invitrogen 
pBR322 Ampr, Tetr; Low copy number cloning vector Bolivar et. al., 
1977 
pUC19 Ampr; High copy number cloning vector; LacZa gene for 
blue/white screening 
Yanisch-




Gmr, Sms; Low copy number suicide vector Quant and 
Hynes, 1993 
Plasmids for FHA-(SP70)3 Cloning 
TOPO1 Ampr, Kanr; TOPO® derivative with HindIII-HindIII fhaB 
fragment containing BglII RE site 
This study 
pBRSY0 Ampr, Tetr; pBR322 derivative with HindIII-HindIII fhaB 
fragment containing BglII RE site, from TOPO1 
This study 
pBRSY1 Ampr, Tetr; pBRSY0 derivative with BglII-opsp70 fragment This study 
pBRSY2 Ampr, Tetr; pBRSY1 derivative with BglII-opsp70 fragment This study 
pBRSY3 Ampr, Tetr; pBRSY2 derivative with BglII-opsp70 fragment This study 
pJQSY1 Gmr, Sms; pJQ200mp18-rpsl derivative with HindIII-HindIII 
fhaB-(opsp70)3 fragment 
This study 
Plasmids for BrkA-(SP70)3 Cloning 
pUCSY0 Ampr; pUC19 derivative with HindIII-HindIII brkA1-brkA2 
fragment containing BamHI site 
This lab (Ho 
S.Y.) 
pUCSY1 Ampr; pUCSY0 derivative with BamHI-opsp70 fragment This study 
pUCSQ1 Ampr; pUCSY1 derivative with BamHI-opsp70 fragment This lab 
(Chua S.Q.) 
pUCSQ2 Ampr; pUCSQ1 derivative with BamHI-opsp70 fragment This lab 
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(Chua S.Q.) 
pJQSY2 Gmr, Sms; pJQ200mp18-rpsl derivative with HindIII-HindIII 
brkA1-(opsp70)-brkA2  fragment 
This study 
pJQSQ1 Gmr, Sms; pJQ200mp18-rpsl derivative with HindIII-HindIII 
brkA1-(opsp70)3-brkA2  fragment 
This lab 
(Chua S.Q.) 
Plasmids for KO-CAPS Cloning 
TOPO2 Ampr, Kanr; TOPO® derivative with HindIII-SalI hmmp 
fragment 
This study 
TOPO3 Ampr, Kanr; TOPO® derivative with SalI-EcoRI wcbO 
fragment 
This study 
pJQSY3 Gmr, Sms; pJQ200mp18-rpsl derivative with HindIII-SalI 
hmmp fragment 
This study 






a. Ampr, Kanr, Tetr, Gmr refer to resistance to ampicillin, kanamycin, tetracycline and gentamicin respectively. Sms 




Table 3.1   E. coli strains and plasmids. 
 
 
3.1.2   Growth Conditions 
 
 All E. coli strains were grown at 37oC overnight in 3 ml fresh Luria-Bertani 
(LB) broth (Difco, Detroit, Mich.) with shaking at 220 rpm, or on LB agar (Difco). 
When appropriate, 50 or 100 mg/ml ampicillin, 50 mg/ml kanamycin or 10 mg/ml 
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3.2   MOLECULAR BIOLOGY 
 
3.2.1   Oligonucleotides and Primers  
 
3.2.1.1   List of oligonucleotides and primers 
 
The sequences of the oligonucleotides and primers (Sigma) are shown in 
Table 3.2. When necessary, restriction sites (in bold) were engineered into the 5’ ends 
of the primers to facilitate cloning. The annealing temperature (TA) of the primers are 
calculated as follows: 
4 × N(G/C) + 2 × N(A/T) - 5 
where N(G/C) and N(A/T) represent the number of G & C bases, and A & T bases 
respectively. 
 
3.2.1.2   Hybridization of oligonucleotides  
 
Ten μl of 50 mM of each of the sense and anti-sense oligonucleotides were 
mixed in a boiling water bath and left to cool slowly to room temperature, allowing 

















Name Sequence 5’ to 3’ 




























Table 3.2   Oligonucleotides and primers used for E. coli work. 
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3.2.2   Plasmid Extraction 
 
Plasmid DNA was isolated and purified using the QIAprep Spin Miniprep Kit 
(Qiagen) following manufacturer’s instructions. High and low copy number plasmids 
were eluted with 50 ml and 30 ml of deionised water respectively.  
 
3.2.3   Polymerase Chain Reaction (PCR) 
 
3.2.3.1   DNA amplification 
 
The HotStarTaq® PCR Kit (Qiagen) was used to carry out all PCR reactions 
according to manufacturer’s instructions, and using the GeneAmp® PCR System 
2400 thermal cycler (PE Applied Biosystems, Foster City, CA). The PCR reaction 
was initiated at 95ºC for 15 min, followed by 25 to 35 cycles of DNA denaturation at 
95ºC for 45 s, primer annealing at TA for 50 s and extension at 72ºC for 1 to 2 min (~1 
min per 1 kb DNA). Finally, an elongation time of 10 min at 72ºC was included to 
allow complete extension of the PCR products. 
 
3.2.3.2   Colony PCR screening 
 
A loopful of bacteria was dissolved in 30 μl of ultrapure water, heated at 95ºC 
for 10 min and centrifuged at 13,000 rpm for 5 min. PCR was performed as described 
in Section 3.2.3.1 for 35 cycles, using 5 μl of the supernatant as template.  
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3.2.4   Restriction Enzyme Digestion 
 
 DNA digestion was carried out with the appropriate restriction enzymes (RE) 
in their corresponding buffers (New England Biolabs, Ipswich, MA) following 
manufacturer’s protocol. When only one RE was involved or when the two REs 
shared buffer compatibility, a single-step digestion of 1 to 2 h at 37oC was performed. 
When two or more REs with incompatible buffers were involved, sequential digestion 
was carried out; after the initial digestion, the first RE was heat inactivated according 
to manufacturer’s instructions, followed by membrane dialysis (Millipore, Billerica, 
MA) against deionized water for 10 min before setting up the second digestion 
reaction. Analysis of the restriction profile was conducted by DNA gel electrophoresis 
(Section 3.2.5). 
 
3.2.5   Agarose Gel Electrophoresis 
 
3.2.5.1   Gel migration 
 
DNA/RNA electrophoresis was performed using 0.8% to 1.5% agarose in 1x 
Tris-acetate (TAE) running buffer (0.04 M Tris-acetate and 0.001 M ethylenedinitrilo 
tetraacetic acid (EDTA), pH 7.8). Each DNA/RNA sample to be analyzed was mixed 
with 1/5 volume of 6x loading dye (0.25% bromophenol blue, 0.25% xylene cyanol 
and 25% Ficoll in water) before being loaded into the gel wells. 5 ml of 1 kb or 100 bp 
DNA ladder (Promega and Research Biolabs) were used as markers for estimation of 
band size.  Electrophoresis was carried out at 80 V for 45 min, after which the gel was 
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stained in 0.5 mg/ml of ethidium bromide solution (Invitrogen) for 15 min before 
viewing under an ultra-violet (UV) transilluminator (ChemiGenius, Syngene, UK). 
 
3.2.5.2   Gel extraction 
 
After agarose gel electrophoresis, the DNA fragments of interest were cut 
under low UV light (366 nm) (to prevent DNA damage and/or mutations) and gel-
extracted using the QIAquick Gel Extraction and PCR Purification Kit (Qiagen, 
Mississauga, Ont.) according to manufacturer’s protocol.  
 
3.2.6   DNA Cloning 
 
Digestion (Section 3.2.4) with the appropriate RE(s) was performed on 
plasmid DNA to open up the vectors and generate the inserts. Both digested vectors 
and inserts were electrophoresed on agarose gel and the DNA bands of interest were 
excised and purified from the gel as shown in Section 3.2.5. Cloning of inserts into 
the TOPO® vector was performed using the TOPO® TA Cloning Kit (Invitrogen, 
Carlsbad, CA) while DNA inserts were ligated into the pBR322, pUC19 and pJQ 
vectors using the Fast-LinkTM DNA Ligation Kit (Epicentre Technologies, Madison, 
WI). Recircularization of vectors digested with a single RE was prevented by 
dephosphorylation with alkaline phosphatase (Research Biolabs, Singapore) 
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3.2.7   Transformation of Chemically Competent E. coli 
 
Chemically competent One Shot® TOP10 E. coli (Invitrogen) were 
transformed with slight modifications to manufacturer’s protocol. Half volume of 
ligation mix was added to one vial of TOP10 cells and mixed gently. The tube was 
incubated on ice for 30 min, followed by a heat shock at 42ºC for 45 s. The tube was 
then immediately transferred to ice and 500 μl of LB medium without antibiotics was 
added to the mixture. After incubation at 37ºC for 1 h, 100 μl of transformation 
mixture was plated on LB agar supplemented with the appropriate antibiotic or on 
imMediaTM Amp Blue ready-mix agar (Invitrogen) for blue/white screening. The 
plates were incubated at 37ºC overnight. 
 
3.2.8   DNA Sequencing 
 
 Plasmids from the recombinant clones were sent for DNA sequencing 
(Research Biolabs) with suitable primers (Table 3.2). Alignment of the obtained 
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(B)   BORDETELLA PERTUSSIS WORK 
 
3.3   BACTERIAL STRAINS AND GROWTH CONDITIONS 
 
3.3.1   B. pertussis Strains 
 
 The B. pertussis strains used in this study are summarized in the following 
table.  
 
Strain  Descriptiona Source/ 
Reference 
BPZE1 Attenuated TohamaI derivative, mutant rpsL, ptx gene 
mutated (inactive pertussis toxin), dermonecrotic 
toxin gene deleted, ampG gene overexpressed 
(reduced tracheal cytotoxin production); Smr 
Pasteur Institute 
of Lille 
BPSY13.1 BPZE1 derivative expresssing FHA-(SP70)3 chimera This study 
BPSY1 BrkA-knockout BPZE1 This lab (Ho 
S.Y.) 
BPSY15.3 BPZE1 derivative expressing BrkA-(SP70) chimera This study 
BPSQ5 BPZE1 derivative expressing BrkA-(SP70)3 chimera This lab (Chua 
S.Q.) 
BPSM TohamaI derivative, mutant rpsL; Smr Pasteur Institute 
of Lille 
BPSY2 Capsule-knockout BPSM This study 
 
 
a. Smr refers to resistance to streptomycin. 
 
Table 3.3   B. pertussis strains.    
 
3.3.2   Growth Conditions 
 
All B. pertussis strains were grown at 37ºC on pre-warmed sterile Bordet- 
Gengou (BG) agar (Difco) supplemented with 1% glycerol and 10% defibrinated 
sheep blood or in pre-warmed sterile modified Stainer-Scholte (SS) medium 
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containing 1 g/L 2,6-O-dimethyl-ß-cyclodextrin (Sigma) as described previously 
(Menozzi et. al., 1991). When appropriate, 10 μg/ml gentamicin or 100 μg/ml 
streptomycin (Sigma) were added to select for antibiotic-resistant strains. 
 
3.4   MOLECULAR BIOLOGY 
 
3.4.1   List of Primers 
 
















                         
 








Name Sequence 5’ to 3’ 









Primers for Southern Blot Probe Synthesis 
P1-F tgctcgccgttcttcgatcg 
P2-R tcctggacctcgcgcatatc 
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3.4.2   Transformation of B. pertussis 
 
3.4.2.1   Preparation of electrocompetent cells 
 
Ten ml of bacteria exponentially grown (OD600 4 to 5) in SS medium were 
centrifuged at 7,000 rpm for 10 min at room temperature, and the pellet was washed 
three times in 10 ml of sterile 10% glycerol. After the final wash, the pellet was 
resuspended in 1 ml of 10% glycerol and the cells were immediately used for 
electroporation. 
 
3.4.2.2   Electroporation of plasmid DNA into B. pertussis 
 
Between 100 ng to 1 mg of plasmid DNA was mixed with 200 ml of 
electrocompetent B. pertussis cells in an electroporation cuvette (0.2 cm) (Biorad 
Laboratories, Hercules, CA), and an electrical pulse of 2.5 kV, 800 W resistance and 
25 mF capacitance was administered. One ml of pre-warmed SS medium without 
antibiotics was then added to the cells and the bacteria was incubated for 5 h at 37oC 
with shaking, before plating 200 ml of cells onto pre-warmed BG agar plates 
containing the appropriate antibiotic and incubating for 5-7 days at 37oC. 
 
3.4.3   Selection of Transformants 
 
Gentamicin-resistant (Gmr) colonies obtained upon electroporation were   
patched onto streptomycin and gentamicin plates, in this order. Clones were observed 
within 24 h and streptomycin-sensitive (Sms), Gmr clones were identified as 
Chapter 3: Materials and Methods 
 88
transformants that had successfully undergone the first event of recombination. These 
intermediate strains were streaked onto a streptomycin plate to allow the second event 
of recombination to occur. After incubation at 37ºC for 5-7 days, 10 isolated Smr 
colonies were patched onto gentamicin and streptomycin plates, in this order. Gms, 
Smr clones were identified as having undergone the second event of recombination. 
 
3.4.4   Screening for True Recombinants 
 
Colony PCR screening was performed on the Smr, Gms clones to 
genotypically distinguish true recombinants from revertant clones. Preparation of the 
template DNA was performed as described in Section 3.2.3.2 except that the 
dissolved bacteria was heated for 30 min instead of 10 min. PCR was carried out as 
shown in Section 3.2.3.1 for 35 cycles using appropriate primers (Table 3.4) followed 
by agarose gel electrophoresis to analyze the PCR products (Section 3.2.5.1). When 
necessary, colony PCR screening was also performed on the Gmr, Sms intermediate 
clones to confirm integration of the pJQ construct.  
 
3.4.5   Chromosomal DNA Extraction 
 
A 10 ml B. pertussis liquid culture exponentially grown in SS medium was 
centrifuged at 8,000 rpm for 10 min and DNA extraction was carried out using the 
Genomic-tip 100/G Anion-Exchange Resin and Genomic DNA Buffer Set (Qiagen) 
according to manufacturer’s instructions. The final DNA precipitate was dissolved in 
0.5 to 1 ml of ultrapure water at 4oC overnight. The extracted chromosomal DNA was 
visualized by DNA gel electrophoresis (Section 3.2.5.1) using 0.8% agarose and 
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quantified by measuring the OD260 of the dissolved DNA solution using Beckman 
Quartz cuvettes. 
 
3.4.6   Southern Blot Analysis 
 
3.4.6.1   Synthesis of DIG-labeled probes 
 
Probes for Southern blot analysis were synthesized and labeled with 
digoxigenin (DIG) using the PCR DIG Probe Synthesis Kit (Roche) according to 
manufacturer’s instructions. An unlabeled control reaction without the addition of the 
PCR DIG labeling mix was included to evaluate probe-labeling efficiency. 
Amplification was conducted in the GeneAmp® PCR System 2400 thermal cycler 
(PE Applied Biosystems, Foster City, CA) using the primers P1-F and P2-R (Table 
3.4) with the following conditions: initial denaturation at 95oC for 2 min, followed by 
35 cycles of DNA denaturation at 95oC for 30 s, primer annealing at 59oC for 30 s, 
and DNA elongation at 72oC for 1 min. Finally, an additional 7 min of DNA 
extension at 72oC was included, after which the reaction was maintained at 4oC. The 
synthesized probe was analyzed and quantified by gel electrophoresis (Section 3.2.5.1) 
on a 1% agarose gel and purified from the gel as described in Section 3.2.5.2. 
 
3.4.6.2   Southern blot 
 
 Prior to Southern blot, 3 mg of B. pertussis chromosomal DNA was digested 
with the appropriate RE(s) (Section 3.2.4) for 4 h. The digested DNA was subjected 
to gel electrophoresis (Section 3.2.5.1) on a 1% agarose gel, which was then soaked 
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twice in depurination solution (0.25 M hydrochloric acid) for 10 min with gentle 
agitation, rinsed in deionised water, soaked twice in denaturation solution (5% 10 N 
sodium hydroxide solution, 8.75% sodium chloride) for 15 min, and finally soaked 
twice in neutralization solution (7.7% ammonium acetate, 0.2% 10 N sodium 
hydroxide solution) for 30 min. The DNA fragments were then transferred onto a 
nitrocellulose membrane (Millipore) as described in Figure 3.1. Before assembly, the 
nitrocellulose membrane was pre-wet in neutralization solution. 
After 2 h of transfer, the membrane was UV-fixed for 1 min, then equilibrated 
in 10 ml of pre-heated DIG Easy Hyb solution (Roche) at 65oC for 20 min, with 
gentle agitation. About 5-25 ng/ ml of denatured DIG-labeled DNA probe was added 
to the membrane in the DIG Easy Hyb solution and incubated in a hybridization oven 
at 65oC overnight. Denaturation of the DIG-labeled probe was performed by boiling 
at 95oC for 5 min and immediately transferring to ice. After hybridization, the 
membrane was washed twice in 2x SSC (0.15 M sodium chloride and 0.015 M 
sodium citrate) containing 0.1% SDS for 5 min at room temperature, followed by 2 
wash steps in 0.1x SSC containing 0.1% SDS for 15 min at 68oC. 
Blocking, washing and immunological detection was done using the DIG 
Wash and Block Buffer Set (Roche) according to manufacturer’s instructions. 
Detection was performed with an alkaline phosphatase (AP)-conjugated anti-DIG 
antibody (Roche) at a dilution of 1:5000, and revelation was carried out using 
NBT/BCIP AP substrate (Chemicon, Temecula, CA).  
 





3.4.7   RNA Extraction 
 
An equal volume of RNAlater solution (Qiagen) was added to 3 ml of an 
exponentially-grown B. pertussis liquid culture before centrifuging at 8,000 rpm for 
10 min at 4oC. The pellet was then resuspended and incubated for 5 min in 100 ml of 
Tris-EDTA buffer containing 2 ml of 20 mg/ ml lysozyme (Sigma). RNA extraction 
from B. pertussis was performed using the RNeasy Mini Kit (Qiagen) following 
manufacturer’s instructions. On-column DNase digestion was performed using the 
RNase-free DNase Set (Qiagen) according to manufacturer’s protocol. To further 
remove any traces of contaminating DNA, the eluted RNA was treated with Turbo 
DNA-free DNase (Ambion) following manufacturer’s instructions. The final treated 
RNA was quantified by measuring the OD260 of the RNA solution using Beckman 
Quartz cuvettes and visualized by agarose gel electrophoresis (Section 3.2.5.1) on a 
1% gel. To protect the RNA from RNase degradation, the electrophoresis apparatus 




1 3M WhatmanTM filter paper 
Nitrocellulose membrane 
Gel 
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3.4.8   Reverse-Transcription Polymerase Chain Reaction (RT-PCR) 
 
The OneStep RT-PCR Kit (Qiagen) was used to carry out RT-PCR on B. 
pertussis RNA using appropriate primers (Table 3.4). A 50 ml reaction mix was set up 
for each RT-PCR according to manufacturer’s instructions and both reverse 
transcription and subsequent cDNA amplification were carried out in a single reaction 
in the GeneAmp® PCR System 2400 thermal cycler (PE Applied Biosystems, Foster 
City, CA). RNA reverse transcription was carried out at 50ºC for 30 min, followed by 
incubation at 95oC for 15 min to inactivate the reverse transcriptase, activate the 
HotStarTaq DNA polymerase and denature the cDNA. Thirty cycles of 94ºC for 45 s, 
63oC for 50 s and 72ºC for 40 s were performed. Analysis of the RT-PCR products 
was done by agarose gel elctrophoresis on a 1.2% gel (Section 3.2.5.1). 
 
3.5   PROTEIN EXPRESSION STUDIES 
 
3.5.1   Preparation of B. pertussis Samples 
 
3.5.1.1   Supernatant 
 
Ten ml of exponentially-grown B. pertussis liquid culture was centrifuged at 
7,000 rpm for 10 min at room temperature. The pellet was stored at –80oC until 
further use and the supernatant was subjected to further spinning for 10 min at 
maximum speed, to remove any remaining cell debris. An equal volume of 2x protein 
loading buffer (1 M Tris-HCl at pH 6.8, 100% glycerol, b-mercaptoethanol, 
bromophenol blue, 20% SDS) was then added to 500 ml of the clarified supernatant 
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and the mixture was heated at 95oC for 15 min, and stored at –20oC until further use. 
When necessary, the supernatant was concentrated up to 10 times using the Ultra-4 
Centrifugal Filter Device (Amicon) following manufacturer’s protocol before adding 
the protein loading buffer and heating. 
 
3.5.1.2   Cell extract 
 
The bacterial pellet was thawed and resuspended in 500 μl of RNAse-free 
water, after which an equal volume of protein loading buffer was added and the 
mixture heated at 95ºC for 15 min. The chromosomal DNA was sheared by passing 
the suspension 10 times through a 27G needle followed by heating at 95ºC for 15 min 
and stored at -20ºC until further use. 
 
3.5.2   Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis  
           (SDS-PAGE) 
 
Protein separation was conducted under denaturing conditions via SDS-PAGE 
using a vertical slab gel unit (Hoefer, San Francisco CA, USA) according to 
manufacturer’s instructions. The slab gel was made up of a 4% polyacrylamide 
stacking gel and a 8% or 12% polyacrylamide separating gel, both containing 10% 
SDS. Cell extract and supernatant samples were heated at 95ºC for 5 min immediately 
before loading onto the SDS-gels. 15 μl of BenchMarkTM Pre-Stained Protein Ladder 
(Invitrogen) was used as the molecular weight standard. Electrophoresis was 
conducted in 1x Novex Tris-Gly SDS Running Buffer (Invitrogen) at 25 mA/ gel for 
45 min.  
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3.5.3   Coomassie Blue Staining 
 
To visualize the protein bands after electrophoresis, the SDS-gel was soaked 
in Coomassie Staining Solution (0.2% Coomassie Billiant Blue, 45% ethanol, 10% 
acetic acid) for 1-2 h with constant shaking. The gel was then soaked in Destaining 
Solution (25% ethanol, 10% acetic aid) with constant shaking until the protein bands 
could be visualized as sharp blue bands against a clear background. The gel was then 
rinsed in water and dried between a piece of 3M Whatman™ filter paper and a piece 
of clear cellophane in a BioRad Gel Dryer (Hercules, CA, USA) for 2 h at 80ºC. 
 
3.5.4   Western Blot 
 
After SDS-PAGE, the separated proteins were electro-transferred to a 
nitrocellulose membrane (Bio-Rad) at 65 mA for 2-4 h using a semi-dry transfer 
system (OWL). Prior to assembly (Figure 3.2), the gel, membrane and filter papers 
were soaked in Transfer Buffer containing 1x Towbin Buffer (Bio-Rad) and 20% 
methanol for 15 min. After transfer was complete, the membrane was blocked 
overnight in blocking buffer (1% BSA, 1x TBS, 0.1% Tween20) at 4ºC. The 
membrane was then incubated with the appropriate primary antibody (Table 3.5) 
diluted in blocking buffer for 1 h, with gentle shaking at room temperature, followed 
by 3 washings in an excess of washing buffer (1x TBS, 0.1% Tween20) for 10 min. 
After that, the appropriate AP-conjugated secondary antibody diluted in blocking 
buffer (Table 3.5) was added to the membrane and incubated for 1 h, with gentle 
shaking at room temperature, followed by washing as described above. Finally, the 
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antibody-reactive bands were revealed by chromogenic detection upon adding 
NBT/BCIP AP substrate (Chemicon, Temecula, CA). 
 
 
Table 3.5   Antibodies used in Western Blot. 
 
 
3.5.5   Fluorescence-Activated Cell Sorting (FACS) 
 
3.5.5.1   Preparation for FACS 
 
B. pertussis bacteria grown on BG agar were resuspended in 5 ml of sterile 
PBSG (1x PBS, 5% glycerol), centrifuged at 7,000 rpm for 10 min at room 
temperature, and washed again in the same buffer. Bacterial concentration was 
Primary Antibody Dilution Secondary Antibody 
(Alkaline phosphatase conjugated) 
Dilution 
Mouse anti-SP70 antiserum 
(Kind gift from A/P Poh) 
1:100 Goat anti-mouse IgG (H+L) 
(Sigma) 
1:3,000 
Anti-FHA monoclonal antibody 
(Kind gift from Renauld-
Mongenie et. al., 1996a) 
1:250 Goat anti-mouse IgG (H+L) 
(Sigma) 
1:3,000 
Rabbit anti-BrkA antiserum 
(Kind gift from Oliver et. 
al., 2003b) 
1:30,000 Goat anti-rabbit IgG (H+L) 
(Sigma) 
1:3,000 
Figure 3.2   Western blot transfer sandwich. 
2 pieces 3M WhatmanTM filter paper 
Nitrocellulose membrane 
Gel 
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adjusted to 106 cfu in 500 ml of PBSG. The bacterial suspension was then incubated 
with rabbit anti-BrkA antiserum (Oliver et. al., 2003b) diluted 1:200, for 2 h at 4ºC 
with constant agitation. This was followed by centrifugation at 7,000 rpm for 10 min 
and 3 wash steps in 5 ml of PBSG. The pellet was then resuspended in 500 μl of 
PBSG and incubated with CyTM2-conjugated goat anti-rabbit IgG (Jackson 
Laboratories, West Grove, PA) diluted 1:100, for 2 h at 4ºC with constant agitation. 
After that, the suspension was centrifuged at 7,000 rpm for 10 min, followed by 3 
wash steps in 5 ml of PBSG. Finally, the pellet was resuspended in 100 μl of sterile 1x 
PBS, to which an equal volume of 4% paraformaldehyde was added to fix the cells. 
 
3.5.5.2   FACS 
 
100 ml of each sample was diluted with 700 μl of BD FACSFlowTM sheath 
fluid (Becton-Dickinson, Heidelberg, Germany) prior to FACS profiling. A Coulter 
Epics machine (Beckman Coulter, Palo Alto, CA) was used for the flow cytometric 
study. Samples were analyzed with laser excitation at 488 nm, and data acquisition 
was performed using EXPO Version 2.0 software (Applied Cytometry Systems, 
Sheffield, U.K.) and analyzed with WinMDI-2.8 software. 
 
3.5.6   Immunofluorescence 
 
  The samples for immunofluorescence were prepared as described in Section 
3.5.5.1 before loading the cells onto poly-L-lysine-treated microscope slides. To treat 
the slides, 100 μl of 0.1% poly-L-lysine (Sigma) was spread evenly onto each clean 
glass slide, which was then incubated at 37ºC for 20 min. Excess poly-L-lysine was 
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discarded and the slides were washed with distilled water and air-dried. After that, 
100 μl of fixed bacteria were spread on a slide and one drop of the anti-fading agent 
VectorShieldTM (Oxford Instruments Analytical, U.K.) was added before placing a 
cover slip over each mount. The specimens were viewed under blue light excitation 
(488 nm) using an epifluorescence microscope with 1000x magnification (BX40, 
Olympus, Japan). Phase-contrast and fluorescent images were captured digitally. 
 
 
(C)   VIRUS WORK 
 
3.6   PROPAGATION OF RHABDOMYOSARCOMA (RD) CELLS 
 
3.6.1   Regeneration and Maintenance of Cell Lines 
 
RD cells were propagated in T75 flasks (Nunc) in minimum essential medium 
(MEM) (Gibco, Boston, MA, USA) supplemented with 5% fetal calf serum (FCS), 
1% sodium pyruvate and 1.5% sodium bicarbonate. Each cell line was regenerated 
from 1 ml of cells previously frozen down and stored in liquid nitrogen. The cells 
were incubated at 37oC with 5% carbon dioxide and allowed to grow to confluency, 
usually within 2-3 days, after which they were routinely passaged each time they 
reached confluency to maintain the cell line.  
To passage the cells, the cell monolayer was washed thrice with 10 ml of 
sterile 1x PBS, followed by adding 2 ml of pre-warmed 1x Trypsin-EDTA (0.5%) 
(Gibco). After 1-2 min incubation at room temperature, 8 ml of pre-warmed fresh 
growth media was added to the trypsinized cells and the suspension of RD cells were 
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then split into new tissue culture flasks containing additional pre-warmed fresh media 
and incubated at 37oC with 5% carbon dioxide. 
 
3.6.2   Freezing Down Cells for Storage 
 
RD cell lines were preserved to maintain cells at a low passage. The cells 
obtained from a confluent T75 flask were resuspended in 1 ml of fresh growth media 
containing 10% dimethyl sulphoxide (DMSO) and transferred to a cryo-vial. A 
gradual freezing process was performed: -20oC for 2 h, followed by -80oC overnight, 
followed by liquid nitrogen for long-term storage. 
 
3.7   GROWTH AND PURIFICATION OF EV71  
 
 EV71 strain 41 (5865/SIN/00009) was propagated in RD cells grown as 
described in Section 3.6.1. The infected cells were harvested and completely lysed by 
3 freeze-thaw cycles. To purify the virus, 1 L of virus-cell suspension was centrifuged 
at 10,000 g for 20 min at 4oC, and the virus was precipitated from the supernatant 
with 2.3% sodium chloride and 7% polyethylene glycol 8000 at 4oC overnight. The 
suspension was then centrifuged at 10,000 g for 20 min at 4oC and the pellet was 
resuspended in 10 ml of sterile TN buffer (50 mM Tris-HCl, 50mM sodium chlroride, 
pH7.8) and further centrifuged at 3,000 g for 30 min at 4oC. The supernatant was then 
centrifuged on a 30% sucrose cushion at 25,000 g for 4 h at 4oC, after which the 
purified viral pellet was resuspended in 1 ml of sterile 1x PBS and stored at –20oC 
until further use.  
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3.8   VIRUS INACTIVATION AND QUANTIFICATION 
 
 The virus was inactivated by heating at 56oC for 30 min. Quantification of the 
virus was carried out by Bradford Assay (macromethod) according to manufacturer’s 
instructions. A range of bovine serum albumin (BSA) (New England Biolabs) from 
0.1 to 1 mg/ml was used as the standard. 
 
3.9   IN-VITRO MICRO-NEUTRALIZATION ASSAY 
 
3.9.1   Determination of Virus TCID50 
 
 The virus titer was expressed as 50% tissue culture infective dose (TCID50) in 
RD cells based on a typical cytopathic effect (CPE) produced by EV71 infection. 
TCID50 was determined using the method of Reed and Muench (1938). Briefly, RD 
cells were seeded in a sterile 96-well microtiter plate (Corning, COSTAR) at a 
concentration of 50,000 cells per well and incubated at 37oC with 5% carbon dioxide 
overnight. The next day, 50 ml of serially-diluted virus was added to each well of cells 
and incubated at 37oC with 5% carbon dioxide. The cells were observed under the 
microscope 48 h later and TCID50 was determined as the virus dilution that caused 
50% cell death. 
 
3.9.2   Virus Neutralization Assay 
 
Twenty-five μl of two-fold serial dilutions (neat to 1:128) of heat-treated 
(56oC, 30 min) sera were mixed with equal volumes of 103 TCID50 of virus in a sterile 
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96-well microtiter plate and incubated at 37ºC with 5% carbon dioxide. Two hours 
later, 100 μl of RD cell suspension containing 50,000 cells was added to each well 
and incubated at 37ºC with 5% carbon dioxide. Two days later, the cells were 
observed for CPE and the neutralizing antibody titer was read as the highest dilution 
of serum that inhibited virus growth and prevented CPE. Each serum sample was 
assayed in duplicate and each neutralization assay was repeated twice independently. 
 
 
(D)   ANIMAL WORK 
 
3.10   MOUSE STRAINS 
 
Ten-weeks-old female CD1 outbred mice and 6-weeks-old female Balb/c mice 
were purchased from Biological Resource Center, Biopolis, Singapore. The mice 
were kept under specific pathogen-free (SPF) conditions in individual ventilated cages 
(IVCs). All experiments were carried out under the guidelines of the National 
University of Singapore animal study board. 
 
3.11   INTRANASAL INFECTION 
 
B.pertussis strains grown on BG agar were resuspended in sterile PBST (1x 
PBS, 0.05% Tween80) and adjusted to a concentration of 2.5 × 107 or 2.5 × 108 cfu/ 
ml. Infection of mice was performed by the intranasal route with 20 μl of bacterial 
suspension deposited in the nostrils of each animal, sedated with an anaesthetic 
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cocktail (6% valium, 10% atropine, 20% ketamine, 64% 1x sterile PBS) administered 
intraperitoneally (100-150 μl per mouse). 
 
3.12   LUNG COLONIZATION STUDY 
 
Four CD1 mice per group were sacrificed at the indicated time points after 
intranasal infection with the various B. pertussis strains. The lungs from each mouse 
were aseptically removed and homogenized in 2.5 ml or 5 ml of sterile PBST using 
the High Shear homogenizer (Omni International, Research Biolabs). Serially diluted 
lung homogenates from individual mice were then plated onto BG agar and the total 
cfu per lung was determined after 4-5 days of incubation at 37ºC. Each colonization 
experiment was repeated twice independently. 
 
3.13   IMMUNIZATION STUDY 
 
3.13.1   Immunization Schedule and Serum Collection 
 
Balb/c mice were intranasally infected twice at a 4-weeks interval as described 
in Section 3.11. Two weeks after the boost, blood was collected from the sedated 
mice by retro-orbital plexus puncture and allowed to clot overnight at 4ºC, followed 
by centrifuging at 5,000 rpm for 10 min and the serum was stored at -20ºC until 
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3.13.2   Enzyme-Linked Immunosorbent Assay (ELISA) 
 
3.13.2.1   Coating antigens 
  
The titers of anti-B. pertussis and anti-SP70 antibodies were measured by 
ELISA using BPZE1 total cell lysate and unconjugated SP70 peptide (Mimotopes Pte 
Ltd, Clayton Victoria, Australia) as coating antigens, respectively. To prepare the 
BPZE1 total cell lysate, 10 ml of exponentially grown BPZE1 liquid culture was 
centrifuged at 7,000 rpm for 15 min at room temperature. The pellet was washed three 
times with 5 ml of sterile 1x PBS and resuspended in 1 ml of 1x PBS. The suspension 
was sonicated on ice 15 times for 15 s each, with intervals of 15 s (Model 150V/T 
Ultrasonic Homogenizer, BioLogics Inc., Manassas, VA). Total protein concentration 
of the lysate was measured using the NanoDrop® ND-1000 spectrophotometer 
(NanoDrop, Wilmington, DE, USA). 
 
3.13.2.2   Determination of Antibody Titer 
 
Ninety-six-well microtiter plates (Corning COSTAR, NY, USA) were coated 
overnight at 4ºC with 50 μl of coating buffer (0.1 M NaHCO3, pH 9.6) containing 10 
μg/ ml of BPZE1 total cell lysate or 20 μg/ ml of unconjugated SP70 peptide. The 
wells were washed three times with 100 μl of wash buffer (1x PBS, 0.1% Tween20), 
before blocking with 50 μl of blocking buffer (1x PBS, 0.1% Tween20, 2% BSA) for 
1 h at room temperature. The wells were then washed once and 50 μl of mouse serum 
diluted at 1:800 (for anti-B. pertussis antibodies detection) or 1:50 (for anti-SP70 
antibodies detection) in blocking buffer was added to each well. After incubation at 
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37ºC for 1 h, the plate was washed thrice before adding 50 μl of 1:3,000 diluted 
horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (H+L) secondary 
antibody (Sigma). The plates were again incubated at 37ºC for 1 h followed by 5 
washes. The ELISA was developed by adding 50 μl of o-phenylenediamine 
dihydrochloride (OPD) substrate (Sigma) to each well and incubating at room 
temperature for 30 min in the dark. To stop the reaction, 75 μl of 1 M sulphuric acid 
was added to each well and absorbance at 490 nm was measured using the Biorad 
model 680 Microplate Reader and recorded with the Microplate Manager 5.2 software 
(Biorad). IgG subtyping was carried out using HRP-conjugated goat anti-mouse IgG1, 
IgG2a, IgG2b and IgG3 secondary antibodies (Jackson Laboratories) at 1:5,000 
dilution. 
 
3.14   NEUTROPHIL INFLUX ASSAY 
 
Balb/c mice were intranasally infected with B. pertussis strains as described in 
Section 3.11 except that a concentration of 2.5 × 107 cfu/ ml of bacteria was used 
instead. At 1 and 2 days post-infection, 4 mice per group were sacrificed and 
bronchoalveolar lavage fluids (BALFs) were recovered from each mouse by passing 1 
ml of sterile 1x PBS twice through the lungs. The BALFs were centrifuged at 450 g 
for 5 min and the pellet was resuspended in 500 ml of 1x red blood cell lysis solution 
(CLB, Promega). After 1 min of incubation, an equal volume of 1x PBS was added to 
stop the reaction, followed by centrifugation at 450 g for 5 min to remove the lysed 
red blood cells in the supernatant. The pellet was washed twice in 500 ml of PBS and 
finally resuspended in 200 ml of PBS. The cells were spun down onto a glass slide 
using Shandon single cytofunnels (Thermo Electron Corporation, Pittsburgh, PA) in 
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the Cytospin3 centrifuge (Thermo Shandon) at 800 rpm for 5 min with medium 
acceleration. The slide was air-dried and the cells were stained using the Hemacolor 
kit (Merck) according to manufacturer’s instructions. The number of neutrophils for a 
total of 500 cells was estimated under an upright microscope at 40x magnification. 
The experiment was repeated twice independently.  
 
3.15   STATISTICAL ANALYSIS 
 
Statistical analysis of all results was performed using the unpaired Student t 
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Chapter 4:   COMPARISON BETWEEN TWO B. PERTUSSIS ANTIGEN  
                      CARRIER SYSTEMS FOR EV71 ANTIGEN SP70 
 
4.1   RESULTS 
 
4.1.1   Construction of Recombinant B. pertussis Strains Expressing SP70 
 
4.1.1.1   Design and synthesis of optimized sp70 (opsp70) 
 
The neutralizing SP70 peptide covers nucleotides 3063-3017 of the VP1 
capsid protein of EV71 strain 5865/Sin/000009 (Foo et. al., 2007a). To prevent any 
problems in protein translation due to codon usage (Yazdani et. al., 2006), the sp70 
DNA sequence was optimized to B. pertussis codon usage preference as shown in 
Figure 4.1. For the FHA-(SP70)3 chimera, the forward and reverse strands of opsp70 
named FSP70-S and FSP70-A respectively (Table 3.2), were synthesized and 
annealed to give double stranded opsp70 with BglII-compatible ends to clone the 3 
copies of SP70 into FHA. For the BrkA-(SP70)3 chimera, the forward and reverse 
strands of opsp70 named BSP70-S1 and BSP70-A1 respectively (Table 3.2), were 
synthesized and annealed to give double stranded opsp70 with BamHI-compatible 
ends to clone the first copy of SP70 into BrkA. To clone the second and third copies 
of SP70, the forward and reverse strands of opsp70 named BSP70-S2 and BSP70-A2 
respectively (table 3.2), were synthesized and annealed to give double stranded 
opsp70 with BamHI-compatible ends. This was necessary to keep the brka-(sp70)3 
gene in frame.      
 
 



















Figure 4.1   Codon optimization of sp70.  
The original sp70 gene sequence (unopSP70) is aligned with its optimized 
sequence (opSP70). Substituted nucleotides are indicated in red. AA encoded 
by the codons (in blue) remain unchanged.  
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4.1.1.2   Cloning opsp70 into fhaB  
 
 Three copies of SP70 were cloned in tandem into FHA as follows: A 1620-bp 
fhaB fragment encompassing the unique BglII site in FHA was PCR-amplified from B. 
pertussis BPZE1 chromosomal DNA using the primers FHA1-F and FHA2-R (Figure 
4.2). The PCR product was then sequenced and transferred into pBR322 plasmid 
(Bolivar et. al., 1977) to obtain pBRSY0 (Figure 4.3). A first copy of opsp70 was 
cloned into BglII-digested pBRSY0 such that only the 3’ terminal BglII site was 
restored. A second and third copy of opsp70 were then sequentially added using the 
same procedure to eventually yield pBRSY3 (Figure 4.3). Finally, the entire fhaB-
(opsp70)3 fragment was cloned into the suicide vector pJQ200mp18-rpsl (Quant and 
Hynes, 1993) to give pJQSY1 (Figure 4.3). RE digestion analysis (Figure 4.4) and 
colony PCR screening (Figure 4.5) were used to screen for and verify the E. coli 
































1620-bp fhaB fragment 
FHA1-F FHA2-R 
Figure 4.2   Schematic diagram showing the 1620-bp HindIII-HindIII fhaB 
fragment cloned into pBRSY0. 
The fragment spanning nucleotide 5221 to 6840 of fhaB gene was PCR 
amplified from B. pertussis BPZE chromosomal DNA using primers FHA1-F 
and FHA2-R (block arrows) with HindIII sites incorporated at the two ends. 
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Figure 4.3   Overview of cloning strategy for FHA-(SP70)3. 
 





Figure 4.4   RE digestion profiles of recombinant plasmid constructs for cloning 
opsp70 into fhaB. 
A: HindIII digestion of pBRSY0 constructs. Lanes: M, 1 kb ladder (5 ml); C, 
HindIII-treated pBR322 vector as negative control (10 ml); 1-3, E. coli clones 1-3 
transformed with pBRSY0 (10 ml). All clones gave the expected 1620-bp fhaB 
fragment. B: HindIII digestion of pJQSY1 constructs. Lanes: M, 1 kb ladder (5 
ml); C, HindIII-treated pJQ vector as negative control (10 ml); 1-3, E. coli clones 1-3 
transformed with pJQSY1 (10 ml). All clones gave the expected 1782-bp fhaB-
(sp70)3 fragment. 
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Figure 4.5   Colony PCR screening of recombinant plasmid constructs for 
cloning opsp70 into fhaB.  
A: PCR screening strategy to differentiate between pBRSY1, pBRSY2 and 
pBRSY3 constructs. Primers FHA3-F and FHA4-R (block arrows) (Table 3.2) 
were used to carry out PCR on E. coli transformed with the various constructs to 
give different band sizes allowing differentiation between the 1, 2 and 3-copy 
constructs. B: PCR screening for pBRSY1, pBRSY2 and pBRSY3-positive E. 
coli transformants. Lanes: M, 100 bp ladder (5ml); C, pBRSY0 construct as 
negative control (10 ml); 1, pBRSY1 construct (10 ml); 2, pBRSY2 construct (10 ml); 
3, pBRSY3 construct (10 ml). Only 1 positive clone per construct showing the 
expected PCR fragment is represented. The light band obtained for pBRSY0 is due 
to some non-specific primer annealing.    
 
75 bp (1 copy opsp70) 
B 
100 bp 
129 bp (2 copies) 
183 bp (3 copies) 200 bp 
















 183 bp 
Chapter 4: Comparison between two Antigen Carriers 
 112
4.1.1.3   Cloning opsp70 into brkA 
 
 Plasmid pUCSY0 was previously constructed in the lab (Ho, S.Y.) and 
contains a 1-kb brkA1 fragment with HindIII and BamHI sites at the 5’ and 3’ ends 
respectively, and a 945-bp brkA2 fragment with BamHI and HindIII sites at the 5’ and 
3’ ends respectively (Figure 4.6). The first copy of opsp70 was cloned into BamHI-
digested pUCSY0 such that only the 3’ BamHI site was restored, to yield pUCSY1 
(Figure 4.7). The second and third copies of opsp70 were sequentially cloned into 
pUCSY1 using the same procedure to eventually give pUCSQ2 (Chua, S.Q.) (Figure 
4.7). Finally, the entire BrkA-(SP70) and BrkA-(SP70)3 fragments were digested from 
pUCSY1 and pUCSQ2 respectively with HindIII and each cloned into pJQ200mp18-
rpsl plasmid digested with the same RE to give pJQSY2 and pJQSQ1 respectively 
(Figure 4.7). E. coli clones successfully transformed with the various constructs were 
screened and verified using colony PCR screening (Figure 4.8) and RE digestion 
analysis (Figure 4.9). In addition, DNA sequencing was performed using primers 




























































Figure 4.6   Schematic diagram showing the localization of brkA1 and brkA2 
fragments in B. pertussis genome. brkA1 includes the first 300 nucleotides of 
brkB, the promoter region P shared by the 2 divergent genes, and the first 150 
nucleotides of brkA. brkA2 extends from nucleotide 790 to 1734 of brkA. The 
region between nucleotides 151 to 789 of brkA is removed and replaced by the 

















































































  brkA2 
Insertion of opsp70 1st  




































  opsp703 















Figure 4.8   Colony PCR screening of recombinant plasmid constructs for 
cloning opsp70 into brkA.  
A: PCR screening strategy to differentiate between pUCSY1, pUCSQ1 and 
pUCSQ2 constructs. Primers BrkA1-F and BrkA2-R (block arrows) (Table 3.2) 
were used to carry out PCR on E. coli transformed with the various constructs to 
give different band sizes allowing differentiation between the 1, 2 and 3-copy 
constructs. B: PCR screening for pUCSY1, pUCSQ1 and pUCSQ2-positive E. 
coli transformants. Lanes: M, 100 bp ladder (5ml); C, pUCSY0 construct as 
negative control (10 ml); 1, pUCSY1 construct (10 ml); 2, pUCSQ1 construct (10 ml); 
3, pUCSQ2 construct (10 ml). Only 1 positive clone per construct showing the 
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Figure 4.9   RE digestion profiles of recombinant plasmid constructs for cloning 
opsp70 into brkA. 
A: HindIII digestion of pJQSY2 constructs. Lanes: M, 1 kb ladder (5 ml); C, 
HindIII-treated pJQ vector as negative control (10 ml); 1-3, E. coli clones 1-3 
transformed with pJQSY2 (10 ml). All clones gave the expected 1998-bp brkA1-
(opsp70)1-brkA2 fragment. B: HindIII digestion of pJQSQ1 constructs. Lanes: M, 
1 kb ladder (5 ml); C, HindIII-treated pJQ vector as negative control (10 ml); 1-3, E. 
coli clones 1-3 transformed with pJQSQ1 (10 ml). All clones gave the expected 
2100-bp brkA1-(opsp70)3-brkA2 fragment. 
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4.1.1.4   Obtaining recombinant B. pertussis strains 
 
Electrocompetent BPZE1 B. pertussis was separately electroporated with 
pJQSY1, pJQSY2 and pJQSQ1 constructs. The recombinant pJQ constructs were 
integrated into the B. pertussis genome via double homologous recombination as 
shown in Figure 4.10. pJQSY1 was integrated into the fhaB gene locus while pJQSY2 
and pJQSQ1 were integrated into the brkA gene locus. Gentamicin-resistant (Gmr) 
and streptomycin-sensitive (Sms) clones were PCR-screened for first event 
recombinants (Figure 4.11B, 4.12B and 4.13B). PCR-verified first event recombinants 
were then streaked on Sm plates to allow second event recombination. Isolated 
colonies were then patched on Sm and Gm plates whereby Smr and Gms clones were 
PCR-screened for second event recombinants (Figure 4.11C, 4.12C and 4.13C). 
Primers (Table 3.4) were designed to fulfill two purposes: 1) detect the integration of 
sp70 in first and second event recombinants and 2) verify the genomic locus into 
which the chimeric constructs were integrated in second event recombinants (Figure 






































Figure 4.10   Integration of opsp70 into B. pertussis fhaB or brkA gene locus 
via double homologous recombination.  
h1’ and h2’ represent the fhaB or brkA sequences flanking the opsp70 sequence 
in the pJQ constructs while h1 and h2 are the regions within the B. pertussis 
genome homologous to h1’ and h2’ respectively. Wild type rpsL gene, which 
causes streptomycin sensitivity (Sms) has a dominant effect over mutant rpsL 
gene (DrpsL), which gives rise to streptomycin resistance (Smr). Gmr: 
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Figure 4.11   PCR-based detection for FHA-(SP70)3 fusion first and second 
event recombinants.  
A: PCR screening strategy for first and second event recombinants. Primers 
FHA3-F and FHA4-R were used to screen for first event recombinants. Primers 
FHA3-F and FHA7-R were used to screen for second event recombinants. B: PCR 
screening for first event recombinants. Lanes: M, 100 bp ladder (5 ml); P, 
pJQSY1 as positive control (10 ml); N, BPZE1 chromosomal DNA as negative 
control (10 ml); 1-5, B. pertussis clones 1-5 (10 ml). All clones gave the expected 
183-bp band. C: PCR screening for second event recombinants. Lanes: M, 1 kb 
ladder (5 ml); N, BPZE1 chromosomal DNA as negative control (10 ml); 1-7, B. 
pertussis clones 1-7 (10 ml). Positive clones (1, 2, 4, 7) showing the expected 
1015-bp band are indicated in red. 
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Figure 4.12   PCR-based detection for BrkA-(SP70)1 fusion first and second 
event recombinants.  
A: PCR screening strategy for first and second event recombinants. Primers 
BrkA1-F and BrkA2-R were used to screen for first event recombinants. Primers 
BrkA1-F and BrkA6-R were used to screen for second event recombinants. B: PCR 
screening for first event recombinants. Lanes: M, 100 bp ladder (5 ml); P, pJQSY2 
as positive control (10 ml); N, BPZE1 chromosomal DNA as negative control (10 
ml); 1, B. pertussis clone 1 (10 ml). Only 1 Gmr, Sms clone was obtained from 
electroporation and it gave the expected 356-bp band. C: PCR screening for 
second event recombinants. Lanes: M, 1 kb ladder (5 ml); N, BPZE1 chromosomal 
DNA as negative control (10 ml); 1-10, B. pertussis clones 1-10 (10 ml). Positive 
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Figure 4.13   PCR-based detection for BrkA-(SP70)3 fusion first and second 
event recombinants.  
A: PCR screening strategy for first and second event recombinants. Primers 
BrkA1-F and BrkA2-R were used to screen for first event recombinants. Primers 
BrkA1-F and BrkA6-R were used to screen for second event recombinants. B: PCR 
screening for first event recombinants. Lanes: M, 100 bp ladder (5 ml); N, BPZE1 
chromosomal DNA as negative control (10 ml); P, pJQSQ1 as positive control (10 
ml); 1-9, B. pertussis clones 1-9 (10 ml). All clones gave the expected 458-bp band. 
C: PCR screening for second event recombinants. Lanes: M, 1 kb ladder (5 ml); 
N, BPZE1 chromosomal DNA as negative control (10 ml); 1-10, B. pertussis clones 
1-10 (10 ml). Positive clones (2, 4-10) showing the expected 1132-bp band are 
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4.1.2   Expression of FHA and BrkA Recombinant Proteins  
 
4.1.2.1   Western blot detection of FHA and BrkA chimera 
 
 Expression of the FHA-(SP70)3, BrkA-(SP70)1 and BrkA-(SP70)3 chimeric 
proteins by BPSY13.1, BPSY15.3 and BPSQ5 (Table 3.3) respectively, were 
analyzed by western blot using polyclonal mouse anti-SP70 antisera and monoclonal 
anti-FHA antibody or polyclonal rabbit anti-BrkA antisera (Table 3.5). The parental 
strain BPZE1 was included as a control for all three chimera, while a BrkA-knockout 
strain previously constructed in the lab, named BPSY1 (Table 3.3), was used as a 
negative control for the BrkA recombinant proteins.  
A 225-kDa band corresponding to the predicted size of FHA-(SP70)3 was 
detected in the culture supernatant of BPSY13.1 using anti-FHA and anti-SP70 
antibodies, while the 220-kDa band corresponding to wild type FHA in parental strain 
BPZE1 was only detected with anti-FHA (Figure 4.15A and 4.15B). This shows that 
the FHA-(SP70)3 chimera is efficiently produced and secreted by recombinant 
BPSY13.1 into the supernatant. The BrkA-(SP70)1 and BrkA-(SP70)3 fusion proteins 
were produced by replacing the region ranging from aa A52-H263 in the BrkA 
passenger domain with 1 or 3 copies of the SP70 peptide (Figure 4.14). Using anti-
BrkA and anti-SP70 antibodies, a 82-kDa band corresponding to the predicted size of 
full-length BrkA-(SP70)1 and a 52-kDa band corresponding to its passenger domain 
were detected in the BPSY15.3 cell extract (Figure 4.15C and 4.15D). Similarly, a 85-
kDa and a 55-kDa band corresponding to the molecular weight of full-length BrkA-
(SP70)3 and its passenger domain respectively, were detected in the BPSQ5 cell 
extract using both antibodies (Figure 4.15C and 4.15D). As expected, the 103-kDa 
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full-length wild type BrkA of parental strain BPZE1 and its 73-kDa passenger domain 
were revealed only with anti-BrkA, while no bands were detected for BPSY1 
regardless of antibodies used (Figure 4.15C and 4.15D). Together, these observations 
indicate that both BrkA-(SP70)1 and BrkA-(SP70)3 chimera are successfully produced 
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Figure 4.14   Schematic diagram of BrkA-(SP70)1/3 chimera.    
































                1                                     2 
220 kDa 
D 
52/ 55 kDa 
82/ 85 kDa 
        1                    2                    3                  4 
C 
52/ 55 kDa 
82/ 85 kDa 
103 kDa 
73 kDa 
          1                 2                  3                4 
Figure 4.15   Western blot detection of FHA-(SP70)3, BrkA-(SP70)1 and 
BrkA-(SP70)3 chimera.  
A: Detection of FHA-(SP70)3 using anti-FHA antibodies. Lanes: 1, BPZE1; 
2, BPSY13.1. 50 ml of ten-fold concentrated culture supernatant was loaded in 
each lane. B: Detection of FHA-(SP70)3 using anti-SP70 antibodies. Lanes: 
1, BPZE1; 2, BPSY13.1. 50 ml of ten-fold concentrated culture supernatant 
was loaded in each lane. C: Detection of BrkA-(SP70)1 and BrkA-(SP70)3 
using anti-BrkA antibodies. Lanes: 1, BPSY15.3; 2, BPSQ5; 3, BPSY1; 4, 
BPZE1. 10 ml of cell extract was loaded in each lane. D: Detection of BrkA-
(SP70)1 and BrkA-(SP70)3 using anti-SP70 antibodies. Lanes: 1, BPSY15.3; 
2, BPSQ5; 3, BPSY1; 4, BPZE1. 10 ml of cell extract was loaded in each lane.    
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4.1.2.2  Cell-surface exposition of BrkA chimera 
 
4.1.2.2.1   FACS analysis  
 
To further address whether the BrkA-(SP70)1/3 chimera are expressed on the 
bacterial surface, FACS was performed on intact, non-permeabilized bacteria using 
polyclonal anti-BrkA antiserum as the primary antibody. Parental strain BPZE1 
producing wild type BrkA and the BrkA-knockout BPSY1 were used as controls for 
the assay.  
As expected, 100% of BPZE1 cells tested positive for surface expression of 
BrkA (Figure 4.16). BPSY15.3 and BPSQ5 were found to express BrkA-(SP70)1 and 
BrkA-(SP70)3 respectively on the bacterial surface, with an average of 55% and 86% 
positive cells respectively, with p values > 0.05 as compared to BPZE1 (Figure 4.16). 
These data indicate that both chimera are surface-expressed as efficiently as wild type 
BrkA, suggesting that one or three copies of SP70 do not impair the secretion 
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Figure 4.16   Flow cytometric profiles of intact B. pertussis strains.  
A: FACS histograms of BPSY15.3 and BPSQ5 using anti-BrkA polyclonal 
antibodies. Graphs shown are representative of 2 independent experiments. Values 
indicated denote the percentage of fluorescent cells. B: Bar chart presenting the 
average values for 2 independent experiments. Results are expressed as means ± 
standard deviations. Statistically significant p value is marked with an asterisk.     
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4.1.2.2.2   Verification by immunofluorescence assay 
 
 
To further confirm the data obtained by FACS analysis, an 
immunofluorescence assay using anti-BrkA antiserum as the primary antibody was 
performed on intact B. pertussis strains. As shown in Figure 4.17 panels H, I and J, 
BPZE1, BPSY15.3 and BPSQ5 cells showed significant and comparable fluorescent 
signals while the negative controls of BPZE1 without primary antibodies and BrkA-
knockout BPSY1 showed no fluorescence emission (Figure 4.17 panels F and G). 
This further verifies that the fluorescence observed for BPZE1, BPSY15.3 and 
BPSQ5 cells is BrkA-specific.   
 Together, the results from FACS and immunofluorescence studies provide 
compelling evidence to show that both BrkA-(SP70)1 and BrkA-(SP70)3 are 
successfully transported across the bacterial cell wall and exposed at the surface of the 
recombinant bacteria. Through this study, it is demonstrated for the first time the 
possible use of BrkA as a carrier to express heterologous proteins on the surface of B. 
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Figure 4.17   Epifluorescence microscope images showing surface localization of BrkA, BrkA-(SP70)1 or BrkA-(SP70)3
in intact B. pertussis strains.  
Anti-BrkA antiserum was used to detect BrkA, BrkA-(SP70)1 or BrkA-(SP70)3 on the surface of intact BPSY1 (B and G), 
BPZE1 (C and H), BPSY15.3 (D and I) and BPSQ5 (E and J) cells. Panels A and F depict images from negative control 
whereby BPZE1 was treated exactly the same as the other samples except without addition of primary antibody. Panels A-E 
represent phase contrast images; Panels F-J show images seen under blue light excitation (488nm).   
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4.1.3   Lung Coloniztion by Recombinant B. pertussis Strains 
 
To investigate the ability of the recombinant B. pertussis strains to colonize 
the mouse respiratory tract, CD1 mice were nasally infected with the recombinant 
strains. The lung colonization profile of FHA-(SP70)3-producing BPSY13.1 was 
compared to that of the parental BPZE1 strain, while the BrkA-(SP70)1-producing 
BPSY15.3 and the BrkA-(SP70)3-producing BPSQ5 were compared to the BrkA-
knockout BPSY1 in addition to BPZE1. 
As seen in Figure 4.18A, the colonization profile of BPSY13.1 is similar to 
that of BPZE1 whereby both strains showed a peak of multiplication 3 days post-
infection, followed by progressive clearance from the lungs. This demonstrates that 
the insertion of 3 copies of SP70 into full-length FHA does not impair adhesion 
function of the protein. BPSY1, BPSY15.3 and BPSQ5, however, showed a slightly 
attenuated profile compared to wild type BPZE1, whereby they were gradually 
cleared from the lungs with no peak of multiplication (Figure 4.18B). Compared to 
that of BPZE1, the colonization efficiencies of these three strains were significantly 
reduced at 10 days post-infection (BPSY1, BPSY15.3, BPSQ5 with p = 0.04, 0.008, 
0.01 respectively). In addition, BPSY15.3 also colonized the lungs with a 
significantly lower efficiency than BPZE1 at 7 (p = 0.035) and 14 (p = 0.027) days 
post-infection. This suggests that the BrkA-(SP70)1 and BrkA-(SP70)3 chimera have 
not retained the full adhesion function of wild type BrkA. However, although the 
BrkA recombinant strains did not colonize the respiratory tract as efficiently as 
BPZE1, the bacteria were still able to persist in the lungs for up to 2 weeks post-
infection, likely ensuring suitable priming of the host immune system.  
C 
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Figure 4.18   Lung colonization by B. pertussis strains. 
A: Lung colonization profile of BPSY13.1. CD1 mice were infected intranasally 
with 5 × 106 cfu of B. pertussis BPZE1 (solid squares) or BPSY13.1 (open 
lozenges) at 0 h. The lungs were harvested at the indicated time points and viable 
bacteria in the lungs were counted after plating appropriate dilutions of the lung 
homogenates onto BG agar. 4 mice per group per time point were assessed 
individually. B: Lung colonization profile of BPSY15.3 and BPSQ5. CD1 mice 
were infected intranasally with 5 × 106 cfu of B. pertussis BPZE1 (solid squares), 
BPSY1 (open lozenges), BPSY15.3 (open squares) and BPSQ5 (solid triangles) at 
0 h. The lungs were harvested at the indicated time points and viable bacteria in 
the lungs were counted after plating appropriate dilutions of the lung homogenates 
onto BG agar. 4 mice per group per time point were assessed individually. Results 
are representative of two independent experiments. *: p < 0.05 as compared to 

















3 h 7 18 10 3
B 
Chapter 4: Comparison between two Antigen Carriers 
 131
4.1.4   Mice Systemic Antibody Response Elicited by Recombinant B. pertussis    
           Strains 
 
4.1.4.1   Comparison of serum IgG antibody levels 
 
To evaluate the systemic anti-B. pertussis and anti-SP70 antibody responses 
elicited by intranasal administration of the recombinant B. pertussis strains, groups of 
6 Balb/c mice were intranasally primed with 5 × 106 cfu of BPSY13.1, BPSY15.3, 
BPSQ5 or BPZE1, then boosted 4 weeks later with an equal amount of bacteria. A 
fourth group of mice was intraperitoneally injected with 10 mg of inactivated EV71 
(5865/Sin/000009 strain) following the same immunization schedule, and was used as 
the “gold standard” against which anti-SP70 antibody responses elicited by the 
recombinant B. pertussis strains were compared, while a last group of mice were left 
untreated.  
Two weeks after the boost, sera were collected and analyzed for the presence 
of anti-B. pertussis and anti-SP70 antibodies. High serum anti-B. pertussis IgG 
antibody titers were obtained for BPSY13.1, BPSY15.3 and BPSQ5-infected mice, 
with the levels comparable to that obtained for mice infected with BPZE1 (p>0.05) 
(Figure 4.19). As expected a low background level of anti-B. pertussis IgG was 
obtained for the EV71-injected and naïve mice (Figure 4.19). 
A significant serum anti-SP70 IgG antibody response was obtained for mice 
infected with BPSQ5 (Figure 4.20). However, no significant anti-SP70 antibody 
response was measured in BPSY15.3-infected mice. In addition, a significant anti-
SP70 antibody response was observed in BPSY13.1-infected animals, although the 
titers were significantly lower than that obtained in BPSQ5-infected mice. Two (mice 
M5 and M6) out of six BPSY13.1-infected mice produced significant anti-SP70 IgG, 
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in contrast to five out of six mice with significant anti-SP70 IgG levels for BPSQ5 
(Figure 4.20). Compared to the EV71-injected “gold-standard”, however, the antibody 
titers for both BPSY13.1- and BPSQ5-immunized mice were found to be significantly 
lower (Figure 4.20). A second boost performed 2 weeks after the first boost did not 
improve the anti-SP70 antibody response of all the groups (data not shown). 
Altogether, these data indicate that three, but not one copy of SP70, is able to 
induce a significant anti-SP70 antibody response in mice intranasally infected with 
the recombinant BrkA strain. Moreover, the BrkA-(SP70)3 chimera is able to induce a 
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Figure 4.19   Detection of anti-B. pertussis serum IgG antibodies. 
Mice were bled 2 weeks after the boost, and the antibody titers were 
determined by ELISA on individual serum diluted 1/800, using BPZE1 
whole cell lysate as coating antigen. Legend: Open lozenges – Mouse M1; 
Solid squares – Mouse M2; Open triangles – Mouse M3; Crosses – Mouse 
M4; Solid triangles – Mouse M5; Open squares – Mouse M6. Average is 














































* p = 4.3 x 10-12 
* p = 0.005 
p = 8.5 x 10-5 * 
p = 0.04 
* p = 0.001 
* 
Figure 4.20   Detection of anti-SP70 serum IgG antibodies. 
Mice were bled 2 weeks after the boost, and the antibody titers were 
determined by ELISA on individual serum diluted 1/50, using SP70 
peptide as coating antigen. Legend: Open lozenges – Mouse M1; Solid 
squares – Mouse M2; Open triangles – Mouse M3; Crosses – Mouse M4; 
Solid triangles – Mouse M5; Open squares – Mouse M6. Average is 
represented by a horizontal line. Readings are representative of two 
independent experiments. Statistically significant p values are marked with 
asterisks. 
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4.1.4.2   Isotyping of serum anti-SP70 IgG  
 
 The isotype profiles of the serum anti-SP70 IgG antibodies measured 2 weeks 
after the boost in the sera of BPSQ5- and BPSY13.1-infected mice were analyzed. 
Sera from the naïve, BPZE1- and EV71-infected mice were each pooled since there 
were little differences in the anti-SP70 IgG titers between individual mice within each 
of these groups (Figure 4.20), whereas sera from the six mice infected with BPSY13.1 
and BPSQ5 were individually assessed. Due to their undetectable anti-SP70 antibody 
response, sera from BPSY15.3-infected mice were not further assessed. 
As shown in Table 4.1, high anti-SP70 IgG1, IgG2a, IgG2b and IgG3 titers 
were induced after infection with EV71. Significant anti-SP70 IgG2a and IgG2b 
antibody levels were observed for all BPSQ5-infected mice except Mouse M3, which 
had the lowest anti-SP70 total IgG antibody level (Figure 4.20). On the other hand, 
only 2 BPSY13.1-infected mice (Mouse M5 and M6) had significant anti-SP70 IgG2a 
and IgG2b levels, while 1 mouse, M4, only had significant levels of IgG2a and 
another mouse, M1, only had significant levels of IgG2b. The other two mice (Mouse 
M2 and M3), which had the lowest anti-SP70 total IgG titer (Figure 4.20), had 
insignificant anti-SP70 IgG2a and IgG2b levels. IgG3 level was not significantly 
different from the level measured in naïve mice for all BPSQ5- and BPSY13.1-
infected mice. As for IgG1, only 1 mouse from each group (Mouse M6 from BPSQ5 
and Mouse M5 from BPSY13.1 group) had high levels of anti-SP70 IgG1. These 
animals displayed the highest anti-SP70 total IgG antibody titer in their respective 
groups (Figure 4.20). In conclusion, a predominant IgG2a/2b antibody response is 
observed in the BPSQ5- and BPSY13.1-immunized mice. 
 










0.13/0.19 2.34/2.03 2.17/2.00 1.42/0.39 M6 
0.12/0.17 2.54/1.33 0.65/1.42 0.10/2.16 M5 
0.09/0.08 1.21/0.08 1.52/0.71 0.09/0.27 M4 
0.10/0.07 0.22/0.07 0.13/0.07 0.10/0.09 M3 
0.11/0.09 2.27/0.08 1.57/0.08 0.11/0.08 M2 
0.11/0.07 1.62/0.78 0.80/0.25 0.18/0.22 M1 
    BPSQ5/ BPSY13.1 
2.33 2.36 2.23 2.36 EV71 
0.11 0.12 0.10 0.10 BPZE1 
0.11 0.11 0.08 0.12 Naïve 
IgG3 IgG2b IgG2a IgG1 
OD490nm immunogen 
Table 4.1   Serum anti-SP70 IgG isotype profiles. 
 Mice sera collected 2 weeks after the boost were analyzed by ELISA for the 
presence of specific anti-SP70 IgG1, IgG2a, IgG2b, and IgG3 antibody 
isotypes. Sera from individual mice of naïve, BPZE1 and EV71 groups were 
pooled while serum from each mouse of BPSQ5 and BPSY13.1 (in bold) 
groups was tested individually. Readings are representative of two 
independent experiments. 
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4.1.4.3   Kinetics of serum anti-SP70 IgG response 
 
The anti-SP70 antibody titer of all six mice from the BPSQ5 and BPSY13.1 
groups were monitored over a period of 8 weeks. The mice were bled 2, 6 and 8 
weeks after the boost, and ELISA was performed on sera collected at each time point. 
The highest background titer obtained from the negative control mice (naïve 
and BPZE1 groups) was used as the threshold value above which all antibody titers 
were considered positive for anti-SP70 IgG response. The anti-SP70 antibody titers 
from BPSQ5-immunized mice measured at 6 and 8 weeks were comparable to the 
titers measured at 2 weeks, with the exception of Mouse M4, whose titer dropped 
significantly although still above the threshold value (Figure 4.21A). The sera 
antibody titer of Mouse M5 and M6 of the BPSY13.1 group constantly remained 
significantly higher than the threshold value, while titer for the other four mice 
fluctuated around the threshold (Figure 4.21B). Overall, the BPSQ5- and BPSY13.1-
infected mice maintained their anti-SP70 total IgG antibody titers throughout the 8-
week period. These observations suggest that the systemic anti-SP70 antibody 
responses elicited in BPSQ5- and BPSY13.1-immunized mice are not transient but 
can be sustained for up to at least 2 months after the boost. In addition, the anti-B. 
pertussis antibody responses of all B. pertussis-immunized mice were sustained at a 

































Figure 4.21   Kinetics of serum anti-SP70 IgG antibody response. 
The anti-SP70 serum total IgG antibody titers of Mouse M1 (Open 
lozenges), Mouse M2 (Solid squares), Mouse M3 (Open triangles), 
Mouse M4 (Crosses), Mouse M5 (Solid triangles) and Mouse M6 
(Open squares) from the BPSQ5 group (A) and the BPSY13.1 group 
(B) were monitored over a period of 8 weeks. The antibody titer of 
each mouse was individually assessed by ELISA with SP70 peptide as 
the coating antigen. Antibody titer of pooled serum from EV71-injected 
mice obtained 2 weeks after the boost is denoted by a + sign. 
Horizontal dash line denotes the minimum value for serum positivity 
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4.1.4.4   Comparison of in vitro serum anti-EV71 neutralizing titer 
 
To test the neutralizing potential of the sera from BPSQ5- and BPSY13.1-
immunized mice against the EV71 5865/Sin/000009 strain, an in vitro neutralization 
assay was performed. Serially diluted sera were co-incubated with 103 TCID50 of live 
EV71 virus before infecting RD cells. Sera of individual mice from naïve, BPZE1-
infected and EV71-injected groups were pooled while those from the BPSQ5 and 
BPSY13.1 groups were individually assessed. Additional controls using uninfected 
and infected RD cells not incubated with any serum were included. 
The neutralizing antibody titer was read as the highest dilution of serum that 
inhibited virus growth and prevented cytopathic effect (CPE) of RD cells by 100%. 
RD cells that underwent CPE exhibited a rounded-up morphology in contrast to 
healthy, uninfected cells, which were flattened and spindle-shaped. After 48 h 
incubation, uninfected RD cells remained healthy and viable (Figure 4.22, Panel A) 
while infected RD cells underwent 100% CPE (Figure 4.22, Panel B). As expected, 
sera from the naïve and BPZE1-infected mice failed to prevent CPE even at neat 
concentrations (Figure 4.22, Panels C and D respectively). Complete protection of RD 
cells from CPE was observed for sera obtained from EV71-injected mice at a 
neutralizing titer of 128 (Figure 4.22, Panel E). 
Sera from all the BPSQ5-immunized mice displayed neutralizing activity to a 
certain extent, with the exception of Mouse M3 (Figure 4.22 Panels F-K), whose 
serum had an insignificant anti-SP70 total IgG titer (Figure 4.20). The highest 
neutralizing titer of 32 was obtained from serum of Mou se M1 (Figure 4.22, Panel F), 
M5 (Figure 4.22, Panel J) and M6 (Figure 4.22, Panel K), while sera of Mouse M4 
(Figure 4.22, Panel I) and M2 (Figure 4.22, Panel G) exhibited lower neutralizing 
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titers of 16 and 2 respectively. In contrast, only one out of the six BPSY13.1-
immunized mice, Mouse M5, displayed anti-EV71 neutralizing activity, up to a titer 
of 16 (Figure 4.22, Panel P). Sera from the other five mice offered no protection from 
CPE even at neat concentrations (Figure 4.22, Panels L-Q). The neutralizing activity 
of the sera from BPSQ5- and BPSY13.1-immunized mice is summarized in Table 4.2.  
 In conclusion, both BPSQ5 and BPSY13.1 are capable of eliciting serum anti-
EV71 neutralizing antibodies but the antibody response triggered by BPSQ5 is much 













































































neat 1/2 1/8 1/4 
1/16 1/32 1/64 1/128 
F 
G 
neat 1/2 1/4 1/8 
1/128 1/16 1/32 1/64 
H 
1/4 1/8 neat 1/2 
1/32 1/128 1/16 1/64 








































neat 1/2 1/4 1/8 
1/128 1/64 1/16 1/32 
J 
K 
neat 1/2 1/4 1/8 
1/16 1/32 1/64 1/128 
I 
neat 1/2 1/4 1/8 
1/16 1/64 1/128 1/32 




























































neat 1/2 1/4 1/8 
1/16 1/32 1/64 1/128 
M 
neat 1/2 1/4 1/8 
1/16 1/32 1/64 1/128 
N 
neat 1/2 1/4 1/8 
1/16 1/32 1/64 1/128 




























































neat 1/4 1/8 1/2 
1/64 1/16 1/32 1/128 
P 
neat 1/8 1/2 1/4 
1/32 1/16 1/64 1/128 
Q 
neat 1/2 1/4 1/8 
1/16 1/32 1/64 1/128 















Immunogen Mouse serum Serum dilution * 
Naïve Pooled No protection 
BPZE1 Pooled No protection 
EV71 Pooled 1/128 
BPSQ5;  BPSY13.1 M1 1/32; No protection 
 M2 1/2; No protection 
 M3 No protection; No protection 
 M4 1/16; No Protection 
 M5 1/32; 1/16 
 M6 1/32; No protection 
 












Figure 4.22   EV71 neutralization assay using sera from immunized mice. 
Two-fold serial dilutions of sera from each group were incubated with EV71 
before infecting RD cells. Cell survival was observed 48 h later. Sera from 
individual mice of naïve (C), BPZE1 (D) and EV71 (E) groups were pooled 
while serum from each BPSQ5- (F-K) and BPSY13.1- (L-Q) infected mouse 
was tested individually. Additional controls using non-infected (A) and 
infected (B) cells without incubation with serum were included.  
BPSQ5 mice: M1 – F; M2 – G; M3 – H; M4 – I; M5 – J; M6 – K. 
BPSY13.1 mice: M1 – L; M2 – M; M3 – N; M4 – O; M5 – P; M6 – Q.  
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4.2   DISCUSSION 
 
4.2.1   Construction and Expression of the FHA and BrkA Chimera 
 
 It has been shown by Oliver et. al. (2003b) that the region from aa A52 to 
P600, representing 85% of the BrkA passenger domain, can be deleted without 
affecting surface-exposure of the protein. This finding allows the region to be 
replaced by heterologous protein antigens so that the size of the BrkA chimeric 
protein does not exceed the size of wild type BrkA. However, the passenger domain 
of BrkA has been described to possess adjuvant properties and immunogenic 
activities (Cainelli Gebara et. al., 2007), which may be important when BrkA is used 
as a carrier for the display of vaccine candidates. We thus decided to truncate the 
BrkA protein from aa A52 to H263, a deletion of only 32% of the passenger domain.  
B. pertussis has a GC-rich genome while the DNA sequence of EV71 VP1 is 
more AT-rich. To circumvent any problems in protein translation due to inefficient 
codon usage, the original sp70 gene sequence was changed to optimize B. pertussis 
codon usage. Due to the small size of SP70, three copies of the peptide were inserted 
into FHA and BrkA so as to increase exposure of the SP70 epitopes. As BrkA is a 
novel antigen display system never before used for vaccine delivery in live 
recombinant B. pertussis, a single-copy recombinant was also constructed for 
comparison. Insertion of one or three copies of SP70 into both FHA and BrkA did not 
affect production or localization of the chimera, which were efficiently secreted and 
surface-exposed by the bacteria, respectively.  
 
 
Chapter 4: Comparison between two Antigen Carriers 
 148
4.2.2   Attenuation of BPSY15.3 and BPSQ5 
 
The observation of a reduced lung colonization ability for the BrkA-knockout 
BPSY1 compared to its parental BPZE1 strain is in agreement with an earlier study by 
Elder and Harvill (2004). In addition, we found that the colonization profile for the 
BrkA-(SP70)1- and BrkA-(SP70)3-producing  BPSY15.3 and BPSQ5 strains were 
similar to that of BPSY1. This indicates that the replacement of the A52-H263 region 
in the BrkA passenger domain with SP70 impairs the function of BrkA involved in B. 
pertussis colonization.  
BrkA has been described to play a role in B. pertussis direct adherence to host 
cells (Fernandez and Weiss, 1994). Nevertheless, whether the deletion of the A52-
H263 region in the BrkA passenger domain affects the adhesion function of BrkA 
requires further study. Impaired resistance to serum killing may also account 
indirectly for the lower colonization efficiencies of BPSY15.3 and BPSQ5. Despite 
the slight attenuation, both recombinant strains were able to persist for more than 14 
days in the murine respiratory tract, which likely ensures an efficient priming of the 
host immune system, as shown by the high anti-B. pertussis antibody titer obtained in 
BPSY15.3- and BPSQ5-immunized mice, and the high anti-SP70 antibody titer 
obtained in BPSQ5-immunized mice. 
 
4.2.3   Differential Abilities of the Chimera to Trigger Anti-SP70 Immune   
           Response 
 
 The ability of BrkA to present the SP70 peptide to the host’s immune system 
was compared to that of FHA. Both the BrkA-(SP70)3-producing BPSQ5 and FHA-
(SP70)3-producing BPSY13.1 strains triggered a strong anti-B. pertussis antibody 
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response in mice, with titers comparable to that of the parental strain BPZE1. This 
indicates that the fusion of three copies of SP70 to either carrier has not altered the 
immunogenicity of the bacterial vector. However, only two out of six mice 
immunized with BPSY13.1 developed significant anti-SP70 IgG levels, while five out 
of six mice immunized with BPSQ5 produced a strong and sustained anti-SP70 
antibody response, at levels significantly higher than that of the BPSY13.1-
immunized mice. This observation demonstrates that the BrkA-(SP70)3 chimera was 
more efficiently presented to and processed by the host’s immune system than the 
FHA-(SP70)3 chimera.  
Several factors may account for the differential ability to trigger an anti-SP70 
antibody response using BrkA or FHA as carrier. Firstly, the quantity of chimeric 
molecules produced by each recombinant strain may be different. A significantly 
higher amount of BrkA-(SP70)3 molecules per cell compared to FHA-(SP70)3 might 
be responsible for the better priming of the immune system. Secondly, the localization 
of the chimera is different in each recombinant strain. FHA is mainly secreted 
whereas BrkA remains tightly associated with the bacterial surface (Oliver et. al., 
2003). Moreover, a recent study has shown that B. pertussis BrkA, as well as 
autotransporters from other rod-shaped Gram-negative bacteria, is localized at the 
bacterial pole (Jain et. al., 2006), which may have profound implications for the 
nature and efficiency of host-pathogen interactions. For example, the concentration of 
BrkA-(SP70)3 molecules at one pole of the bacteria may allow a more efficient 
presentation to and processing by the host’s antigen presenting cells. Thirdly, the size 
ratio between the carrier and the heterologous antigen for BPSY13.1 and BPSQ5 are 
very different. A short peptide fused into a large carrier is less likely to prime the 
host’s immune system against the peptide efficiently.  SP70 is a 15-aa peptide and the 
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predicted size of (SP70)3 is only around 5 kDa. FHA is a 220-kDa monomeric protein 
whereas the size of the BrkA passenger domain is 50 kDa after removal of the A52-
H263 region. Furthermore, the BrkA-(SP70)1-producing BPSY15.3 strain was unable 
to elicit any significant anti-SP70 antibodies. Together, these data indicate that three 
copies of SP70 are necessary and sufficient to induce a significant antibody response 
against SP70 using BrkA as the display system. However, three copies of SP70 may 
still be insufficient to efficiently prime the immune system using FHA as the carrier. 
Finally, the two carriers have different immunogenicity. Some adjuvant properties and 
immunogenic activities have been recently reported for the BrkA passenger domain 
(Cainelli Gebara et. al., 2007), which is certainly an asset for this protein to present 
foreign antigens to the host’s immune system. FHA is known to be highly 
immunogenic (Alonso et. al., 2002; Cahill et. al., 1995; Shahih et. al., 1992) and is 
included in most acellular pertussis vaccines. However, this feature, if too prominent, 
may instead represent a handicap for FHA as a carrier by skewing the host’s immune 
response towards itself at the expense of its passenger antigen.  
To further characterize the anti-SP70 immune response, isotyping of the anti-
SP70 IgG antibodies was carried out. The anti-SP70 isotype profile showed the 
presence of IgG1, IgG2a, and IgG2b antibodies in the sera of EV71-injected mice, 
suggestive of a mixed Th1-Th2-type response. Mice immunized with the recombinant 
B. pertussis strains, on the other hand, displayed a clear Th1-skewed immune 
response, as seen from the high IgG2a and IgG2b but insignificant IgG1 antibody 
titers. This is not surprising as a strong Th1 response has been associated with whole-
cell pertussis vaccines (Carter et al., 2004) whereas acellular pertussis vaccines 
trigger mainly a Th2 response (Ryan et al., 2000).  
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4.2.4   Detection of Neutralizing Antibodies    
 
Neutralizing antibodies are important in the defence against EV71, as seen 
from the protection of neonatal mice passively transferred with anti-EV71 antibodies 
(Wu et al., 2002; Chiu et al., 2006). One BPSY13.1-immunized mouse and five 
BPSQ5-immunized mice out of six, produced immune sera with significant 
neutralizing activities against EV71 in vitro, albeit at lower neutralizing titers than 
sera from EV71-injected mice. This may be attributed to additional neutralizing 
epitopes found in EV71 other than SP70. Parenteral administration of SP70 
conjugated peptide was shown to induce a Th2 immune response with the production 
of high levels of anti-SP70 IgG1 antibodies (Foo et. al., 2007a), while the 
recombinant B. pertussis strains in this study mainly triggered a Th1-oriented immune 
response. This apparent discrepancy, very likely due to the means used to deliver the 
SP70 peptide (conjugated SP70 emulsified in Freund’s adjuvant versus a live 
recombinant bacteria), suggests therefore that the neutralizing activity of the anti-
SP70 antibodies is not restrained to one particular IgG isotype. In addition, we found 
that the total IgG antibody titer against SP70 did not correlate with neutralizing 
activity. Sera containing different anti-SP70 total IgG antibody levels were equally 
able to neutralize EV71 in vitro. Currently it is still not clear what parameter(s) 
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4.3   CONCLUSION AND FUTURE DIRECTIONS  
 
4.3.1   Conclusion 
 
Despite high vaccination coverage, B. pertussis infection remains endemic, 
and reports of increasing incidence in Australia (Andrews et. al., 1997), Canada (De 
Serres and Duval, 2005) and Europe (Celentano et. al., 2005) have been accumulating 
for the past twenty years. The resurgence of pertussis is believed to be due to waning 
of vaccine-induced immunity in adolescents and adults, resulting in household 
transmission to vulnerable infants, thereby calling for a reinforcement of vaccination 
strategies. In addition, antigenic shift and adaptation of B. pertussis to the current 
acellular vaccines has also been suggested to contribute to the resurgence of 
whooping cough (Mooi et. al., 2001). Natural infection with B. pertussis has long 
been known to induce strong and long-lasting immunity that wanes later than vaccine-
induced immunity (Amsbaugh et. al., 1993). Strong and long-lasting anti-B. pertussis 
and anti-SP70 antibody responses were observed in BPSQ5- and to a lesser extent, 
BPSY13.1-immunized mice, without the need to be maintained by repeated 
administrations. This suggests that the development of live attenuated B. pertussis-
vectored vaccines represent an interesting approach to provide long-lasting protection 
against both pertussis (the vehicle) and the target disease (the heterologous antigen). 
Like whooping cough, EV71 infection is a childhood disease that requires vaccination 
at a young age. This thus makes the development of a B. pertussis-vectored EV71 
vaccine a highly attractive option.   
In this study, we have explored a novel antigen carrier in a novel highly 
attenuated B. pertussis background, BPZE1. The use of BPZE1 as a vaccine delivery 
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vehicle has not been investigated so far. Here, we show that BPZE1 is a suitable 
vector for vaccine delivery despite its highly attenuated state, thereby setting the 
platform for the development of safe live recombinant B. pertussis vaccines. 
Furthermore, we have identified a novel antigen carrier system in B. pertussis in 
addition to the well-studied FHA carrier system. This as yet unexplored BrkA carrier 
system may be a more efficient alternative to FHA for the presentation of vaccine 
antigen candidates, such as the EV71 SP70 peptide. Therefore, this study opens up 
new avenues for the development of live attenuated B. pertussis as a vaccine delivery 
vehicle through the nasal route.   
 
 
4.3.2   Future Directions  
 
To further assess the EV71 vaccines developed in this study, several 
experiments can be performed in future. It has been shown by Foo et. al. (2007b) that 
the in vitro neutralization ability of sera raised against EV71 and its antigens is a good 
indicator for the ability of the sera to protect against in vivo challenge of the live virus. 
We have shown that the immune sera from most of the BPSQ5-immunized mice and 
one BPSY13.1-immunized mouse were capable of neutralizing EV71 in vitro, which 
is a good indication of the in vivo protective efficacy of these sera. To truly assess 
their protective efficacy, in vivo protection studies can be conducted in future. Since 
adult mice are not susceptible to EV71 infection, the challenge studies must be 
performed using one-day old neonates. Two possible challenge modes can be tested, 
which include passive protection studies by injecting neonatal mice with immune sera 
previously raised in adults, one day after injecting them with virus, or lethally 
challenging baby mice born from immunized dams. Heterologous EV71 strains can 
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also be used to challenge the mice to assess the cross-protective efficacy of the 
vaccines. In addition, local immunity is just as important in preventing EV71 
infection by targeting the virus at its entry site. To assess the local immune response, 
the gastric IgA antibody titer can be measured from gastrointestinal lavages of 
immunized mice to monitor the local IgA response triggered by the recombinant B. 
pertussis strains.  
To further investigate the potential of the B. pertussis BrkA antigen display 
system in live recombinant B. pertussis vaccines, other antigens should be cloned into 
this carrier, and efficiency of the recombinant strains at stimulating immune response 
against both vector and passenger antigen should be tested as has been done here. 
More importantly, for the live recombinant vaccines to be acceptable for human use, 
even more attenuated and safer B. pertussis strains still capable of eliciting a good 
immune response in the host should be developed. BPZE1 represents a good starting 
platform and future generations of even safer attenuated strains can be developed 
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Chapter 5:   PRELIMINARY STUDIES ON THE B. PERTUSSIS CAPSULE 
 
5.1   RESULTS 
 
5.1.1   Construction of B. pertussis Capsule-knockout 
 
5.1.1.1   Cloning of capsule-knockout construct 
 
 The entire intact core of the B. pertussis capsule operon was deleted (Figure 
5.1). To construct this capsule-knockout strain, an 875-bp fragment in the region 282 
bases upstream of the capsule operon kpsm gene (PCR1) was PCR-amplified from B. 
pertussis BPSM chromosomal DNA with HindIII and SalI sites incorporated at the 5’ 
and 3’ ends respectively, using the primers CAPS1-F and CAPS2-R (Figure 5.1). In a 
similar manner, a 907-bp fragment consisting of the last 103 bases of the capsule 
operon wcba gene to nucleotide 791 of the wcbo gene (PCR2) was PCR-amplified 
from B. pertussis BPSM chromosomal DNA with SalI and EcoRI sites incorporated at 
the 5’ and 3’ ends respectively, using the primers CAPS3-F and CAPS4-R (Figure 
5.1). PCR1 and PCR2 were then separately cloned into TOPO plasmids to give 
TOPO2 and TOPO3. PCR1 was then digested from TOPO2 using HindIII and SalI, 
and cloned into pJQ200mp18-rpsl plasmid digested with the same enzymes to give 
pJQSY3, which was then digested with SalI and EcoRI to clone in PCR2, digested 
from TOPO3 with the same enzymes, finally yielding pJQSY4. An overview of the 
cloning strategy is presented in Figure 5.2. Colony PCR screening (Figure 5.3) and 
RE digestion analysis (Figure 5.4) were used to screen for and verify the E. coli 
clones transformed with the various constructs. In addition, DNA sequencing was 
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performed using primers CAPS1-F, CAPS2-R, CAPS3-F and CAPS4-R (Table 3.2) to 









kpsM kpsT kpsE wbpT vipC wza wbpO wbpP wcbA wcbO 






Figure 5.1   Schematic diagram of the intact core of the B. pertussis capsule 
operon. 
The entire intact core of the B. pertussis capsule operon from the kpsm gene to 
the wcba gene was deleted. PCR1 and PCR2 are the homologous regions in the 
B. pertussis genome flanking the region to be deleted. PCR1 was amplified using 
primers CAPS1-F and CPAS2-R (red block arrows) to incorporate HindIII and 
SalI sites into its 5’ and 3’ ends respectively. PCR2 was amplified using primers 
CAPS3-F and CAPS4-R (blue block arrows) to incorporate SalI and EcoRI sites 
into its 5’ and 3’ ends respectively. hmmp is the gene immediately upstream of 
kpsm and is not part of the capsule operon. 
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Figure 5.2   Overview of cloning strategy for capsule-knockout construct. 








875 bp 1 kb 750 bp 
     M       P        N        1       2        3        4       5
Figure 5.3   Colony PCR screening of recombinant plasmid constructs for 
cloning capsule-knockout.  
A: PCR screening for pJQSY3-positive E. coli transformants using primers 
CAPS1-F and CAPS2-R. Lanes: M, 1 kb ladder (5 ml); P, TOPO2 construct as 
positive control (10 ml); N, pJQ plasmid as negative control (10 ml); 1-5, E. coli 
clones 1-5 (10 ml). Positive clones (3 & 4) showing the expected 875-bp band are 
indicated in red. B: PCR screening for pJQSY4-positive E. coli 
transformants using primers CAPS3-F and CAPS4-R. Lanes: M, 1 kb ladder 
(5ml); P, TOPO3 construct as positive control (10 ml); N, pJQSY3 construct as 
negative control (10 ml); 1-5, E. coli cloens 1-5 (10 ml). Positive clones (1 & 4) 
showing the expected 907-bp band are indicated in red.    
B 
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Figure 5.4   HindIII and EcoRI digestion profile of pJQSY4 
constructs. 
Lanes: M, 1 kb ladder (5 ml); 1-5, E. coli clones 1-5 transformed with 
pJQSY4 (10 ml). Positive clones (1 & 4) giving the expected 1782-bp 
PCR1-PCR2 fragment are indicated in red.  
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5.1.1.2   Obtaining capsule-knockout strain 
 
Electrocompetent B. pertussis strain BPSM was electroporated with pJQSY4 
construct. The recombinant pJQSY4 construct was integrated into the B. pertussis 
genome via double homologous recombination (See Chapter 4 Figure 4.9), leading to 
deletion of the entire intact core of the capsule operon. First event recombinants were 
selected for gentamicin resistance and identified for streptomycin sensitivity, then 
streaked on Sm plates to allow second event recombination. Isolated colonies were 
then patched on Sm and Gm plates whereby Smr and Gms clones were PCR-screened 
































945 bp 1 kb 
750 bp 
  M     N     1     2     3      4     5      6     7     8
Figure 5.5   PCR-based detection for capsule-knockout second event 
recombinants.  
A: PCR screening strategy for second event recombinants. Primers 
CAPS5-F and CAPS6-R (green block arrows) were used to screen for 
second event recombinants. PCAPS5-F lies outside the PCR1 
homologous region in the hmmp gene region. PCAPS6-R lies in the 
PCR2 homologous region. B: PCR screening for second event 
recombinants. Lanes: M, 1 kb ladder (5 ml); N, BPSM chromosomal 
DNA as negative control (10 ml); 1-8, B. pertussis clones 1-8 (10 ml). 
Only clone 3 (indicated in red) gave the positive 945-bp band.  
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5.1.2   Verification of B. pertussis Capsule-knockout 
 
5.1.2.1   Southern blot analysis 
 
The BPSY2 capsule-knockout strain was further analyzed by southern blot. 
Chromosomal DNA was extracted from the parental BPSM strain and the capsule-
knockout BPSY2 strain (Figure 5.6A), then digested with SalI followed by 
hybridization of the pre-synthesized DIG-labeled probe (Figure 5.6B) to reveal 
fragments of different sizes for each strain. The 700-bp probe maps from nucleotide 
153 to 853 of PCR2 and was PCR-amplified and labeled with DIG using primers P1-F 
and P2-R (Table 3.4). The strategy for Southern blot analysis is given in Figure 5.7A. 
An extra SalI site not present in BPSM was introduced into BPSY2 from cloning 
PCR1 and PCR2 together, thereby generating a much smaller probe-hybridized 
fragment for BPSY2 than BPSM, following SalI digestion. As shown in Figure 5.7B, 
a 935-bp band corresponding to the fragment bound by the probe after SalI digestion 
was detected for BPSY2, as well as an expected 4160-bp band for parental BPSM 
strain, thus verifying at the genomic level that BPSY2 is indeed a capsule-knockout 
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Figure 5.6   Preparation for southern blot analysis. 
A: Chromosomal DNA extracted from parental and recombinant 
B. pertussis strains. Lanes: M, 1 kb ladder (5 ml); 1, BPSM (1 ml); 2, 
BPSY2 (1 ml). B: Synthesis of DIG-labeled probe. DIG-labeled probe 
was synthesized by PCR amplification using primers P1-F and P2-R 
(Table 3.4). Lanes: M, 100 bp ladder (5 ml); 1, DIG-labeled probe (5 
ml). *: The probe is slightly larger than the calculated 700 bp due to the 
incorporation of DIG labels. 












Figure 5.7   Southern blot analysis for BPSY2. 
A: Strategy for southern blot analysis of BPSM and BPSY2. Chromosomal 
DNA from BPSM and BPSY2 were digested with SalI, then hybridized with the 
DIG-labelled probe to reveal a 4160-bp band for BPSM and a 935-bp band for 
BPSY2. An extra SalI site not present in the BPSM genome was introduced into 
BPSY2 during the process of cloning PCR1 and PCR2 together. hPCR1 and 
hPCR2 represent the regions in the bacterial genome homologous to PCR1 and 
PCR2 respectively. B: Southern blot of BPSM and BPSY2. Lanes: M, DIG-
labeled DNA ladder (10 ml); 1, SalI-digested, probe-hybridized BPSM fragment 
(10 ml); 2, SalI-digested, probe-hybridized BPSY2 fragment (10 ml).  
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5.1.2.2   RT-PCR analysis 
 
 To further confirm the deletion of the capsule operon in BPSY2, RNA was 
extracted and purified from parental BPSM and capsule-knockout BPSY2 (Figure 
5.8), and subjected to one-step RT-PCR using primers RT1-F and RT2-R (Table 3.4). 
These primers map within kpsT gene in the capsule operon, which was deleted in 
BPSY2. As a control, primers RT3-F and RT4-R (Table 3.4), which map within fhaB 
gene (not capsule-related), were also used to carry out RT-PCR on BPSM and BPSY2 
RNA. In addition, PCR without the reverse-transcription step was also carried out on 
the B. pertussis RNA using both sets of primers, as a control for DNA contamination. 
Aliquots of the reactions were obtained after 20, 25, 30 and 35 cycles of PCR reaction 
and subjected to agarose gel electrophoresis to visualize the RT-PCR/PCR bands. 
 As shown in Figure 5.9 panels A and B, no bands were detected after 20 
cycles of PCR reaction, regardless of primers and template. After 25 cycles, however, 
the 450-bp kpsT band was detected using BPSM but not BPSY2 RNA as template 
(Figure 5.9, panel C). In contrast, the 455-bp fhaB band was detected for both BPSM 
and BPSY2 (Figure 5.9, panel D). The results were the same after 30 and 35 cycles, 
with brighter bands obtained for more cycles of reaction, but the 450-bp kpsT band 
remained undetected throughout the reactions using BPSY2 RNA as template (Figure 
5.9, panels E-H). As expected, no bands were detected for all reactions without the 
reverse-transcription step, showing that the bands observed were not due to 
contaminating DNA in the RNA template. Thus, these results further verify at a 
transcriptional level that BPSY2 is indeed a capsule-knockout strain.   
 
 










Figure 5.8   RNA extraction and purification from BPSM and 
BPSY2. 
RNA was extracted from B. pertussis BPSM and BPSY2, and purified 
to remove contaminating DNA. Lanes: 1, BPSM RNA before 
purification (2 ml); 2, BPSY2 RNA before purification (2 ml); M, 1 kb 
ladder (5 ml); 3, BPSM RNA after purification (2 ml); 4, BPSY2 RNA 
after purification (2 ml). 











Figure 5.9   RT-PCR on BPSM and BPSY2 RNA. 
One-step RT-PCR was performed on BPSM and BPSY2 RNA for 20 
(panels A and B), 25 (panels C and D), 30 (panels E and F) and 35 (panels 
G and H) cycles using primers RT1-F and RT2-R (panels A, C, E and G) or 
primers RT3-F and RT4-R (panels B, D, F and H). RT1-F and RT2-R 
amplify a 450-bp fragment in B. pertussis kpsT gene of the capsule operon 
while RT3-F and RT4-R amplify a 455-bp fragment in B. pertussis fhaB 
gene. Lanes: M, 100 bp ladder (5 ml); 1, BPSM RNA with reverse 
transcriptase (10 ml); 2, BPSY2 RNA with reverse transcriptase (10 ml); 3, 
BPSM RNA without reverse transcriptase (10 ml); 4, BPSY2 RNA without 
reverse transcriptase (10 ml).   
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5.1.3   Characterization of B. pertussis Capsule-knockout 
 
5.1.3.1   Lung colonization  
 
To investigate the ability of BPSY2 to colonize the mouse respiratory tract, 
Balb/c mice were infected with parental BPSM or capsule-knockout BPSY2 via the 
nasal route, and their lungs were harvested 3 h and 3, 7, 14 and 21 days post-infection 
to enumerate viable bacteria in the lungs. As shown in Figure 5.10, BPSM showed a 
typical colonization profile with a multiplication peak 7 days post-infection, followed 
by a progressive clearance during the next 3 weeks. In contrast, when mice were 
infected with BPSY2, no multiplication peak was observed. Instead, a rapid decrease 
in the number of bacteria in the murine lungs was observed, with total clearance 
obtained by 14 days post-infection. This demonstrates that the deletion of the B. 
pertussis capsule operon greatly impairs B. pertussis colonization efficiency of the 
mouse respiratory tract, strongly suggesting that B. pertussis produces a functional 






















Figure 5.10   Lung colonization by BPSY2. 
Balb/c mice were infected intranasally with 5 × 105 cfu of B. pertussis 
BPSM (open lozenges) or BPSY2 (solid lozenges) at 0 h. The lungs were 
harvested at the indicated time points and viable bacteria in the lungs were 
counted after plating appropriate dilutions of the lung homogenates onto 
BG agar. 4 mice per group per time point were assessed individually.   


















Infect at 0 h 
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5.1.3.2   Inhibition of neutrophil influx in vivo 
 
 To investigate whether the B. pertussis capsule affects the influx of 
neutrophils into the respiratory tract, we nasally infected Balb/c mice with the 
parental BPSM or capsule-knockout BPSY2 strains and compared the neutrophil 
count in the bronchoalveolar lavage fluids (BALFs) of these mice 18 h and 2 days 
post-infection. As a control, a third group of mice was inoculated with PBS via the 
nasal route and subsequently treated following the same protocol as the BPSM and 
BPSY2 groups. As shown in Figure 5.11, after an initial burst 18 h post-infection, the 
percentage of neutrophils present in the BALFs of BPSM-infected mice dropped 
drastically 2 days post-infection, to values similar to that of the PBS-inoculated mice, 
whose neutrophil count remained low throughout. In contrast, the percentage of 
neutrophils observed in the BALFs of BPSY2-infected mice remained high 2 days 
post-infection and was significantly higher than that of the BPSM-infected mice. 
These data indicate that the deletion of the capsule operon in B. pertussis has affected 
neutrophil turnover or neutrophil trafficking in the lungs of infected mice, with a 
significant difference seen between parental and knockout strain by 2 days post-
infection. A possible mechanism is that deletion of the capsule operon has affected the 
ability of the bacteria to inhibit neutrophil influx into the lungs of infected mice, 


























18 h Day 2 
p = 0.0118 *
Time post-infection 
Figure 5.11   Inhibition of neutrophil influx by BPSY2.    
Balb/c mice were intranasally inoculated with 5 × 105 cfu of B. pertussis 
BPSM (open lozenges) BPSY2 (solid lozenges), or PBS (open circles) at 0 h. 
At the indicated time points post-infection, BALFs were obtained from the 
sacrificed mice and treated to allow enumeration of neutrophils. The number 
of neutrophils for a total of 500 cells was estimated under 40x magnification. 
4 mice per group per time point were assessed individually. Results are 
representative of 2 independent experiments. Statistically significant p value 
is marked with an asterisk.   
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5.2   DISCUSSION AND FUTURE WORK 
 
 The B. pertussis capsule operon has been shown to belong to the family of 
genes expressed under negative BvgA/S regulation known as vrgs (Hot et. al., 2003). 
Thus, under non-modulating in vitro conditions, where the bacteria is in the Bvg+ 
phase, the capsule genes are down-regulated. The detection of a kpsT PCR band in 
wild type BPSM grown under non-modulating in vitro conditions indicates that 
during the Bvg+ phase, the capsule operon is transcribed at a basal level.  
The deletion of one of the numerous virulence factors in B. pertussis has been 
shown to cause only mild or no attenuation whereas multiple deletions lead to more 
severe attenuation, suggesting a redundancy among the virulence factors (Alonso et. 
al., 2001). In this study, we found that the single deletion of the capsule operon in B. 
pertussis led to a strong attenuated phenotype, similar to the attenuation observed 
with a bvgAS-deleted mutant, in which all the so far known virulence genes are 
repressed (Bock and Gross, 2001). As further evidence to show that this highly 
attenuated phenotype is due to deletion of the capsule operon, a complementation 
study to re-introduce the deleted genes into the capsule-knockout to restore the wild 
type phenotype is warranted. The major obstacle to do this for the BPSY2 capsule-
knockout, however, is the size of the operon, which makes it highly challenging to 
clone the entire operon (10 kb) for re-introduction into the knockout. To circumvent 
this problem, another recombinant strain whereby a single gene of the capsule operon 
would be deleted, can thus be constructed and investigated in future.   
 Studies have shown that the S. typhi Vi capsular antigen, whose biosynthesis 
genes are homologous to those encoding the B. pertussis capsule polysaccharide 
biosynthesis enzymes (Parkhill et. al., 2003), plays a role in inhibiting neutrophil 
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influx in the infected host (Raffatellu et. al., 2005). Similarly, our data suggests that 
the B. pertussis capsule contributes to the inhibition of neutrophil recruitment into the 
lungs early post-infection. PT was previously shown to also inhibit neutrophil 
recruitment in the lungs of infected mice (Kirimanjeswara et. al., 2005), suggesting 
that there may be functional redundancy. Alternatively, the B. pertussis capsule may 
play a synergistic role with PT or have an indirect role in neutrophil influx inhibition 
through PT. The exact mechanism(s) of how the capsule inhibits neutrophil influx 
remains to be elucidated and future studies include the identification of cytokines and 
chemokines associated with this neutrophil influx. 
 It is likely that the B. pertussis capsule plays several roles in bacterial 
virulence, as seen from the multiple roles of the other B. pertussis virulence factors. 
For example, in addition to its role in adherence, FHA has also been shown to have 
immunosuppressive and immunomodulatory activities (McGuirk et. al., 2002). To 
better elucidate the function(s) of the capsule and the mechanisms involved, in vitro 
studies such as complement killing and adherence assays have to be conducted in 
addition to the in vivo studies done here. As the capsule genes are only expressed 
under the Bvg- phase, all future in vitro experiments will have to be conducted under 
modulating conditions where the bacterial strains are grown in the presence of 
magnesium sulphate or nicotinic acid, or at a lower temperature of 25oC. Alternatively, 
a recombinant strain over-expressing the capsule genes under a strong promoter in the 
Bvg+ phase, such as the fhaB promoter, can be constructed.      
 Finally, it will be interesting to carry out immunization studies with the 
BPSY2 knockout to see if this highly attenuated strain is still capable of eliciting 
immune responses and protection against the wild type bacteria. If so, it will represent 
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a highly attractive and promising candidate as a live attenuated vaccine and carrier 
against whooping cough and other diseases. 
 
5.3   CONCLUSION 
  
In conclusion, we have shown in this preliminary study that the deletion of the 
capsule operon greatly impairs the colonization ability of B. pertussis, suggesting that 
the capsule is indeed intact and functional in this pathogen. More importantly, the 
capsule represents a novel major virulence factor in B. pertussis, playing a role in 
inhibition of neutrophil influx into the host’s lungs upon infection by the bacteria. 
Compared to the vags, very few vrgs have been studied and their role in B. pertussis 
infection has not been clearly established yet. A previous study suggested that the 
Bvg+ phase is necessary and sufficient for B. pertussis infection (de Tejada et. al., 
1998). Our work here suggests otherwise and identifies for the first time, a bvg-
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APPENDIX 1: REAGENTS FOR GEL ELECTROPHORESIS 
 
1.1     DNA Electrophoresis 
 
 
1.1.1     50 × Tris-Acetate-EDTA (TAE) Buffer 
                                                                                                 Per L 
 
Tris base                                                                                   242 g 
 
Glacial acetic acid                                                                  57.1 ml 
 
0.5 M EDTA (pH 8)                                                                100 ml 
 
 
Final pH adjusted to 7.8 
 
 
1.1.2     Agarose Gel 
                                                                                      1%                      1.5% 
 
Agarose                                                                        0.5 g                   0.75 g 
 
1 × TAE                                                                       50 ml                   50 ml 
 
 
1 × TAE was prepared by adding 20 ml of 50 × TAE buffer to 980 ml of ddH2O. 
 
 
1.1.3     6 × DNA Loading Dye 
 
Bromophenol blue                                                                   0.25% 
 
Xylene cyanol                                                                          0.25% 
 










1.2     Protein Electrophoresis 
 
 
1.2.1     SDS-PAGE 
 
 
1.2.1.1     5 × SDS/Glycine Electrophoresis Buffer 
                                                                                                 Per L 
 
Tris-base                                                                                 15.1 g 
 
Glycine                                                                                     72 g 
 
SDS                                                                                           5 g 
 
 
1.2.1.2     10% or 12% Separating Gel 
                                                                                              Per 30 ml 
 
30% Acrylamide-bisacrylamide (29:1)                         8.75 ml or 10.5 ml 
 
1 M Tris-HCl (pH 8.8)                                                            7.5 ml 
 
10% SDS                                                                                 300 μl 
 
20% APS                                                                                 400 μl 
 
TEMED                                                                                   40 μl 
 
ddH2O                                                                         13.01 ml or 11.26 ml 
 
 
1.2.1.3     4% Stacking Gel 
                                                                                               Per 10 ml 
 
30% Acrylamide-bisacrylamide (29:1)                                      2 ml 
 
1 M Tris-HCl (pH 8.8)                                                            1.25 ml 
 
10% SDS                                                                                  100 μl 
 
20% APS                                                                                  400 μl 
 
TEMED                                                                                    40 μl 
 
ddH2O                                                                                    11.26 ml 
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1.2.1.4     2 × Protein Loading Buffer 
                                                                                              Per 50 ml 
 
1 M Tris-HCl (pH 6.8)                                                           6.25 ml 
 
100% glycerol                                                                           5 ml 
 
SDS powder                                                                               5 g 
 
Bromophenol blue                                                                  1 drop 
 
b-mercaptoethanol                                                                    5 ml 
 
 
1.2.2     Coomasie Staining of SDS Gel 
 
 
1.2.2.1     Coomasie Blue Staining Solution 
 
Coomasie brilliant blue                                                           0.2% 
 
Ethanol                                                                                    45% 
 
Acetic acid                                                                              10% 
 
ddH2O                                                                                     45% 
 
 
1.2.2.2     Destaining Solution 
 
Ethanol                                                                                    25% 
 
Acetic acid                                                                              10% 
 














APPENDIX 2: REAGENTS FOR GROWTH MEDIA 
 
2.1     E. coli Culture Media 
 
 
2.1.1     Luria-Bertani (LB) Agar 
                                                                                       Per L 
 
Tryptone                                                                         10 g 
 
Yeast extract                                                                    5 g 
 
NaCl                                                                                10 g 
 
Agar                                                                                15 g 
 
 
Autoclaved at 121ºC for 15 mins. 
 
 
2.1.2     LB Broth 
                                                                                       Per L 
 
Tryptone                                                                         10 g 
 
Yeast extract                                                                    5 g 
 
NaCl                                                                               10 g 
 
 
















2.2     B. pertussis Culture Media 
 
 
2.2.1     Stainer-Scholte (SS) Medium 
 
Fraction A: 
                                                                                         Per L 
 
Na-L-Glutamate                                                             11.84 g 
 
L-Proline                                                                         0.24 g 
 
NaCl                                                                                 2.5 g 
 
KH2PO4                                                                            0.5 g 
 
KCl                                                                                   0.2 g 
 
MgCl2.6H2O                                                                     0.1 g 
 
CaCl2.2H2O                                                                     0.02 g 
 
Tris                                                                                   1.5 g 
 
Casamino acids                                                                10 g 
 
Dimethyl-ß-Cyclodextrine                                                1 g 
 
 
Final pH adjusted to 7.4. Autoclaved at 121ºC for 15 mins. 
 
Fraction B: 
                                                                                       Per 10 ml 
 
L-Cysteine                                                                        0.04 g 
 
FeSO4.7H2O                                                                     0.01 g 
 
Nicotinic acid                                                                   0.04 g 
 
Ascorbic acid                                                                    0.4 g 
 
Glutathione                                                                       0.15 g 
 
Filter-sterilize with 0.2 μm filter unit.  
Add 10 ml of filter-sterilized Fraction B to 1 L of autoclaved Fraction A. 
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2.2.2     Bordet-Gengou (BG) Agar 
                                                                                         Per L 
 
Potato infusion from 125 g                                              4.5 g 
 
NaCl                                                                                 5.5 g 
 
Agar                                                                                  20 g 
 
Glycerol                                                                            10 g 
 
 
Autoclaved at 121ºC for 15 mins. 




2.3     Tissue Culture Media 
 
 
2.3.1     Minimum Essentail Medium (MEM) 
                                                                                          Per L  
 
MEM                                                                              1 packet 
 
FCS                                                                                  50 ml 
 
1 M HEPES                                                                      20 ml 
 
Sodium bicarbonate                                                          15 ml 
 
Penicillin-streptomycin                                                    10 ml 
 
Nanopure H2O                                                                 905 ml 
 
 
Filter-sterilized with 0.2 mm filter unit. 
 
 
2.3.2     1 × Trypsin 
 
 
To prepare the working 1 × trypsin, 10 × trypsin stock was diluted 1: 10 with 





APPENDIX 3: REAGENTS FOR ANIMAL WORK 
 
3.1     Anaesthetic Cocktail for Nasal Administration 
 
 
Valium                                                                               6% 
 
Atropine                                                                           10% 
 
Ketamine                                                                          20% 
 
1 × PBS                                                                            64% 
 
 
Cocktail must be prepared under sterile conditions. 
120 ml cocktail is injected intraperitoneally for a mouse of approximately 17 g of body 
weight. 
 
 
